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Preface
When a foreign antigen plans to reside in the body, innate immunity attempts to 
define the frontier lines of defense and, if necessary, helps to formulate a more 
specific line of defense. There is a recognition system required for innate immunity 
to work efficiently in such a highly responsible position. Toll-like receptors (TLRs) 
are an essential part of this system. They are present on innate and adaptive 
immune cells making them key switches incorporated in bridging innate and 
adaptive immunity. The non-immune cells express TLRs and, in turn, their value 
increases.
This book first provides readers with basic facts about TLR structure, cellular 
distribution, and signaling pathways. It then discusses in detail the role of natural 
killer cells expressing TLRs in linking innate and adaptive immunity. Furthermore, 
the book includes chapters that focus on the role of TLRs in infections and neurode-
generative diseases.
Nima Rezaei
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Introductory Chapter: Toll-Like 
Receptors
Amene Saghazadeh and Nima Rezaei
1.  The first line of defense is filled with a variety of pattern recognition 
receptors
Pattern recognition receptors (PRRs), which are germ line-encoded recep-
tors, probably provided the host with the best possible innate property to identify 
“nonself” invaders from both exogenous and endogenous sources. PRRs can 
discriminate self-microorganisms and molecules from nonself ones through recog-
nizing conserved parts of microorganisms—which are known as microorganism-
associated molecular patterns (MAMPs). If it is nonself, then they will direct the 
induction of inflammatory responses. In addition, PRRs allow the innate immunity 
to identify endogenous danger signals—which are released by stressed, damaged, 
or dying cells and known as damage-associated molecular patterns (DAMPs)—and 
thereby help in initiation of sterile inflammation. In this manner, PRRs participate 
in the clearance of invading pathogens by regulating infectious inflammation and 
contribute to tissue repair and regeneration in addition to elimination of autoimmu-
nity and tumorigenesis by regulating sterile inflammatory processes.
They display three types of localization. Toll-like receptors (TLRs) are a kind of 
PRRs located in the membrane along with C-type lectin receptors. Also, nucleotide 
oligomerization domain (NOD)-like receptors (NLR) and retinoic acid-inducible 
gene I (RIG-I)-like receptors (RLR) are found in the nucleus and contribute to 
recognition of intracellular microorganisms. Finally, there are some proteins that 
their synthesis occurs in the cells and can be used as receptors by various micro-
organisms. TLRs—which are the subject of this book—were the first discovered 
family of PRRs.
2. Toll-like receptors
They exist in mammals and insects and mediate actions essential to achieve 
control over immune homeostasis. The major cells expressing TLRs are antigen-
presenting cells (APCs). Activation of TLRs in APCs can affect maturation of 
these cells and T helper 1 (Th1) cell differentiation for processing more specific 
immune mechanisms [1]. However, different cell types of the body have the 
capacity to induce the expression of TLRs, allowing them to carry TLR-mediated 
signaling pathways and production of inflammatory mediators and type I inter-
ferons (IFN). When handling a number of immune and inflammatory pathways, 
TLRs are able to have a role in the induction of innate immune responses and 
to link the innate immunity with the acquired immunity. Interfering with TLR 
function leads inevitably to immunological anomalies seen in common conditions 
ranging from immunodeficiency and infection to allergy, autoimmunity, cancer 
and more generally to diseases of many organ systems including the central 
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nervous system, lung, cardiovascular system, kidney, skin, and gastrointestinal 
system which are rooted in chronic inflammation. This has been fuel for advances 
in prophylactic and therapeutic applications of TLRs, especially in the last two 
decades.
2.1 Cells expressing TLRs
TLRs are found on the different cells of both the innate and adaptive immu-
nity. Notably, they are expressed by nonimmune cells in the body. Normal non-
transformed cells, such as endothelial cells, epithelial cells, fibroblasts, glial cells, 
neurons, and neural progenitor cells, as well as transformed cells of the body, i.e., 
cancer cells, may mediate the expression of TLRs. In humans, intestinal epithelial 
cells (IECs) are the main nonimmune source of TLRs. It is not aimless—there is 
evidence that the recognition of commensal bacteria by TLRs is required for the 
regulation of intestinal homeostasis [2].
2.2 Structure of TLRs
To date, 13 TLRs have been described in mammals, 10 of which are present in 
humans (TLR1–10). Each TLR consists of three domains: intracellular, transmem-
brane, and extracellular. The intracellular or cytoplasmic domain is conserved 
between TLRs and interleukin-1 family of receptors (IL-1R). It is, thus, referred to 
as the Toll-IL-1R (TIR) domain. The extracellular domain includes tandem leucine-
rich repeats (LRRs), which with their curved surface appear to determine which 
ligand(s) a TLR can bind. The transmembrane location of TLRs makes them very 
suitable to transmit signals from the extracellular matrix to the cytoplasm (signal 
transduction).
2.3 Cellular distribution of TLRs
TLRs are located either within the cell membrane or in the intracellular com-
partments including the endoplasmic reticulum, endosomes, lysosomes, and 
endolysosomes:
Cell-membrane TLRs: TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10
Intracellular TLRs: TLR3, TLR7, TLR8, and TLR9
Like other receptors, TLRs act in relation to their cellular distribution. Cell-
membrane TLRs are eligible for identification of membrane components of micro-
organisms, e.g., lipids, proteins, and lipoproteins, while intracellular TLRs are for 
identification of nuclear components of microorganisms, i.e., nucleic acids.
2.4 Ligands of TLRs
In general, MAMPs are divided into three: glycans, proteins, and nucleic acids. 
Particularly, ligands that participate in host-pathogen interactions vary based on 
the pathogen identity and include:
 Bacteria: lipoteichoic acid, peptidoglycan, lipoprotein/lipopeptides, deoxyribo-
nucleic acid (DNA), flagellin, and lipopolysaccharide
Viruses: coat proteins and nucleic acids
Parasites: glycosylphosphatidylinositol (GPI) protein-membrane anchors
Yeast: zymosan
3
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TLRs have been reported to bind endogenous and exogenous ligands. There is a 
wide range of microorganisms including bacteria, viruses, protozoa and helminth 
parasites, and fungi that TLRs can defend against. Table 1 provides an overview 
of ligands and associated pathogens that interact with TLRs. However, below are 
representative examples for MAMPs that can be recognized by TLRs:
TLR1: lipoproteins
TLR2: lipoteichoic acid, peptidoglycan, lipoproteins, and zymosan
TLR3: viral dsRNA
TLR4: lipopolysaccharide, viral envelope protein, and viral fusion protein
TLR5: flagellin
TLR6: lipoteichoic acid, lipoproteins, and zymosan
 TLR7 and TLR8: viral ssRNA, synthetic antiviral compounds 
(imidazoquinolines)
TLR9: bacterial and viral DNA
TLR10: triacylated lipopeptides
Endogenous ligands that can be recognized by TLRs are numerous but 
mainly include extracellular matrix components, high-mobility group box 1, 
heat shock proteins (HSP), tenascin-C, cardiac myosin, and S100 proteins (for 
review see [5]).
3.  TLR-mediated signaling pathways: network of adaptor molecules and 
transcription factors
Ligand recognition by TLRs involves the recruitment of different TIR domain-
containing adaptor proteins. The types of adaptor proteins they use at least in part 
explain distinct functions of TLRs.
To date, there have been four adaptor proteins found to interact with specific 
TLRs (Table 2). Myeloid differentiation primary response 88 (MyD88) was the first 
of its kind. It is an intracytoplasmic adaptor molecule that consists of a C-terminal 
TIR domain and an N-terminal death domain. Its TIR domain—which is funda-
mental to ligand site recognition—can interact with all TLRs with the exception of 
TLR3. Recruitment of MyD88 by TLRs initiates the cascades of mitogen-activated 
protein kinases (MAPKs) and nuclear factor-κB (NF-κB) that result in the produc-
tion of inflammatory cytokines.
In this context, TIR-domain-containing adapter-inducing interferon-β (TRIF) 
is another adaptor protein. TLR3 and also TLR4 can act as a trigger for TRIF-
dependent signaling. This signaling then utilizes transcription factors NF-κB and 
interferon regulatory factor 3 (IRF3) to produce inflammatory cytokines and type 
I IFN.
Toll-interleukin 1 receptor (TIR) domain-containing adaptor protein 
(TIRAP) and TRIF-related adaptor molecule (TRAM) are last two remaining 
TIR domain-containing adaptor proteins. They are specialized for directing 
other adaptors to specific TLRs and thus are referred to as sorting adaptors. 
TIRAP serves as the sorting adaptor for MyD88 and facilitates its recruitment to 
TLR1, TLR2, TLR4, and TLR6, while TRAM is merely involved in the interaction 
between TRIF and TLR4.
In this manner, the discussion on signaling pathways mediated by TLRs is com-
monly held in MyD88-dependent and TRIF-dependent settings (for review see [7]). 
Figure 1 is a schematic diagram of TLR location and pathways.
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3.1 TLRs and different disease entities
Studies in mice have demonstrated that TLR signaling change underlies a range 
of pathologies. Supporting this, human studies propose that single nucleotide 
polymorphisms (SNPs) that alter—whether upregulated or downregulated—TLR 
signaling may predispose to or protect from development of diseases [8].
Figure 1. 
Toll-like receptor (TLR) location and signaling pathways.















TLR1  × TIRAP NF-κB  ×
TLR2  × TIRAP NF-κB  ×
TLR3 ×  × NF-κB, IRF3, 
and IRF7
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TLR5  × × NF-κB  ×
TLR6  × TIRAP NF-κB  ×
TLR7  × × NF-κB and IRF7  
TLR8  × × NF-κB and IRF7  
TLR9  × × NF-κB and IRF7  
Table 2. 
Toll-like receptor: signaling pathways and products [6].
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All 10 TLRs that are present in humans (except to TLR5) have been associated 
with autoimmune and inflammatory diseases including arthritis, systemic lupus 
erythematosus, scleroderma, and Sjogren’s syndrome [9]. There are potential 
opposing views on involvement of TLRs in autoimmunity.
Autoimmunity is referred to as conditions where the immune system is fighting 
against the body itself by production of antibodies, the so-called autoantibodies, 
against self molecules, the so-called autoantigens. Autoantibodies bind to autoanti-
gens and form immune complexes. The cytokine interferon-alpha (IFNα) was first 
thought to have a pure white role of antiviral immunity. However, the observations 
of autoimmune features caused by the use of recombinant IFNα in patients with 
chronic viral infections have expanded the former function of IFNα far beyond 
antiviral immunity to autoantibody production and autoimmunity. A hypoth-
esis is that immune complexes having nucleic acids can act as ligands for TLRs, 
thereby making the innate immune cells to induce more than wanted or unwanted 
responses. TLRs that can recognize nucleic acids, i.e., TLR7 and TLR9, and plas-
macytoid dendritic cells (pDCs) that express these receptors and produce IFNα in 
response are of particular importance in this context [9]. In contrast, some TLRs 
have been reported to turn the knob in the opposite direction. When reviewing the 
role of TLRs in inflammatory arthritis, TLRs may stimulate osteoclastogenesis, and 
on the other side, there are TLRs that inhibit activation of osteoclasts and thus can 
prevent bone destruction [10].
3.3 Brain diseases
Different brain cells reveal the expression of TLRs:
Microglia express all TLRs.
Neurons express TLR3, TLR7, TLR8, and TLR9.
Astrocytes express TLR2, TLR3, and TLR9.
Oligodendrocytes express TLR2 and TLR3.
The role of TLRs has been characterized in the normal central nervous system 
(CNS) as well as in disease states of the CNS. Experimental evidence suggests the pos-
sible role of TLR2 in neurogenesis, whereas TLR3 and TLR4 apparently act as downreg-
ulators of neurogenesis. Enhancement of hippocampal-dependent working memory in 
mice lacking TLR3 implicates this receptor as a negative regulator of cognitive functions 
as well. In bacterial infections of the brain and abscess formation, TLR2, TLR4, and 
TLR9 are essential to elicit immune responses. In the cases of viral meningitis, TLR3 
and TLR9 engagement can help to localize infection and diminish neural injury as well. 
In parasite infections of the brain, TLR1, TLR2, and TLR9 show paradoxical effects—
they may worsen disease rather than clear parasites from the brain. Both models of 
neuronal injury and of spinal cord injury indicate a role for TLR2 and TLR4 in inducing 
neuronal death and axon and myelin damage. Finally, evidence points to the potential 
role that TLR2, TLR4, TLR5, TLR7, and TLR9 can play in preventing the accumulation 
of amyloid plaques and progression of Alzheimer’s disease [11].
3.4 Cardiovascular diseases
Cardiac myocytes show the expression of TLR2, TLR3, TLR4, and TLR6. TLRs 
play paradoxical roles in different myocardial diseases. For example, TLR2 was 
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shown to mediate apoptosis of cardiac myocytes induced by hydrogen peroxide 
and doxorubicin, while TLR4 attenuated apoptosis of cardiac myocytes. Targeting 
both TLR2 and TLR4 provided protection in septic cardiomyopathy. TLR4 blockade 
implied benefit to ischemia-reperfusion injury and cardiac hypertrophy as well (for 
review see [12]).
TLR4 is also said to be highly expressed in atherosclerotic lesions which 
inflammation is supposed to corporate in its nature. There are possible explana-
tions which can be given to this fact. The oxidization of lipids as a way to form 
atherosclerotic lesions accompanies thermal stress through HSP production. 
Oxidized lipids and HSPs can act as ligands and upregulate MyD88-dependent 
TLR4 relevant to inflammatory cytokine production. Another explanation is 
that TLR4 mediates recognition of Chlamydia pneumoniae, which in turn is 
closely related to atherosclerosis. In this manner, it would be understandable 
that individuals carrying Asp299Gly and Thr399Ile—which interfere with TLR4 
function—develop less atherosclerotic vascular events, such as carotid stenosis, 
acute coronary events, acute myocardial infarction, diabetic neuropathy, and 
allograft rejection [13]. On the other hand, TLRs, in particular TLR2, TLR4, TLR7, 
and TLR9, by the aid of adenosine, can succeed in angiogenesis after myocardial 
injury [12].
3.5 Infections
As described above, TLR4 is critical in recognizing LPS of gram-negative 
bacteria (GNB). People’s reactions are different to LPS inhalation and range 
from tolerance, i.e., no reaction, to strong asthma-like reactions. SNPs of human 
TLR4 gene, i.e., Asp299Gly and Thr399Ile, have been reported to affect the 
degree of reaction to LPS among healthy subjects and allergic asthmatic patients, 
development of septic shock by GNB, incidence of severe respiratory syncytial 
virus (RSV) bronchiolitis, risk of GNB colonization and of premature birth in 
pregnant women, and incidence of infections by GNB in patients on an intensive 
care unit [13].
3.6 Kidney diseases
Less is understood about the role of TLRs in kidney diseases. However, experi-
mental evidence suggests that all TLRs are involved in sepsis and renal infections. 
Each TLR has its own associations with distinct renal diseases as well (for review 
see [14]).
3.7 Liver diseases
In the liver, TLR expression is observed on a variety of cells including Kupffer 
cells (TLR2, TLR3, TLR4, and TLR9), hepatocytes (all TLRs), hepatic stellate cells 
(TLR2, TLR4, and TLR9), biliary epithelial cells (TLR2, TLR3, TLR4, and TLR5), 
sinusoidal epithelial cells (TLR4), hepatic dendritic cells (TLR2, TLR4, TLR7, and 
TLR9), hepatic natural killer cells (TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, and 
TLR9), and hepatic B cells (TLR2, TLR4, TLR7, and TLR9). Undoubtedly, such 
widely distrusted TLRs have been an important part of multiple liver diseases 
including infections of the liver by L. monocytogenes, and S. typhimurium, P. 
falciparum, hepatitis C virus, and hepatitis B virus, alcohol-induced liver diseases, 
nonalcoholic fatty liver disease, hepatic fibrosis, liver injury, liver regeneration, 
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As for other sections, TLRs present positive and negative effects in tumorigen-
esis which have been discussed in [16].
3.9 Other diseases
The possible role of TLRs in periodontal health, lung diseases, and dermatologi-
cal diseases has been reviewed in detail elsewhere [17–19].
4. Clinical implications
4.1 TLR agonists
TLR agonists have offered to help boosting the immune responses to vaccination 
as well as potential for immunotherapy of cancer, allergy, and infections. Three of 
which have received approval by the Food and Drug Administration (FDA) and are 
listed here:
 Bacillus Calmette-Guérin (BCG) can act as an agonist of TLR2/TLR4 and be 
used for treatment of superficial transitional cell carcinoma of the bladder.
 Monophosphoryl lipid A (MPL) can cause activation of TLR2/TLR4 recom-
mended for the prophylaxis of human papilloma virus (HPV)-associated 
cervical cancer.
 Imiquimod functions as a TLR7 agonist with implications for the treatment of 
actinic keratosis, basal cell carcinoma, and genital and perianal warts [20].
4.2 TLR antagonists
Antagonists targeting TLR-mediated signaling have displayed anti-inflamma-
tory features that may be effective against invading pathogens and autoimmune 
diseases.
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Natural killer (NK) cells represent a heterogeneous subpopulation of lym-
phocytes of the innate immune system with a powerful antitumor activity, a 
function given by a complex collection of receptors. They act synergistically 
to recognize, regulate, or amplify the response according to the microenviron-
ment, thus highlighting Toll-like receptors (TLRs), a type of receptors that 
allows sensing evolutionarily molecules conserved of pathogens known as 
pathogen-associated molecular patterns (PAMPs) and/or damage-associated 
molecular patterns (DAMPs). Those TLRs are essential to start the immune 
response. There is little information about the different subpopulations that 
form NK cells as well as their expression profile of innate immune response 
receptors in hematological cancers.
Keywords: Toll-like receptors, natural killer cells, innate immunity,  
pathogen-associated molecular patterns, damage-associated molecular  
patterns
1. Introduction
Natural killer (NK) cells represent a highly specialized subpopulation of 
lymphocytes that are part of the innate immune system, whose functions vary 
according to the microenvironment. NK cells are involved in the early defense 
against foreign cells or own cells subjected to some stress (bacterial infection, viral 
or tumor transformation) through the recruitment of neutrophils, macrophages, 
dendritic cells, or B/T lymphocytes. They induce an effective adaptive response; 
regulate, directly or indirectly, the activity of antigen-presenting cells (APCs); and 
activate T lymphocytes through the natural cytotoxic activity that characterizes 
them or through the production of cytokines and chemokines that generate an 
inflammatory environment [1, 2].
NK cells play an important role in the surveillance and suppression of tumor 
cells; despite the significant advances that have been reached in the last decades, it 
is still unknown if there is a direct relationship among the population dynamics, 
functionality, and the phenotype of these cells. Its role in the establishment and 
development of malignant hematological disorders such as acute lymphoblastic 
leukemia (ALL), a disease characterized by the uncontrolled proliferation of B or T 
lymphoid precursors, is still unknown.
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2. Overview of natural killer cells and toll-like receptors
2.1 NK cells
NK cells, although they are larger and present granules in their cytoplasm, 
morphologically are indistinguishable from the other lymphocytes. According to 
different authors, they comprise from 5 to 15% [3], 20% [2, 4], or even 25% [5] of 
total peripheral blood mononuclear cells and are derived from a CD34+ hematopoi-
etic progenitor, as are dendritic cells (DC) and B and T lymphocytes [6].
NK cells are phenotypically defined by the expression of CD56 (neural cell 
adhesion molecule (NCAM) and CD16a (also known as Fcγ-RIIIA), but not CD3 
and CD19, which are molecules of T and B lymphocytes, respectively [7, 8]. For a 
long time, they were considered as the only population of non-B or T lymphocytes. 
It is currently accepted that NK cells are within a subgroup of the so-called innate 
lymphoid cells (ILCs), whose subpopulations are differentiated according to the 
immunophenotype, the profile of cytokines they produce, and the transcription 
factors they possess [9, 10].
The NK cells were classified in group 1 of the ILCs (ILC1) due to their ability 
to produce INF-γ, but not cytokines such as IL-4, IL-5, IL-9, IL-13, IL-17, or IL-22, 
characteristic of the ILC2 and ILC3 groups, respectively [9, 11, 12]. Even within the 
same subgroup, they differ by having cytotoxic capacity and selectively expressing 
the eomesodermin (EOMES) transcription factor of other ILC non-NK that also 
produce INF-γ [13].
NK cells maintain a pro-inflammatory environment through the release of 
cytokines and recruit cells of the immune system to combat infectious agents 
through the release of chemokines [14] and regulate the activity of dendritic cells or 
activated lymphocytes [1]; they are in charge of antitumor surveillance and toler-
ance to healthy own cells, which conditions the rejection of transplants [15] among 
other functions.
In recent years, it has been reported that in addition to NK cytotoxic or regula-
tory NK cells, there are memory NK cells [16, 17] and NK cooperators, which 
secrete Th1-type cytokines (NK1) and Th2 (NK2) [18]. Even, NK cells are similar to 
antigen-presenting cells [19, 20], although this is in controversy.
2.2  Population diversification of NK cells and their role in the immune 
response
According to what was compiled by Huntington et al., NK cell precursors 
(NKPs) originate mainly in the bone marrow from hematopoietic precursor 
cells (HSCs), although they can also do so in organs such as the thymus from 
early lymphoid progenitor (ELP). These NKPs can mature into competent NK 
cells in the bone marrow or other organs, such as the liver, spleen, thymus, and 
lymphoid nodules, to finally enter to the circulation [21]. They migrate to other 
sites such as the lung, liver, mucous membranes and skin, uterus, pancreas, 
joints, and central nervous system (CNS), where they can exhibit unique char-
acteristics ranging from the increase or decrease of the expression of activation 
receptors or effector cytotoxic molecules to the modulation of resident immune 
cells (Figure 1) [22].
According to the expression of CD56 (NCAM), NK cells can be divided into two 
subpopulations: NKDim and NKBright. However, according to the relative expression 
of the CD56 and CD16 (FcγRIIIa) markers, their functionality, and their distribu-
tion in peripheral blood or lymphoid organs, it is possible to differentiate five 
subpopulations of mature NK cells (Figure 2).
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The NKBright populations, also known as NK regulators, comprise about 
10% of total peripheral blood NK cells. From these, about 50–70% have a 
[CD56High CD16Neg] phenotype and 30–50% a [CD56High/CD16Low] phenotype 
Figure 1. 
Origin and distribution of NK cells in humans. The precursors of NK cell precursor (NKP) can originate from 
hematopoietic progenitor cells (HSC) in the bone marrow or from early lymphoid progenitor (ELP). NK cells 
mature mainly in the bone marrow, although the immature NKP and NK (iNK) can recirculate among the 
liver, spleen, and lymphoid nodes as alternative maturation sites. Mature NK cells (mNK) that leave the bone 
marrow reach different organs through blood circulation where they reside and modify their phenotypic and 
functional characteristics.
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Subpopulations of NK cells in peripheral blood based on the relative expression of CD56 and CD16. 
(1) CD56Bright CD16Neg, recognized for its immunoregulatory activity, represents between 50 and 70% 
of the CD56Bright population; (2) CD56Bright CD16Dim represent between 30 and 50% of the CD56Bright 
population; (3) CD56Dim CD16Neg; (4) CD56Dim CD16Bright is recognized for its cytotoxic activity; and (5) 
CD56Neg CD16Bright whose function is still unknown. Modified from [23].
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2. Overview of natural killer cells and toll-like receptors
2.1 NK cells
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The NKBright populations, also known as NK regulators, comprise about 
10% of total peripheral blood NK cells. From these, about 50–70% have a 
[CD56High CD16Neg] phenotype and 30–50% a [CD56High/CD16Low] phenotype 
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hematopoietic progenitor cells (HSC) in the bone marrow or from early lymphoid progenitor (ELP). NK cells 
mature mainly in the bone marrow, although the immature NKP and NK (iNK) can recirculate among the 
liver, spleen, and lymphoid nodes as alternative maturation sites. Mature NK cells (mNK) that leave the bone 
marrow reach different organs through blood circulation where they reside and modify their phenotypic and 
functional characteristics.
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Subpopulations of NK cells in peripheral blood based on the relative expression of CD56 and CD16. 
(1) CD56Bright CD16Neg, recognized for its immunoregulatory activity, represents between 50 and 70% 
of the CD56Bright population; (2) CD56Bright CD16Dim represent between 30 and 50% of the CD56Bright 
population; (3) CD56Dim CD16Neg; (4) CD56Dim CD16Bright is recognized for its cytotoxic activity; and (5) 
CD56Neg CD16Bright whose function is still unknown. Modified from [23].
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[23]; they are mainly characterized by their poor cytotoxic capacity and their 
high capacity to secrete several types of post-activation cytokines, mainly 
INF-γ but also TNF-β, IL-5, IL-10, and IL-13 [7, 8] and constitutively some 
chemokines such as MIP-1α, MIP-1β, and RANTES [24]. They also have the 
ability to proliferate in culture when exposed to low doses of IL-2 (picomoles) 
compared to the cytotoxic NK cells, which does not show an evident prolifera-
tion under the same conditions [25]. The NKBright cells [CD56High CD16Neg] are 
assigned an exclusively regulatory function, since their cytotoxic activity is 
poor and their genetic profile is directed mainly to the production of cytokines 
and not to the cytotoxic activity, in comparison with the NKDim, whereas the 
NKBright subpopulation [CD56High CD16Low] is considered more as a transition 
phenotype [26]; because despite having the same characteristics of the previ-
ous phenotype, it has a lower rate of cell division when stimulated with IL-2 
and does not change its activity even with ligands for c-KIT [27]. It exhibits 
cytotoxic activity [28], and it has also been seen that it represents the high-
est percentage of NK cells in circulation in bone marrow transplants, until 
its normalization around the fourth month [29, 30]. NKBright cells are usually 
not found in peripheral blood, bone marrow, and spleen as they are mainly 
distributed in secondary lymphoid nodules (parafollicular zone of T cells) [31] 
and tonsils [32].
On the other hand, the NKDim population represents around 90% of peripheral 
blood NK cells; they have a phenotype [CD56Low CD16Neg] whose main function 
has not been well established [23] and a main phenotype [CD56Low CD16High] that 
exhibits potent cytotoxic activity. Although they are generally poor producers of 
cytokines [7, 8, 33], they tend to predominate in the spleen, peripheral blood, and 
bone marrow [32, 34].
It is important to clarify that the behavior of each subpopulation, in terms of 
post-activation secretion of cytokines and chemokines, will depend largely on the 
stimuli they receive either by recognizing target cells (tumor or transformed) or 
responding to exogenous cytokines.
Compared with NKDim cells, NKBright cells produce more TNF-α and INF-γ after 
activation with PMA/ionomycin [35] or exogenous cytokines such as IL-12, IL-15, 
or IL-18, alone or in combination [8].
On the contrary, when it comes to a response to the recognition of target cells, 
NKDim cells significantly increase their production of cytokines and chemokines 
compared to NKBright, such as MCP-1 (CCL2), IL-8 (CXCL8), IP-10 (CXCL10), 
soluble IL-2Rα (CD25), GM-CSF, and IL-5 and low levels of IL-1β, IL-6, IL-7, IL-10, 
IL-12p40, IFN-α, and MIG (CXCL9). In addition, it increases the production of 
chemokines such as MIP-1α (CCL3), MIP-1β (CCL4), and RANTES (CCL5) that 
produce constitutively [24].
The cytotoxic activity exhibited by NK cells does not require prior sensitization 
to kill their target cells, since it is not dependent on the presentation of a specific 
antigen as in the case of CD8+ T cells [7, 36] and can be mediated through membra-
nolitic and/or apoptotic mechanisms (Figure 3).
The membranolitic mechanisms include the production of perforins, enzymes 
that when integrated into the cell membrane form a pore that allows water to enter 
and cause osmotic lysis [37]. In the past, it was believed that both NKBright and 
NKDim cells had similar levels of perforins [38]; however, more recent studies by 
flow cytometry indicate that NKDim cells have at least 10 times more perforins than 
NKBright ones [35].
Regarding apoptotic mechanisms, these can induce the death of the target 
cell through complex mechanisms that involve both death-inducing proteins and 
specific ligand-receptor interactions through one of the following routes:
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2.3 Granzyme pathway
Granzymes are proteins capable of activating the apoptosis program [39] follow-
ing two mechanisms. The first does not depend on the activity of caspase proteins 
and is mediated mainly by granzyme A, and this fraction is single-stranded DNA 
(ssDNA) and interferes in the repair of genetic material without producing cell lysis 
[40, 41], while the second promotes the activity of caspase proteins and is mediated 
mainly by granzyme B [42].
The NK cell presents granzymes A, B, K, and M; NKDim cells present a high 
expression of granzymes A and B, whereas NKBright cells mainly express granzyme 
K [35, 43]. There are reports that NK cells express almost exclusively granzyme 
M; this enzyme is capable of mediating cell death independent of the activation of 
caspase proteins and in the presence of perforins, without fractionating DNA or 
producing changes in mitochondria [44].
In mice, deficient in granzymes A/B and/or perforins, it has been seen that there 
is uncontrolled growth of solid tumors, which suggests that these enzymes play an 
important role in the immunosurveillance of tumor cells mediated by NK cells [45].
2.4  NK cell ligand binding pathway to the cell death receptors expressed  
by the target cell
They include Fas ligands [FasL (CD95L)-Fas (CD95)] and/or the ligand that 
induces apoptosis related to tumor necrosis factor α (TRAIL) [46, 47].
2.5 Antibody-dependent cellular cytotoxicity (ADCC)
NK cells express FcγRIIC/CD32c [48] and FcγRIIIA/CD16a [34]. These recep-
tors interact with opsonized target cells, through the Fc regions of the antibodies, 
which combined with cellular antigens that cause the death of the target cell 
[49]. To through of mechanisms that involve the release of cytotoxic granules 
Figure 3. 
Recognition and elimination of abnormal cells by NK cells. NK cells possess the ability to discriminate normal 
cells of tumor or transformed cells by detecting alterations at the HLA-I level; the target cells are eliminated by 
membranolitic and/or apoptotic mechanisms.
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(perforin-granzyme), or by stimulation of apoptosis through of TNF-related 
apoptosis-inducing ligand (TRAIL) and/or by release of pro-inflammatory 
cytokines that promote the activity of other cells [50].
NKDim cells with [CD56Low CD16High] phenotype direct this mechanism in 
comparison with NKBright cells. Although it has been seen that the subpopulation 
with [CD56High CD16Low] phenotype exhibits low cytotoxic activity [51], NKDim 
cells [CD56Low CD16Neg] show a higher antitumor activity against cell lines (natural 
cytotoxicity) than other subpopulations [52]. This is supported by other studies 
where it is reported that NKDim cells [CD56Low CD16High] lose the expression of 
CD16 and increase the expression of CD107a (a degranulation marker), through a 
disintegrin and a metalloprotease-17 (ADAM-17), to become [CD56Low CD16Neg] 
with high cytotoxic capacity [53].
The role of the [CD56Neg CD16High] subpopulation is still not clearly defined. It is 
known that it is found in a low frequency in healthy individuals. It does not express 
surface molecules of other lymphoid lineages and that in chronic viral diseases, 
such as the human immunodeficiency virus (HIV). It presents changes in the 
level of expression of their activity receptors, characterized by the increase in the 
expression of inhibitory receptors and the decrease of natural cytotoxicity receptors 
(NCRs), together with other effector molecules that are hardly observed in healthy 
people [54–56].
It is considered that the [CD56Neg CD16High] subpopulation is dysfunctional in 
terms of its lytic and antiviral activity, although it retains the ability to produce 
pro-inflammatory chemokines [54–56].
Zulu et al. demonstrated that the HIV induces the expansion of the negative 
CD56 population of NK cells through the upregulation of NKG2C receptors and the 
negative regulation of Siglec-7, NKG2A, and CD57 receptors [57].
2.6 Receptors of the NK cells
NK cells have signals through a wide variety of receptors that allow them to 
respond to different types of stimuli and grant great flexibility when exercising 
their effector and/or cytotoxic function.
The function of the NK cell is given by a complex collection of receptors that act 
in a synergistic way to recognize, regulate, or amplify the response according to the 
microenvironment. Thus highlighting the pattern recognition receptors (PRRs), 
such as Toll-like receptors or natural cytotoxicity receptors, and inhibitory killing 
receptors (iNKRs), such as receptors that are activated during early response to 
pathogens, cells transformed by virus or tumor cells [58].
PRRs are a family of innate immune response receptors that recognize 
evolutionarily conserved microbial products whose activation favors the pro-
duction of pro-inflammatory cytokines. Within the PRR group, the TLRs are the 
most studied, although they are not the only ones; there are also the NOD-like 
receptors (NLRs) and the retinoid acid-inducible gene I (RIG-I)-like receptors 
(RLRs) [59].
NK cells express innate immune response receptors, such as NOD2, NLRP3, 
TLR3, TLR7, and TLR9, and promote the production of inflammatory cytokines 
and chemokines that are capable of amplifying the immune response [60]. The 
modulation of these cells through their innate immune response receptors, mainly 
via TLR, has gained interest and represents a promising therapeutic alternative 
against conditions such as cancer. Since there have been studies for a long time that 
support the possibility of its use, it has been observed that when ODNs (ligands of 
TLR9) are intraperitoneally administered in lymphoma murine models, an effective 
elimination of tumor cells occurs in 80% of cases [61].
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2.7 Toll-like receptors and their role in NK cells
Toll-like receptors are among the most important group of pattern recognition 
receptors, since they orchestrate a wide variety of activities related to the immune 
response.
These receptors recognize a wide variety of molecules evolutionarily conserved, 
associated with microorganisms, such as lipopolysaccharides, lipoproteins, mycolic 
acids, non-methylated DNA, and double-stranded RNA, generically known as 
pathogen-associated molecular patterns [62–64]. TLRs also recognize endogenous 
molecules called damage-associated molecular patterns, which originate from 
damaged cells [65] or are products of altered metabolism of transformed cells in 
conditions such as cancer [66, 67] and autoimmune diseases [67–70] or associated 
with chronic inflammation [71, 72]. They play an important role in the evolution of 
these conditions.
2.8 Overview of the toll-like receptors
Structurally, TLRs are type I integral glycoproteins that present an extracellular 
domain with leucine-rich repeats (LRRs) that are responsible for binding and dis-
criminating ligands (PAMPs or DAMPS) present in the cellular microenvironment. 
They have a transmembrane domain and an intracellular Toll/interleukin (IL)-1 
receptor (TIR) domain that triggers the signaling cascade via MyD88/TRIF and is 
highly conserved among each subfamily of TLRs [73].
There are 13 TLRs described in mammals, and 10 are found at the protein level 
in humans and differ according to their cellular localization and to the different 
PAMPs/DAMPs to which they respond. TLR11 in humans is a pseudogene, so it is 
not expressed [74].
The TLRs that are found mainly in the cell membrane are TLRs 1, 2, 4, 5, and 6.  
They sense structural components of bacteria, fungi, helminthes, or protozoa, 
whereas TLRs that are mainly found in intracellular compartments, such as TLRs 3, 
7, 8, and 9, sense nucleic acids of viral and/or bacterial origin [73, 75] (Figure 4).
The stimulation of the TLRs is capable of initiating an immune response to vari-
ous stimuli on its own, as well as of controlling the adaptive response through the 
inflammatory process with  the production of pro-inflammatory cytokines (IL-1β, 
IL-6, TNF-α), chemokines (IL-8, MCP-1) [76]; defensins [77]; type I interferons 
[78]; co-stimulation and MHC molecules [79]. The union between the different 
types of immune responses through the TLRs takes as a classic example the den-
dritic cells. They inspect their environment through the TLRs [80]; and once they 
detect a ligand (bacterial product, viral or stress protein),  increase the expression 
of co-stimulatory molecules capable of stimulating T naive cells [81] and polarizes 
the adaptive immune response toward Th1 or Th2 profiles [82].
The cellular response through direct stimulation with TLR ligands will depend 
largely on the type of lineage in question. The information that is reported about 
activity and expression in NK cells is relatively new, and it is more associated with 
innate antibacterial or antiviral immune response [83], but not in cancer.
2.9 Expression of TLRs in NK cells
The expression profile of TLRs in NK cells was initially limited to the detection 
of mRNA. However, the results do not always reflect the expression of the protein 
since it is difficult to identify the receptors in the NK cell.
NK cells express most of the human TLRs reported to date, although the detec-
tion and level of mRNA expression of each receptor vary depending on the author. 
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activity and expression in NK cells is relatively new, and it is more associated with 
innate antibacterial or antiviral immune response [83], but not in cancer.
2.9 Expression of TLRs in NK cells
The expression profile of TLRs in NK cells was initially limited to the detection 
of mRNA. However, the results do not always reflect the expression of the protein 
since it is difficult to identify the receptors in the NK cell.
NK cells express most of the human TLRs reported to date, although the detec-
tion and level of mRNA expression of each receptor vary depending on the author. 
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There are authors who indicate that NK cells express high levels of TLR1, followed 
by TLR2, TLR3, TLR5, TLR6, and low levels of TLR4 [85, 86]. Other authors agree 
that TLR2 and TLR3 have greater expression, followed by TLR5 and TLR6; in those 
studies, TLR1 mRNA was not quantified [87–89]. On the other hand, TLR7 [85, 89, 
90] and TLR10 [83, 86] present levels so low that they are practically undetectable.
There is a controversy about whether or not NK cells express TLR8 [86, 87, 89] 
and TLR9 [86, 88], although some authors point out that the cells constitutively 
express mRNA of all TLRs [85, 91, 92].
NK cells have higher levels of TLR3 mRNA than any other peripheral blood 
mononuclear cell, such as monocytes, B and T lymphocytes, or plasmacytoid 
dendritic cells [85].
Through techniques such as flow cytometry, Western blot, and immunopre-
cipitation, it is possible to know that NK cells of healthy people have a defined TLR 
expression profile (Table 1) and the expression of receptors is independent of their 
activation state [58].
In addition, there are variations in the level of TLR expression within the same 
subpopulations of NK cells. It is accepted that both NKBright and NKDim exhibit a 
similar mRNA profile of TLRs, although it is not always reflected at the protein level 
and there is a great controversy regarding the distribution and presence of some of 
these receptors in both subpopulations, especially TLR2, TLR4, and TLR3.
TLR2 and TLR4 are mainly distributed on the cell surface, whereas TLR3 is 
generally found in intracellular vesicles [75]; however, it has been seen that in NK 
cells, TLR3 is expressed both within [93] and on the cell surface [94]. There are 
publications reporting that TLR2 and TLR4 exhibit a marked intracellular distribu-
tion [95], although other authors indicate otherwise [96, 97].
The relative amount of some TLRs may vary according to the phenotype (Dim 
or Bright), although expression levels appear to be higher in cells with regulatory 
Figure 4. 
Toll-like receptors and their ligands. TLRs are transmembrane proteins of a glycoprotein nature that possess the 
ability to sense highly conserved microorganism molecules known as pathogen-associated molecular patterns 
(PAMPs), such as flagellin, LPS, or genetic material (ssDNA, ssRNA, dsDNA, dsRNA). In humans, 10 of the 
13 TLRs present in mammals have been detected [84].
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phenotype [89], which suggests that the type of response could be conditioned 
to promote a cytotoxic or immunomodulatory response when using one ligand or 
another in TLR activation assays (Table 2).
It has been seen that NKBright cells express more TLR1, TLR2, and TLR6 than 
NKDim [97], although other studies report that less than 1% of total NK cells express 
these three receptors [98].
NKDim cells can express, under normal conditions, more TLR4 than NKBright cells 
[99] although other authors seem to find no differences in the expression in TLR2, 
TLR4 [95], and TLR9 [95, 100].
There is no information about whether there is differential expression of TLRs 3, 
5, 7, or 8, and the distribution pattern of TLR5 is not known. However, it is inferred 
that NK cells express it, since they respond to flagellin and there are several studies 
that demonstrate it [88, 101, 102]. To date there are no reports about the presence, 
distribution, or role of TLR10 in NK cells.
The therapeutic use of TLR ligands in the modulation of NK cells against cancer, 
especially in malignant hematological disorders such as leukemia, is an interest-
ing alternative for the treatment of this type of diseases, since there are reports 
that reveal their therapeutic use as potential antitumor agents and as adjuvants in 
vaccines and other therapeutic modalities [103]. It is currently the subject of an 
extensive review by several research groups [104, 105].
TLR mRNA1 Protein Detection method
Presence
1 Very high Yes Flow cytometry [97]
Western blot [97]




3 High/moderate Yes Flow cytometry [93, 94]
Western blot [94]
4 Low Yes4 Flow cytometry [94, 95, 99]
5 High/moderate Yes5 S/R
6 High/moderate Yes Flow cytometry and Western blot [97]
7 Very low/undetectable Yes Flow cytometry [93, 94]
Western blot [94]
8 Low2 Yes Flow cytometry [94]
Western blot [90, 94]
9 Low2 Yes Flow cytometry [93, 95, 100]
Western blot [100]
10 Very low/undetectable N/R N/R
N/R, not reported.1The levels of relative expression are given according to what was reported by [85, 91] and refer to 
the comparison of expression among the 10 TLRs.
2There is a controversy whether or not they express mRNA of these TLRs, since some reports indicate that it was not 
possible to detect it.
3In previous studies, TLR2 could not be detected by flow cytometry or by immunoprecipitation.
4More recent studies indicate that it is expressed mainly as intracellular [95, 99].
5No reports were found indicating the presence of TLR5; however it is inferred that it is present as it responds specifically 
to flagellin [88, 101, 102], a molecule that it is only recognized through this receptor.
Table 1. 
Expression of TLRs in human natural killer cells.
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phenotype [89], which suggests that the type of response could be conditioned 
to promote a cytotoxic or immunomodulatory response when using one ligand or 
another in TLR activation assays (Table 2).
It has been seen that NKBright cells express more TLR1, TLR2, and TLR6 than 
NKDim [97], although other studies report that less than 1% of total NK cells express 
these three receptors [98].
NKDim cells can express, under normal conditions, more TLR4 than NKBright cells 
[99] although other authors seem to find no differences in the expression in TLR2, 
TLR4 [95], and TLR9 [95, 100].
There is no information about whether there is differential expression of TLRs 3, 
5, 7, or 8, and the distribution pattern of TLR5 is not known. However, it is inferred 
that NK cells express it, since they respond to flagellin and there are several studies 
that demonstrate it [88, 101, 102]. To date there are no reports about the presence, 
distribution, or role of TLR10 in NK cells.
The therapeutic use of TLR ligands in the modulation of NK cells against cancer, 
especially in malignant hematological disorders such as leukemia, is an interest-
ing alternative for the treatment of this type of diseases, since there are reports 
that reveal their therapeutic use as potential antitumor agents and as adjuvants in 
vaccines and other therapeutic modalities [103]. It is currently the subject of an 
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to flagellin [88, 101, 102], a molecule that it is only recognized through this receptor.
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In this chapter, we included the overview of NK cells, their population diversifi-
cation and role in the immune response, and their expression and role of TLRs.
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TLR Cellular localization Population distribution
1 Extracellular [97] NKBright > NKDim [97]
2 Extracellular [96, 97] and intracellular [95] NKBright > NKDim [97]
3 Intracellular [93] and extracellular1 [94] N/R
4 Extracellular [94] and intracellular2 [95, 99] NKBright < NKDim [99]
NKBright = NKDim [95]
5 N/R N/R
6 Extracellular [97] NKBright > NKDim [97]
7 Intracellular [93, 94] N/R
8 Intracellular [94] N/R4
9 Mainly intracellular3 [93, 95, 100] NKBright = NKDim5 [95]
10 N/R N/R
N/R, not reported.1It was found that both, in cell lines (NKL, NK92, and YT) and in NK of peripheral blood, TLR3 
is expressed on the surface [94].
2Studies that are more recent indicate that it is mainly expressed as intracellular [95, 99].
3TLR9 expression exists in plasma membrane, but it is quite low compared to intracellular expression.
4There are no studies that determine whether there is differential expression, although it has been seen that NKBright 
cells are better activated with ssRNA40 than NKDim cells, suggesting that the latter have a lower expression of 
TLR8.
5In other studies, it seems that NKDim cells express more TLR9 than NKBright cells and its expression conditions the 
response to ligands of this TLR [100].
Table 2. 
Localization and differential distribution of TLRs in human natural killer cells.
27
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 




Immunology and Proteomics Research Laboratory, Children’s Hospital of Mexico 
Federico Gómez, Mexico City, Mexico




In this chapter, we included the overview of NK cells, their population diversifi-
cation and role in the immune response, and their expression and role of TLRs.
Acknowledgment
We thank doctors Jacques Zimmer, MD, PhD, and Sankar Ghosh, PhD, for 
allowing us to use some of their figures, Figures 2 and 4, in this chapter of the 
book.
Conflict of interest
The authors declare that there is no conflict of interest.
TLR Cellular localization Population distribution
1 Extracellular [97] NKBright > NKDim [97]
2 Extracellular [96, 97] and intracellular [95] NKBright > NKDim [97]
3 Intracellular [93] and extracellular1 [94] N/R
4 Extracellular [94] and intracellular2 [95, 99] NKBright < NKDim [99]
NKBright = NKDim [95]
5 N/R N/R
6 Extracellular [97] NKBright > NKDim [97]
7 Intracellular [93, 94] N/R
8 Intracellular [94] N/R4
9 Mainly intracellular3 [93, 95, 100] NKBright = NKDim5 [95]
10 N/R N/R
N/R, not reported.1It was found that both, in cell lines (NKL, NK92, and YT) and in NK of peripheral blood, TLR3 
is expressed on the surface [94].
2Studies that are more recent indicate that it is mainly expressed as intracellular [95, 99].
3TLR9 expression exists in plasma membrane, but it is quite low compared to intracellular expression.
4There are no studies that determine whether there is differential expression, although it has been seen that NKBright 
cells are better activated with ssRNA40 than NKDim cells, suggesting that the latter have a lower expression of 
TLR8.
5In other studies, it seems that NKDim cells express more TLR9 than NKBright cells and its expression conditions the 
response to ligands of this TLR [100].
Table 2. 
Localization and differential distribution of TLRs in human natural killer cells.
27
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 




Immunology and Proteomics Research Laboratory, Children’s Hospital of Mexico 
Federico Gómez, Mexico City, Mexico
*Address all correspondence to: cmaldobe@yahoo.com
28
Toll-like Receptors
[1] LongEO KHS, Liu D, Peterson ME,  
Rajagopalan S. Controlling NK cell 
responses: Integration of signals 
for activation and inhibition. 
Annual Review of Immunology. 
2013;31:227-258. DOI: 10.1146/
annurev-immunol-020711-075005
[2] Campbell KS, Hasegawa J. Natural 
killer cell biology: An update and future 
directions. The Journal of Allergy and 
Clinical Immunology. 2013;132(3):536-
544. DOI: 10.1016/j.jaci.2013.07.006
[3] Cooper MA, Fehniger TA, 
Caligiuri MA. The biology of human 
natural killer-cell subsets. Trends in 
Immunology. 2001;22(11):633-640
[4] Rojas-Pandales F, Bolaños N, 
Mercado M, Gonzále JM, Cuéllar A, 
Cifuentes-Rojas C. Reference values of 
the natural killer cells (NK and NKT) 
on blood donors in Bogota. Acta médica 
colombiana. 2007;32(3):124-128
[5] Pittari G, Filippini P, Gentilcore G,  
Grivel JC, Rutella S. Revving up natural 
killer cells and cytokine-induced 
killer cells against hematological 
malignancies. Frontiers in Immunology. 
2015;6:230. DOI:  10.3389/
fimmu.2015.00230
[6] Galy A, Travis M, Cen D, Chen B.  
Human T, B, natural killer, and 
dendritic cells arise from a common 
bone marrow progenitor cell subset. 
Immunity. 1995;3(4):459-473
[7] Caliguri MA. Human natural killer 
cells. Blood. 2008;112(3):461-469. DOI: 
10.1182/blood-2007-09-077438
[8] Cooper MA, Fehniger TA, Turner 
SC, Chen KS, Ghaheri BA, Ghayur 
T, et al. Human natural killer cells: A 
unique innate immunoregulatory role 
for the CD56 bright subset. Blood. 
2001;97:3146-3151
[9] Walker JA, Barlow JL, McKenzie AN.  
Innate lymphoid cells—How did 
we miss them? Nature Reviews 
Immunology. 2013;13:75. DOI: 10.1038/
nri3349
[10] Spits H, Artis D, Colonna M, 
Diefenbach A, Di Santo JP, Eberl G, 
et al. Innate lymphoid cells—A proposal 
for uniform nomenclature. Nature 
Reviews Immunology. 2013;13:145-149. 
DOI: 10.1038/nri3365
[11] Artis D, Spits H. The biology 
of innate lymphoid cells. Nature. 
2015;517(7534):293-301. DOI: 10.1038/
nature14189
[12] Hazenberg MD, Spits H. Human 
innate lymphoid cells. Blood. 
2014;124(5):700-709. DOI: 10.1182/
blood-2013-11-427781
[13] Gordon SM, Chaix J, Rupp LJ, 
Wu J, Madera S, Sun JC, et al. The 
transcription factors T-bet and Eomes 
control key checkpoints of natural 
killer cell maturation. Immunity. 
2012;36(1):55-67. DOI: 10.1016/j.
immuni.2011.11.016
[14] Souza-Fonseca-Guimaraes F, 
Adib-Conquy M, Cavaillon JM. Natural 
killer (NK) cells in antibacterial innate 
immunity: Angels or devils? Molecular 
Medicine. 2012;18(1):270-285. DOI: 
10.2119/molmed.2011.00201
[15] Benichou G, Yamada Y, Aoyama A,  
Madsen JC. Natural killer cells in 
rejection and tolerance of solid organ 
allografts. Current Opinion in Organ 
Transplantation. 2011;16(1):47. DOI: 
10.1097/MOT.0b013e32834254cf
[16] Sun JC, Beilke JN, Lanier 
LL. Adaptive immune features 





Toll-Like Receptors and Natural Killer Cells
DOI: http://dx.doi.org/10.5772/intechopen.86393
[17] O’Sullivan TE, Sun JC, Lanier LL.  
Natural killer cell memory. Immunity. 
2015;43(4):634-645
[18] Kimura MY, Nakayama T.  
Differentiation of NK1 and NK2 cells. 
Critical Reviews in Immunology. 
2005;25(5):361-374. PMID: 16167886
[19] Spits H, Lanier LL. Natural killer or 
dendritic: What’s in a name? Immunity. 
2007;26(1):11-16
[20] Hanna J, Mandelboim O. Novel 
APC-like properties of human NK 
cells directly regulate T cell activation. 
The Journal of Clinical Investigation. 
2015;125(4):1763. DOI: 10.1172/JCI81527
[21] Huntington ND, Vosshenrich CA, Di 
Santo JP. Developmental pathways that 
generate natural-killer-cell diversity 
in mice and humans. Nature Reviews 
Immunology. 2007;7(9):703-714. DOI: 
10.1038/nri2154
[22] Shi FD, Ljunggren HG, La Cava A, 
Van Kaer L. Organ-specific features 
of natural killer cells. Nature Reviews 
Immunology. 2011;11(10):658
[23] Poli A, Michel T, Thérésine M, 
Andrès E, Hentges F, Zimmer J.  
CD56bright natural killer (NK) 
cells: An important NK cell subset. 
Immunology. 2009;126(4):458-465. 
DOI: 10.1111/j.1365-2567.2008.03027.x
[24] Fauriat C, Long EO, Ljunggren HG,  
Bryceson YT. Regulation of human 
NK-cell cytokine and chemokine 
production by target cell recognition. 
Blood. 2010;115(11):2167-2176. DOI: 
10.1182/blood-2009-08-238469
[25] Carson WE, Giri JG, Lindemann M, 
Linett ML, Ahdieh M, Paxton R, et al. 
Interleukin (IL) 15 is a novel cytokine 
that activates human natural killer cells 
via components of the IL-2 receptor. 
The Journal of Experimental Medicine. 
1994;180(4):1395-1403
[26] Béziat V, Duffy D, Quoc SN, 
Le Garff-Tavernier M, Decocq J, 
Combadière B, et al. CD56brightCD16+ 
NK cells: A functional intermediate 
stage of NK cell differentiation. Journal 
of Immunology. 2011;186(12):6753-
6761. DOI: 10.4049/jimmunol.1100330
[27] Carson WE, Fehniger TA,  
Caligiuri MA. CD56 bright natural killer 
cell subsets: Characterization of distinct 
functional responses to interleukin-2 
and the c-kit ligand. European Journal 
of Immunology. 1997;27(2):354-360. 
DOI: 10.1002/eji.1830270203
[28] Takahashi E, Kuranaga N, Satoh K,  
Habu Y, Shinomiya N, Asano T, et al. 
Induction of CD16+ CD56bright NK 
cells with antitumour cytotoxicity 
not only from CD16− CD56bright NK 
cells but also from CD16− CD56dim 
NK cells. Scandinavian Journal of 
Immunology. 2007;65(2):126-138. DOI: 
10.1111/j.1365-3083.2006.01883.x
[29] Gottschalk LR, Bray RA, Kaizer H, 
Gebel HM. Two populations of CD56 
(Leu-19)+/CD16+ cells in bone marrow 
transplant recipients. Bone Marrow 
Transplantation. 1990;5(4):259-264
[30] Jacobs R, Stoll M, Stratmann G,  
Leo R, Link H, Schmidt 
RE. CD16-CD56+ natural killer cells 
after bone marrow transplantation. 
Blood. 1992;79(12):3239-3244
[31] Fehniger TA, Cooper MA, Nuovo GJ, 
Cella M, Facchetti F, Colonna M, 
et al. CD56 bright natural killer cells 
are present in human lymph nodes 
and are activated by T cell–derived 
IL-2: A potential new link between 
adaptive and innate immunity. Blood. 
2003;101(8):3052-3057. DOI: 10.1182/
blood-2002-09-2876
[32] Ferlazzo G, Thomas D, Lin SL, 
Goodman K, Morandi B, Muller WA, 
et al. The abundant NK cells in human 
secondary lymphoid tissues require 
28
Toll-like Receptors
[1] LongEO KHS, Liu D, Peterson ME,  
Rajagopalan S. Controlling NK cell 
responses: Integration of signals 
for activation and inhibition. 
Annual Review of Immunology. 
2013;31:227-258. DOI: 10.1146/
annurev-immunol-020711-075005
[2] Campbell KS, Hasegawa J. Natural 
killer cell biology: An update and future 
directions. The Journal of Allergy and 
Clinical Immunology. 2013;132(3):536-
544. DOI: 10.1016/j.jaci.2013.07.006
[3] Cooper MA, Fehniger TA, 
Caligiuri MA. The biology of human 
natural killer-cell subsets. Trends in 
Immunology. 2001;22(11):633-640
[4] Rojas-Pandales F, Bolaños N, 
Mercado M, Gonzále JM, Cuéllar A, 
Cifuentes-Rojas C. Reference values of 
the natural killer cells (NK and NKT) 
on blood donors in Bogota. Acta médica 
colombiana. 2007;32(3):124-128
[5] Pittari G, Filippini P, Gentilcore G,  
Grivel JC, Rutella S. Revving up natural 
killer cells and cytokine-induced 
killer cells against hematological 
malignancies. Frontiers in Immunology. 
2015;6:230. DOI:  10.3389/
fimmu.2015.00230
[6] Galy A, Travis M, Cen D, Chen B.  
Human T, B, natural killer, and 
dendritic cells arise from a common 
bone marrow progenitor cell subset. 
Immunity. 1995;3(4):459-473
[7] Caliguri MA. Human natural killer 
cells. Blood. 2008;112(3):461-469. DOI: 
10.1182/blood-2007-09-077438
[8] Cooper MA, Fehniger TA, Turner 
SC, Chen KS, Ghaheri BA, Ghayur 
T, et al. Human natural killer cells: A 
unique innate immunoregulatory role 
for the CD56 bright subset. Blood. 
2001;97:3146-3151
[9] Walker JA, Barlow JL, McKenzie AN.  
Innate lymphoid cells—How did 
we miss them? Nature Reviews 
Immunology. 2013;13:75. DOI: 10.1038/
nri3349
[10] Spits H, Artis D, Colonna M, 
Diefenbach A, Di Santo JP, Eberl G, 
et al. Innate lymphoid cells—A proposal 
for uniform nomenclature. Nature 
Reviews Immunology. 2013;13:145-149. 
DOI: 10.1038/nri3365
[11] Artis D, Spits H. The biology 
of innate lymphoid cells. Nature. 
2015;517(7534):293-301. DOI: 10.1038/
nature14189
[12] Hazenberg MD, Spits H. Human 
innate lymphoid cells. Blood. 
2014;124(5):700-709. DOI: 10.1182/
blood-2013-11-427781
[13] Gordon SM, Chaix J, Rupp LJ, 
Wu J, Madera S, Sun JC, et al. The 
transcription factors T-bet and Eomes 
control key checkpoints of natural 
killer cell maturation. Immunity. 
2012;36(1):55-67. DOI: 10.1016/j.
immuni.2011.11.016
[14] Souza-Fonseca-Guimaraes F, 
Adib-Conquy M, Cavaillon JM. Natural 
killer (NK) cells in antibacterial innate 
immunity: Angels or devils? Molecular 
Medicine. 2012;18(1):270-285. DOI: 
10.2119/molmed.2011.00201
[15] Benichou G, Yamada Y, Aoyama A,  
Madsen JC. Natural killer cells in 
rejection and tolerance of solid organ 
allografts. Current Opinion in Organ 
Transplantation. 2011;16(1):47. DOI: 
10.1097/MOT.0b013e32834254cf
[16] Sun JC, Beilke JN, Lanier 
LL. Adaptive immune features 





Toll-Like Receptors and Natural Killer Cells
DOI: http://dx.doi.org/10.5772/intechopen.86393
[17] O’Sullivan TE, Sun JC, Lanier LL.  
Natural killer cell memory. Immunity. 
2015;43(4):634-645
[18] Kimura MY, Nakayama T.  
Differentiation of NK1 and NK2 cells. 
Critical Reviews in Immunology. 
2005;25(5):361-374. PMID: 16167886
[19] Spits H, Lanier LL. Natural killer or 
dendritic: What’s in a name? Immunity. 
2007;26(1):11-16
[20] Hanna J, Mandelboim O. Novel 
APC-like properties of human NK 
cells directly regulate T cell activation. 
The Journal of Clinical Investigation. 
2015;125(4):1763. DOI: 10.1172/JCI81527
[21] Huntington ND, Vosshenrich CA, Di 
Santo JP. Developmental pathways that 
generate natural-killer-cell diversity 
in mice and humans. Nature Reviews 
Immunology. 2007;7(9):703-714. DOI: 
10.1038/nri2154
[22] Shi FD, Ljunggren HG, La Cava A, 
Van Kaer L. Organ-specific features 
of natural killer cells. Nature Reviews 
Immunology. 2011;11(10):658
[23] Poli A, Michel T, Thérésine M, 
Andrès E, Hentges F, Zimmer J.  
CD56bright natural killer (NK) 
cells: An important NK cell subset. 
Immunology. 2009;126(4):458-465. 
DOI: 10.1111/j.1365-2567.2008.03027.x
[24] Fauriat C, Long EO, Ljunggren HG,  
Bryceson YT. Regulation of human 
NK-cell cytokine and chemokine 
production by target cell recognition. 
Blood. 2010;115(11):2167-2176. DOI: 
10.1182/blood-2009-08-238469
[25] Carson WE, Giri JG, Lindemann M, 
Linett ML, Ahdieh M, Paxton R, et al. 
Interleukin (IL) 15 is a novel cytokine 
that activates human natural killer cells 
via components of the IL-2 receptor. 
The Journal of Experimental Medicine. 
1994;180(4):1395-1403
[26] Béziat V, Duffy D, Quoc SN, 
Le Garff-Tavernier M, Decocq J, 
Combadière B, et al. CD56brightCD16+ 
NK cells: A functional intermediate 
stage of NK cell differentiation. Journal 
of Immunology. 2011;186(12):6753-
6761. DOI: 10.4049/jimmunol.1100330
[27] Carson WE, Fehniger TA,  
Caligiuri MA. CD56 bright natural killer 
cell subsets: Characterization of distinct 
functional responses to interleukin-2 
and the c-kit ligand. European Journal 
of Immunology. 1997;27(2):354-360. 
DOI: 10.1002/eji.1830270203
[28] Takahashi E, Kuranaga N, Satoh K,  
Habu Y, Shinomiya N, Asano T, et al. 
Induction of CD16+ CD56bright NK 
cells with antitumour cytotoxicity 
not only from CD16− CD56bright NK 
cells but also from CD16− CD56dim 
NK cells. Scandinavian Journal of 
Immunology. 2007;65(2):126-138. DOI: 
10.1111/j.1365-3083.2006.01883.x
[29] Gottschalk LR, Bray RA, Kaizer H, 
Gebel HM. Two populations of CD56 
(Leu-19)+/CD16+ cells in bone marrow 
transplant recipients. Bone Marrow 
Transplantation. 1990;5(4):259-264
[30] Jacobs R, Stoll M, Stratmann G,  
Leo R, Link H, Schmidt 
RE. CD16-CD56+ natural killer cells 
after bone marrow transplantation. 
Blood. 1992;79(12):3239-3244
[31] Fehniger TA, Cooper MA, Nuovo GJ, 
Cella M, Facchetti F, Colonna M, 
et al. CD56 bright natural killer cells 
are present in human lymph nodes 
and are activated by T cell–derived 
IL-2: A potential new link between 
adaptive and innate immunity. Blood. 
2003;101(8):3052-3057. DOI: 10.1182/
blood-2002-09-2876
[32] Ferlazzo G, Thomas D, Lin SL, 
Goodman K, Morandi B, Muller WA, 
et al. The abundant NK cells in human 
secondary lymphoid tissues require 
Toll-like Receptors
30
activation to express killer cell Ig-like 
receptors and become cytolytic. Journal 
of Immunology. 2004;172(3):1455-1462. 
DOI: 10.4049/jimmunol.172.3.1455
[33] Lanier LL, Ruitenberg JJ, Phillips JH.  
Functional and biochemical analysis of 
CD16 antigen on natural killer cells and 
granulocytes. Journal of Immunology. 
1988;141(10):3478-3485
[34] Yokoyama WM, Kim S, French AR.  
The dynamic life of natural killer 
cells. Annual Review of Immunology. 
2004;22:405-429. DOI: 10.1146/annurev.
immunol.22.012703.104711
[35] Jacobs R, Hintzen G, Kemper A, 
Beul K, Kempf S, Behrens G, et al. 
CD56bright cells differ in their KIR 
repertoire and cytotoxic features from 
CD56dim NK cells. European Journal  
of Immunology. 2001;31(10):3121-3126. 
DOI: 10.1002/1521-4141(2001010)31: 
10<3121:AID-IMMU3121gt;3.0.CO;2-4
[36] Kärre K. Natural killer cell 
recognition of missing self. Nature 
Immunology. 2008;9(5):477-480. DOI: 
10.1038/ni0508-477
[37] Podack ER. Functional significance 
of two cytolytic pathways of cytotoxic 
T lymphocytes. Journal of Leukocyte 
Biology. 1995;57(4):548-552
[38] Konjevic G, Schlesinger B,  
Cheng L, Olsen KJ, Podack ER, Spuzic I.  
Analysis of perforin expression in 
human peripheral blood lymphocytes, 
CD56+ natural killer cell subsets 
and its induction by interleukin-2. 
Immunological Investigations. 
1995;24(3):499-507
[39] Simon MM, Hausmann M, Tran T,  
Ebnet K, Tschopp J, ThaHla R, et al. In 
vitro- and ex vivo-derived cytolytic 
leukocytes from granzyme A × B double 
knockout mice are defective in granule-
mediated apoptosis but not lysis of 
target cells. The Journal of Experimental 
Medicine. 1997;186(10):1781-1786
[40] Beresford PJ, Xia Z, Greenberg AH,  
Lieberman J. Granzyme A loading 
induces rapid cytolysis and a novel 
form of DNA damage independently 
of caspase activation. Immunity. 1999, 
1999;10(5):585-595
[41] Lieberman J, Fan Z. Nuclear 
war: The granzyme A-bomb. 
Current Opinion in Immunology. 
2003;15(5):553-559
[42] King KL, Cidlowski JA. Cell cycle 
regulation and apoptosis. Annual 
Review of Physiology. 1998;60(1): 
601-617. DOI: 10.1146/annurev.
physiol.60.1.601
[43] Bratke K, Kuepper M, Bade B, 
Virchow JC, Luttmann W. Differential 
expression of human granzymes A, B,  
and K in natural killer cells and 
during CD8+ T cell differentiation in 
peripheral blood. European Journal of 
Immunology. 2005;35(9):2608-2616
[44] Kelly JM, Waterhouse NJ,  
Cretney E, Browne KA, Ellis S,  
Trapani JA, et al. Granzyme M mediates 
a novel form of perforin-dependent 
cell death. The Journal of Biological 
Chemistry. 2004;279(21):22236-22242. 
DOI: 10.1074/jbc.M401670200
[45] Pardo J, Balkow S, Anel A, Simon 
MM. Granzymes are essential for 
natural killer cell-mediated and 
perf-facilitated tumor control. 
European Journal of Immunology. 
2002;32(10):2881-2886. DOI: 
10.1002/1521-4141(2002010)32:10<2881
[46] Zamai L, Ahmad M, Bennett IM, 
Azzoni L, Alnemri ES, Perussia B.  
Natural killer (NK) cell-mediated 
cytotoxicity: Differential use of TRAIL 
and Fas ligand by immature and 
mature primary human NK cells. The 
Journal of Experimental Medicine. 
1998;188(12):2375-2380
[47] Srivastava S, Lundqvist A, Childs RW.  
Natural killer cell immunotherapy 
31
Toll-Like Receptors and Natural Killer Cells
DOI: http://dx.doi.org/10.5772/intechopen.86393
for cancer: A new hope. Cytotherapy. 
2008;10(8):775-783. DOI: 
10.1080/14653240802648181
[48] Morel PA, Ernst LK, Metes D.  
Functional CD32 molecules on 
human NK cells. Leukemia & 
Lymphoma. 1999;35(1-2):47-56. DOI: 
10.3109/10428199909145704
[49] Leibson PJ. Signal transduction 
during natural killer cell activation: 
Inside the mind of a killer. Immunity. 
1997;6(6):655-661. DOI: org/10.1016/
S1074-7613(00)80441-0
[50] Smyth MJ, Cretney E, Kelly JM, 
Westwood JA, Street SE, Yagita H,  
et al. Activation of NK cell 
cytotoxicity. Molecular Immunology. 
2005;42(4):501-510. DOI: 10.1016/j.
molimm.2004.07.034
[51] Nagler A, Lanier LL, Cwirla S, 
Phillips JH. Comparative studies of 
human FcRIII-positive and negative 
natural killer cells. Journal of 
Immunology. 1989;143(10):3183-3191
[52] Penack O, Gentilini C, Fischer L, 
Asemissen AM, Scheibenbogen C,  
Thiel E, et al. CD56 dim CD16 neg cells 
are responsible for natural cytotoxicity 
against tumor targets. Leukemia. 
2005;19(5):835-840. DOI: 10.1038/
sj.leu.2403704
[53] Romee R, Foley B, Lenvik T, 
Wang Y, Zhang B, Ankarlo D. NK cell 
CD16 surface expression and function 
is regulated by a disintegrin and 
metalloprotease-17 (ADAM17). Blood. 
2013;121(18):3599-3608. DOI: 10.1182/
blood-2012-04-425397
[54] Tarazona R, Casado JG, Delarosa O, 
Torre-Cisneros J, Villanueva JL,  
Sanchez B, et al. Selective depletion 
of CD56 dim NK cell subsets and 
maintenance of CD56 bright NK cells 
in treatment-naive HIV-1-seropositive 
individuals. Journal of Clinical 
Immunology. 2002;22(3):176-183
[55] Mavilio D, Lombardo G,  
Benjamin J, Kim D, Follman D, 
Marcenaro E, et al. Characterization 
of CD56–/CD16+ natural killer (NK) 
cells: A highly dysfunctional NK subset 
expanded in HIV-infected viremic 
individuals. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2005;102(8):2886-
2891. DOI: 10.1073/pnas.0409872102
[56] Björkström NK, Ljunggren HG, 
Sandberg JK. CD56 negative NK cells: 
Origin, function, and role in chronic 
viral disease. Trends in Immunology. 
2010;31(11):401-406. DOI: 10.1016/j.
it.2010.08.003
[57] Zulu MZ, Naidoo KK, Mncube Z, 
Jaggernath M, Goulder PJ, Ndung'u T, 
et al. Reduced expression of Siglec-7, 
NKG2A, and CD57 on terminally 
differentiated CD56− CD16+ natural 
killer cell subset is associated with 
natural killer cell dysfunction in 
chronic HIV-1 clade C infection. AIDS 
Research and Human Retroviruses. 
2017;33(12):1205-1213. DOI: 10.1089/
AID.2017.0095
[58] Sivori S, Carlomagno S, Pesce S, 
Moretta A, Vitale M, Marcenaro E. TLR/
NCR/KIR: Which one to use and when? 
Frontiers in Immunology. 2014;5:105. 
DOI: 10.3389/fimmu.2014.00105
[59] Mogensen TH. Pathogen recognition 
and inflammatory signaling in innate 
immune defenses. Clinical Microbiology 
Reviews. 2009;22(2):240-273. DOI: 
10.1128/CMR.00046-08
[60] Qiu F, Maniar A, Diaz MQ , 
Chapoval AI, Medvedev AE. Activation 
of cytokine-producing and antitumor 
activities of natural killer cells and 
macrophages by engagement of toll-
like and NOD-like receptors. Innate 
Immunity. 2011;17(4):375-387. DOI: 
10.1177/1753425910372000




activation to express killer cell Ig-like 
receptors and become cytolytic. Journal 
of Immunology. 2004;172(3):1455-1462. 
DOI: 10.4049/jimmunol.172.3.1455
[33] Lanier LL, Ruitenberg JJ, Phillips JH.  
Functional and biochemical analysis of 
CD16 antigen on natural killer cells and 
granulocytes. Journal of Immunology. 
1988;141(10):3478-3485
[34] Yokoyama WM, Kim S, French AR.  
The dynamic life of natural killer 
cells. Annual Review of Immunology. 
2004;22:405-429. DOI: 10.1146/annurev.
immunol.22.012703.104711
[35] Jacobs R, Hintzen G, Kemper A, 
Beul K, Kempf S, Behrens G, et al. 
CD56bright cells differ in their KIR 
repertoire and cytotoxic features from 
CD56dim NK cells. European Journal  
of Immunology. 2001;31(10):3121-3126. 
DOI: 10.1002/1521-4141(2001010)31: 
10<3121:AID-IMMU3121gt;3.0.CO;2-4
[36] Kärre K. Natural killer cell 
recognition of missing self. Nature 
Immunology. 2008;9(5):477-480. DOI: 
10.1038/ni0508-477
[37] Podack ER. Functional significance 
of two cytolytic pathways of cytotoxic 
T lymphocytes. Journal of Leukocyte 
Biology. 1995;57(4):548-552
[38] Konjevic G, Schlesinger B,  
Cheng L, Olsen KJ, Podack ER, Spuzic I.  
Analysis of perforin expression in 
human peripheral blood lymphocytes, 
CD56+ natural killer cell subsets 
and its induction by interleukin-2. 
Immunological Investigations. 
1995;24(3):499-507
[39] Simon MM, Hausmann M, Tran T,  
Ebnet K, Tschopp J, ThaHla R, et al. In 
vitro- and ex vivo-derived cytolytic 
leukocytes from granzyme A × B double 
knockout mice are defective in granule-
mediated apoptosis but not lysis of 
target cells. The Journal of Experimental 
Medicine. 1997;186(10):1781-1786
[40] Beresford PJ, Xia Z, Greenberg AH,  
Lieberman J. Granzyme A loading 
induces rapid cytolysis and a novel 
form of DNA damage independently 
of caspase activation. Immunity. 1999, 
1999;10(5):585-595
[41] Lieberman J, Fan Z. Nuclear 
war: The granzyme A-bomb. 
Current Opinion in Immunology. 
2003;15(5):553-559
[42] King KL, Cidlowski JA. Cell cycle 
regulation and apoptosis. Annual 
Review of Physiology. 1998;60(1): 
601-617. DOI: 10.1146/annurev.
physiol.60.1.601
[43] Bratke K, Kuepper M, Bade B, 
Virchow JC, Luttmann W. Differential 
expression of human granzymes A, B,  
and K in natural killer cells and 
during CD8+ T cell differentiation in 
peripheral blood. European Journal of 
Immunology. 2005;35(9):2608-2616
[44] Kelly JM, Waterhouse NJ,  
Cretney E, Browne KA, Ellis S,  
Trapani JA, et al. Granzyme M mediates 
a novel form of perforin-dependent 
cell death. The Journal of Biological 
Chemistry. 2004;279(21):22236-22242. 
DOI: 10.1074/jbc.M401670200
[45] Pardo J, Balkow S, Anel A, Simon 
MM. Granzymes are essential for 
natural killer cell-mediated and 
perf-facilitated tumor control. 
European Journal of Immunology. 
2002;32(10):2881-2886. DOI: 
10.1002/1521-4141(2002010)32:10<2881
[46] Zamai L, Ahmad M, Bennett IM, 
Azzoni L, Alnemri ES, Perussia B.  
Natural killer (NK) cell-mediated 
cytotoxicity: Differential use of TRAIL 
and Fas ligand by immature and 
mature primary human NK cells. The 
Journal of Experimental Medicine. 
1998;188(12):2375-2380
[47] Srivastava S, Lundqvist A, Childs RW.  
Natural killer cell immunotherapy 
31
Toll-Like Receptors and Natural Killer Cells
DOI: http://dx.doi.org/10.5772/intechopen.86393
for cancer: A new hope. Cytotherapy. 
2008;10(8):775-783. DOI: 
10.1080/14653240802648181
[48] Morel PA, Ernst LK, Metes D.  
Functional CD32 molecules on 
human NK cells. Leukemia & 
Lymphoma. 1999;35(1-2):47-56. DOI: 
10.3109/10428199909145704
[49] Leibson PJ. Signal transduction 
during natural killer cell activation: 
Inside the mind of a killer. Immunity. 
1997;6(6):655-661. DOI: org/10.1016/
S1074-7613(00)80441-0
[50] Smyth MJ, Cretney E, Kelly JM, 
Westwood JA, Street SE, Yagita H,  
et al. Activation of NK cell 
cytotoxicity. Molecular Immunology. 
2005;42(4):501-510. DOI: 10.1016/j.
molimm.2004.07.034
[51] Nagler A, Lanier LL, Cwirla S, 
Phillips JH. Comparative studies of 
human FcRIII-positive and negative 
natural killer cells. Journal of 
Immunology. 1989;143(10):3183-3191
[52] Penack O, Gentilini C, Fischer L, 
Asemissen AM, Scheibenbogen C,  
Thiel E, et al. CD56 dim CD16 neg cells 
are responsible for natural cytotoxicity 
against tumor targets. Leukemia. 
2005;19(5):835-840. DOI: 10.1038/
sj.leu.2403704
[53] Romee R, Foley B, Lenvik T, 
Wang Y, Zhang B, Ankarlo D. NK cell 
CD16 surface expression and function 
is regulated by a disintegrin and 
metalloprotease-17 (ADAM17). Blood. 
2013;121(18):3599-3608. DOI: 10.1182/
blood-2012-04-425397
[54] Tarazona R, Casado JG, Delarosa O, 
Torre-Cisneros J, Villanueva JL,  
Sanchez B, et al. Selective depletion 
of CD56 dim NK cell subsets and 
maintenance of CD56 bright NK cells 
in treatment-naive HIV-1-seropositive 
individuals. Journal of Clinical 
Immunology. 2002;22(3):176-183
[55] Mavilio D, Lombardo G,  
Benjamin J, Kim D, Follman D, 
Marcenaro E, et al. Characterization 
of CD56–/CD16+ natural killer (NK) 
cells: A highly dysfunctional NK subset 
expanded in HIV-infected viremic 
individuals. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2005;102(8):2886-
2891. DOI: 10.1073/pnas.0409872102
[56] Björkström NK, Ljunggren HG, 
Sandberg JK. CD56 negative NK cells: 
Origin, function, and role in chronic 
viral disease. Trends in Immunology. 
2010;31(11):401-406. DOI: 10.1016/j.
it.2010.08.003
[57] Zulu MZ, Naidoo KK, Mncube Z, 
Jaggernath M, Goulder PJ, Ndung'u T, 
et al. Reduced expression of Siglec-7, 
NKG2A, and CD57 on terminally 
differentiated CD56− CD16+ natural 
killer cell subset is associated with 
natural killer cell dysfunction in 
chronic HIV-1 clade C infection. AIDS 
Research and Human Retroviruses. 
2017;33(12):1205-1213. DOI: 10.1089/
AID.2017.0095
[58] Sivori S, Carlomagno S, Pesce S, 
Moretta A, Vitale M, Marcenaro E. TLR/
NCR/KIR: Which one to use and when? 
Frontiers in Immunology. 2014;5:105. 
DOI: 10.3389/fimmu.2014.00105
[59] Mogensen TH. Pathogen recognition 
and inflammatory signaling in innate 
immune defenses. Clinical Microbiology 
Reviews. 2009;22(2):240-273. DOI: 
10.1128/CMR.00046-08
[60] Qiu F, Maniar A, Diaz MQ , 
Chapoval AI, Medvedev AE. Activation 
of cytokine-producing and antitumor 
activities of natural killer cells and 
macrophages by engagement of toll-
like and NOD-like receptors. Innate 
Immunity. 2011;17(4):375-387. DOI: 
10.1177/1753425910372000





CpG motifs enhance the 
efficacy of monoclonal antibody 
therapy of lymphoma. Blood. 
1997;89(8):2994-2998
[62] Janeway CA Jr, Medzhitov R. Innate 




[63] Iwasaki A, Medzhitov R. 
 Toll-like receptor control of the 
adaptive immune responses. Nature 
Immunology. 2004;5(10):987-995. DOI: 
10.1038/ni1112
[64] De Nardo D. Toll-like receptors: 
Activation, signalling and 
transcriptional modulation. Cytokine. 
2015;74(2):181-189. DOI: 10.1016/j.
cyto.2015.02.025
[65] Zhang Z, Schluesener HJ.  
Mammalian toll-like receptors: 
From endogenous ligands to tissue 
regeneration. Cellular and Molecular 
Life Sciences. 2006;63(24):2901-2907. 
DOI: 10.1007/s00018-006-6189-1
[66] Demaria S, Pikarsky E, Karin M, 
Coussens LM, Chen YC, El-Omar EM,  
et al. Cancer and inflammation: 
Promise for biological therapy. J 
Immunother (Hagerstown, Md.: 1997). 
2010;33(4):335-351. DOI: 10.1097/
CJI.0b013e3181d32e74
[67] Łagiedo M, Sikora J, Kaczmarek M.  
Damage-associated molecular patterns 
in the course of lung cancer—A review. 
Scandinavian Journal of Immunology. 
2015;82(2):95-101. DOI: 10.1111/
sji.12308
[68] Rifkin IR, Leadbetter EA, 
Busconi L, Viglianti G, Marshak-
Rothstein A. Toll-like receptors, 
endogenous ligands, and systemic 
autoimmune disease. Immunological 
Reviews. 2005;20(1):27-42. DOI: 
10.1111/j.0105-2896.2005.00239.x
[69] Marshak-Rothstein A. Toll-like 
receptors in systemic autoimmune 
disease. Nature Reviews Immunology. 
2006;6(11):823-835. DOI: 10.1038/
nri1957
[70] Goh FG, Midwood KS. Intrinsic 
danger: Activation of toll-like receptors 
in rheumatoid arthritis. Rheumatology. 
2012;51(1):7-23. DOI: 10.1093/
rheumatology/ker257
[71] Drexler SK, Foxwell BM. The role of 
toll-like receptors in chronic inflammation. 
The International Journal of Biochemistry 
& Cell Biology. 2010;42(4):506-518. DOI: 
10.1016/j.biocel.2009.10.009
[72] Joosten LA, Abdollahi-Roodsaz S, 
Dinarello CA, O'Neill L, Netea MG.  
Toll-like receptors and chronic 
inflammation in rheumatic diseases: 
New developments. Nature Reviews 
Rheumatology. 2016;12(6):344-357. 
DOI: 10.1038/nrrheum.2016.61
[73] Liu Q , Ding JL. The molecular 
mechanisms of TLR-signaling cooperation 
in cytokine regulation. Immunology and 
Cell Biology. 2016;94(6):538-542. DOI: 
10.1038/icb.2016.18
[74] Roach JC, Glusman G, Rowen L, 
Kaur A, Purcell MK, Smith KD, et al. 
The evolution of vertebrate Toll-like 
receptors. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2005;102(27): 
9577-9582. DOI: 10.1073/
pnas.0502272102
[75] Uematsu S, Akira S. Toll-like 
receptors and type I interferons. 
The Journal of Biological Chemistry. 
2007;282(21):15319-15323. DOI: 
10.1074/jbc.R700009200
[76] Gaudreault E, Fiola S, Olivier M, 
Gosselin J. Epstein-Barr virus induces 
MCP-1 secretion by human monocytes 




Toll-Like Receptors and Natural Killer Cells
DOI: http://dx.doi.org/10.5772/intechopen.86393
[77] Hertz CJ, Wu Q , Porter EM,  
Zhang YJ, Weismüller KH, Godowski PJ, 
et al. Activation of toll-like receptor 2 
on human tracheobronchial epithelial 
cells induces the antimicrobial peptide 
human β defensin-2. Journal of 
Immunology. 2003;171(12):6820-6826. 
DOI: 10.4049/jimmunol.171.12.6820
[78] Guillot L, Le Goffic R, Bloch S, 
Escriou N, Akira S, Chignard M, et al. 
Involvement of toll-like receptor 3 in the 
immune response of lung epithelial cells 
to double-stranded RNA and influenza 
a virus. The Journal of Biological 
Chemistry. 2005;280(7):5571-5580. 
DOI: 10.1074/jbc.M410592200
[79] Vivier E, Biron CA. A pathogen 
receptor on natural killer cells. Science. 
2002;296(5571):1248-1249. DOI: 
10.1126/science.1072447
[80] Kadowaki N, Antonenko S, Ho S, 
Rissoan MC, Soumelis V, Porcelli SA,  
et al. Distinct cytokine profiles of 
neonatal natural killer T cells after 
expansion with subsets of dendritic 
cells. The Journal of Experimental 
Medicine. 2001;193(10):1221-1226
[81] Uehori J, Matsumoto M, Tsuji S, 
Akazawa T, Takeuchi O, Akira S,  
et al. Simultaneous blocking of 
human Toll-like receptors 2 and 4 
suppresses myeloid dendritic cell 
activation induced by Mycobacterium 
bovis bacillus Calmette-Guerin 
peptidoglycan. Infection and Immunity. 
2003;71(8):4238-4249. DOI: 10.1128/
IAI.71.8.4238-4249.2003
[82] Cella M, Salio M, Sakakibara Y, 
Langen H, Julkunen I, Lanzavecchia A.  
Maturation, activation, and 
protection of dendritic cells induced 
by double-stranded RNA. The 
Journal of Experimental Medicine. 
1999;189(5):821-829
[83] Adib-Conquy M, Scott-Algara D, 
Cavaillon JM, Souza-Fonseca-Guimaraes 
F. TLR-mediated activation of NK cells 
and their role in bacterial/viral immune 
responses in mammals. Immunology 
and Cell Biology. 2014;92(3):256-262. 
DOI: 10.1038/icb.2013.99
[84] Hayden MS, Ghosh S. NF-κB 
in immunobiology. Cell Research. 
2011;21(2):223-244. DOI: 10.1038/
cr.2011.13
[85] Hornung V, Rothenfusser S,  
Britsch S, Krug A, Jahrshdörfer B, Giese 
T, et al. Quantitative expression of 
toll-like receptor 1-10 mRNA in cellular 
subsets of human peripheral blood 
mononuclear cells and sensitivity to 
CpG oligodeoxynucleotides. Journal of 
Immunology. 2002;168(9):4531-4537. 
DOI: 10.4049/jimmunol.168.9.4531
[86] He S, Chu J, Wu LC, Mao H,  
Peng Y, Alvarez-Breckenridge CA, et al. 
MicroRNAs activate natural killer cells 
through toll-like receptor signaling. 
Blood. 2013;121(23):4663-4671. DOI: 
10.1182/blood-2012-07-441360
[87] Saikh KU, Lee JS, Kissner TL, 
Dyas B, Ulrich RG. Toll-like receptor 
and cytokine expression patterns of 
CD56+ T cells are similar to natural 
killer cells in response to infection with 
Venezuelan equine encephalitis virus 
replicons. The Journal of Infectious 
Diseases. 2003;188(10):1562-1570. DOI: 
10.1086/379196
[88] Chalifour A, Jeannin P, Gauchat JF, 
Blaecke A, Malissard M, N’Guyen T,  
et al. Direct bacterial protein PAMP 
recognition by human NK cells 
involves TLRs and triggers α-defensin 
production. Blood. 2004;104(6):1778-
1783. DOI: 10.1182/blood-2003-08-2820
[89] Gorski KS, Waller EL, Bjornton-
Severson J, Hanten JA, Riter CL, 
Kieper WC, et al. Distinct indirect 
pathways govern human NK-cell 
activation by TLR-7 and TLR-8 






CpG motifs enhance the 
efficacy of monoclonal antibody 
therapy of lymphoma. Blood. 
1997;89(8):2994-2998
[62] Janeway CA Jr, Medzhitov R. Innate 




[63] Iwasaki A, Medzhitov R. 
 Toll-like receptor control of the 
adaptive immune responses. Nature 
Immunology. 2004;5(10):987-995. DOI: 
10.1038/ni1112
[64] De Nardo D. Toll-like receptors: 
Activation, signalling and 
transcriptional modulation. Cytokine. 
2015;74(2):181-189. DOI: 10.1016/j.
cyto.2015.02.025
[65] Zhang Z, Schluesener HJ.  
Mammalian toll-like receptors: 
From endogenous ligands to tissue 
regeneration. Cellular and Molecular 
Life Sciences. 2006;63(24):2901-2907. 
DOI: 10.1007/s00018-006-6189-1
[66] Demaria S, Pikarsky E, Karin M, 
Coussens LM, Chen YC, El-Omar EM,  
et al. Cancer and inflammation: 
Promise for biological therapy. J 
Immunother (Hagerstown, Md.: 1997). 
2010;33(4):335-351. DOI: 10.1097/
CJI.0b013e3181d32e74
[67] Łagiedo M, Sikora J, Kaczmarek M.  
Damage-associated molecular patterns 
in the course of lung cancer—A review. 
Scandinavian Journal of Immunology. 
2015;82(2):95-101. DOI: 10.1111/
sji.12308
[68] Rifkin IR, Leadbetter EA, 
Busconi L, Viglianti G, Marshak-
Rothstein A. Toll-like receptors, 
endogenous ligands, and systemic 
autoimmune disease. Immunological 
Reviews. 2005;20(1):27-42. DOI: 
10.1111/j.0105-2896.2005.00239.x
[69] Marshak-Rothstein A. Toll-like 
receptors in systemic autoimmune 
disease. Nature Reviews Immunology. 
2006;6(11):823-835. DOI: 10.1038/
nri1957
[70] Goh FG, Midwood KS. Intrinsic 
danger: Activation of toll-like receptors 
in rheumatoid arthritis. Rheumatology. 
2012;51(1):7-23. DOI: 10.1093/
rheumatology/ker257
[71] Drexler SK, Foxwell BM. The role of 
toll-like receptors in chronic inflammation. 
The International Journal of Biochemistry 
& Cell Biology. 2010;42(4):506-518. DOI: 
10.1016/j.biocel.2009.10.009
[72] Joosten LA, Abdollahi-Roodsaz S, 
Dinarello CA, O'Neill L, Netea MG.  
Toll-like receptors and chronic 
inflammation in rheumatic diseases: 
New developments. Nature Reviews 
Rheumatology. 2016;12(6):344-357. 
DOI: 10.1038/nrrheum.2016.61
[73] Liu Q , Ding JL. The molecular 
mechanisms of TLR-signaling cooperation 
in cytokine regulation. Immunology and 
Cell Biology. 2016;94(6):538-542. DOI: 
10.1038/icb.2016.18
[74] Roach JC, Glusman G, Rowen L, 
Kaur A, Purcell MK, Smith KD, et al. 
The evolution of vertebrate Toll-like 
receptors. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2005;102(27): 
9577-9582. DOI: 10.1073/
pnas.0502272102
[75] Uematsu S, Akira S. Toll-like 
receptors and type I interferons. 
The Journal of Biological Chemistry. 
2007;282(21):15319-15323. DOI: 
10.1074/jbc.R700009200
[76] Gaudreault E, Fiola S, Olivier M, 
Gosselin J. Epstein-Barr virus induces 
MCP-1 secretion by human monocytes 




Toll-Like Receptors and Natural Killer Cells
DOI: http://dx.doi.org/10.5772/intechopen.86393
[77] Hertz CJ, Wu Q , Porter EM,  
Zhang YJ, Weismüller KH, Godowski PJ, 
et al. Activation of toll-like receptor 2 
on human tracheobronchial epithelial 
cells induces the antimicrobial peptide 
human β defensin-2. Journal of 
Immunology. 2003;171(12):6820-6826. 
DOI: 10.4049/jimmunol.171.12.6820
[78] Guillot L, Le Goffic R, Bloch S, 
Escriou N, Akira S, Chignard M, et al. 
Involvement of toll-like receptor 3 in the 
immune response of lung epithelial cells 
to double-stranded RNA and influenza 
a virus. The Journal of Biological 
Chemistry. 2005;280(7):5571-5580. 
DOI: 10.1074/jbc.M410592200
[79] Vivier E, Biron CA. A pathogen 
receptor on natural killer cells. Science. 
2002;296(5571):1248-1249. DOI: 
10.1126/science.1072447
[80] Kadowaki N, Antonenko S, Ho S, 
Rissoan MC, Soumelis V, Porcelli SA,  
et al. Distinct cytokine profiles of 
neonatal natural killer T cells after 
expansion with subsets of dendritic 
cells. The Journal of Experimental 
Medicine. 2001;193(10):1221-1226
[81] Uehori J, Matsumoto M, Tsuji S, 
Akazawa T, Takeuchi O, Akira S,  
et al. Simultaneous blocking of 
human Toll-like receptors 2 and 4 
suppresses myeloid dendritic cell 
activation induced by Mycobacterium 
bovis bacillus Calmette-Guerin 
peptidoglycan. Infection and Immunity. 
2003;71(8):4238-4249. DOI: 10.1128/
IAI.71.8.4238-4249.2003
[82] Cella M, Salio M, Sakakibara Y, 
Langen H, Julkunen I, Lanzavecchia A.  
Maturation, activation, and 
protection of dendritic cells induced 
by double-stranded RNA. The 
Journal of Experimental Medicine. 
1999;189(5):821-829
[83] Adib-Conquy M, Scott-Algara D, 
Cavaillon JM, Souza-Fonseca-Guimaraes 
F. TLR-mediated activation of NK cells 
and their role in bacterial/viral immune 
responses in mammals. Immunology 
and Cell Biology. 2014;92(3):256-262. 
DOI: 10.1038/icb.2013.99
[84] Hayden MS, Ghosh S. NF-κB 
in immunobiology. Cell Research. 
2011;21(2):223-244. DOI: 10.1038/
cr.2011.13
[85] Hornung V, Rothenfusser S,  
Britsch S, Krug A, Jahrshdörfer B, Giese 
T, et al. Quantitative expression of 
toll-like receptor 1-10 mRNA in cellular 
subsets of human peripheral blood 
mononuclear cells and sensitivity to 
CpG oligodeoxynucleotides. Journal of 
Immunology. 2002;168(9):4531-4537. 
DOI: 10.4049/jimmunol.168.9.4531
[86] He S, Chu J, Wu LC, Mao H,  
Peng Y, Alvarez-Breckenridge CA, et al. 
MicroRNAs activate natural killer cells 
through toll-like receptor signaling. 
Blood. 2013;121(23):4663-4671. DOI: 
10.1182/blood-2012-07-441360
[87] Saikh KU, Lee JS, Kissner TL, 
Dyas B, Ulrich RG. Toll-like receptor 
and cytokine expression patterns of 
CD56+ T cells are similar to natural 
killer cells in response to infection with 
Venezuelan equine encephalitis virus 
replicons. The Journal of Infectious 
Diseases. 2003;188(10):1562-1570. DOI: 
10.1086/379196
[88] Chalifour A, Jeannin P, Gauchat JF, 
Blaecke A, Malissard M, N’Guyen T,  
et al. Direct bacterial protein PAMP 
recognition by human NK cells 
involves TLRs and triggers α-defensin 
production. Blood. 2004;104(6):1778-
1783. DOI: 10.1182/blood-2003-08-2820
[89] Gorski KS, Waller EL, Bjornton-
Severson J, Hanten JA, Riter CL, 
Kieper WC, et al. Distinct indirect 
pathways govern human NK-cell 
activation by TLR-7 and TLR-8 





[90] Alter G, Suscovich TJ, Teigen N, Meier 
A, Streeck H, Brander C, et al. Single-
stranded RNA derived from HIV-1 serves 
as a potent activator of NK cells. Journal 
of Immunology. 2007;178(12):7658-7666. 
DOI: 10.4049/jimmunol.178.12.7658
[91] Lauzon NM, Mian F, MacKenzie R,  
Ashkar AA. The direct effects of 
toll-like receptor ligands on human 
NK cell cytokine production and 
cytotoxicity. Cellular Immunology. 
2006;241(2):102-112. DOI: 10.1016/j.
cellimm.2006.08.004
[92] Siednienko J, Miggin SM.  
Expression analysis of the toll-like 
receptors in human peripheral blood 
mononuclear cells. Methods in 
Molecular Biology. 2009;517:3-14. DOI: 
10.1007/978-1-59745-541-1_1
[93] Girart MV, Fuertes MB, Domaica CI, 
Rossi LE, Zwirner NW. Engagement 
of TLR3, TLR7, and NKG2D regulate 
IFN-γ secretion but not NKG2D-
mediated cytotoxicity by human NK 
cells stimulated with suboptimal doses 
of IL-12. Journal of Immunology. 
2007;179(6):3472-3479. DOI: 10.4049/
jimmunol.179.6.3472
[94] Hart OM, Athie-Morales V, 
O’Connor GM, Gardiner CM. TLR7/8-
mediated activation of human NK cells 
results in accessory cell-dependent 
IFN-γ production. Journal of 
Immunology. 2005;175(3):1636-1642. 
DOI: 10.4049/jimmunol.175.3.1636
[95] Souza-Fonseca-Guimaraes F,  
Parlato M, Philippart F, Misset B, 
Cavaillon JM, Adib-Conquy M. Toll-like 
receptors expression and interferon-γ 
production by NK cells in human sepsis. 
Critical Care. 2012;16(5):R206. DOI: 
10.1186/cc11838
[96] Martinez J, Huang X, Yang Y. Direct 
TLR2 signaling is critical for NK cell 
activation and function in response 
to vaccinia viral infection. PLoS 
Pathogens. 2010;6(3):e1000811. DOI: 
10.1371/journal.ppat.1000811
[97] Cañeda-Guzmán IC, Salaiza-Suazo 
N, Fernández-Figueroa EA, Carrada-
Figueroa G, Aguirre-García M, Becker 
I. NK cell activity differs between 
patients with localized and diffuse 
cutaneous leishmaniasis infected with 
leishmania mexicana: A comparative 
study of TLRs and cytokines. PLoS 
ONE. 2014;9(11):e112410. DOI: 10.1371/
journal.pone.0112410. eCollection 2014
[98] Lindgren Å, Pavlovic V, Flach CF, 
Sjöling Å, Lundin S. Interferon-gamma 
secretion is induced in IL-12 stimulated 
human NK cells by recognition of 
Helicobacter pylori or TLR2 ligands. 
Innate Immunity. 2011;17(2):191-203. 
DOI: 10.1177/1753425909357970
[99] Kanevskiy L, Telford WG, 
Sapozhnikov AM, Kovalenko EI.  
Lipopolysaccharide induces IFN-γ 
production in human NK cells. Frontiers 
in Immunology. 2013;4:1-10. DOI: 
10.3389/fimmu.2013.00011
[100] Roda JM, Parihar R, 
Carson WE. CpG-containing 
oligodeoxynucleotides act through 
TLR9 to enhance the NK cell cytokine 
response to antibody-coated tumor 
cells. Journal of Immunology. 
2005;175(3):1619-1627. DOI: 10.4049/
jimmunol.175.3.1619
[101] Merlo A, Calcaterra C, Mènard S,  
Balsari A. Cross-talk between Toll-
like receptors 5 and 9 on activation of 
human immune responses. Journal of 
Leukocyte Biology. 2007;82(3):509-518. 
DOI: 10.1189/jlb.0207100
[102] Tsujimoto H, Uchida T, Efron PA, 
Scumpia PO, Verma A, Matsumoto T,  
et al. Flagellin enhances NK cell 
proliferation and activation directly 
and through dendritic cell-NK cell 
interactions. Journal of Leukocyte 
Biology. 2005;78(4):888-897. DOI: 
10.1189/jlb.0105051
[103] Vacchelli E, Prada N, Kepp O,  
Galluzzi L. Current trends of 
35





[104] Lu H. TLR agonists for cancer 
immunotherapy: Tipping the balance 
between the immune stimulatory 
and inhibitory effects. Frontiers in 
Immunology. 2014;5:83. DOI: 10.3389/
fimmu.2014.00083
[105] Li K, Qu S, Chen X, Wu Q , Shi M.  
Promising targets for cancer 
immunotherapy: TLRs, RLRs, and 
STING-mediated innate immune 
pathways. International Journal of 




[90] Alter G, Suscovich TJ, Teigen N, Meier 
A, Streeck H, Brander C, et al. Single-
stranded RNA derived from HIV-1 serves 
as a potent activator of NK cells. Journal 
of Immunology. 2007;178(12):7658-7666. 
DOI: 10.4049/jimmunol.178.12.7658
[91] Lauzon NM, Mian F, MacKenzie R,  
Ashkar AA. The direct effects of 
toll-like receptor ligands on human 
NK cell cytokine production and 
cytotoxicity. Cellular Immunology. 
2006;241(2):102-112. DOI: 10.1016/j.
cellimm.2006.08.004
[92] Siednienko J, Miggin SM.  
Expression analysis of the toll-like 
receptors in human peripheral blood 
mononuclear cells. Methods in 
Molecular Biology. 2009;517:3-14. DOI: 
10.1007/978-1-59745-541-1_1
[93] Girart MV, Fuertes MB, Domaica CI, 
Rossi LE, Zwirner NW. Engagement 
of TLR3, TLR7, and NKG2D regulate 
IFN-γ secretion but not NKG2D-
mediated cytotoxicity by human NK 
cells stimulated with suboptimal doses 
of IL-12. Journal of Immunology. 
2007;179(6):3472-3479. DOI: 10.4049/
jimmunol.179.6.3472
[94] Hart OM, Athie-Morales V, 
O’Connor GM, Gardiner CM. TLR7/8-
mediated activation of human NK cells 
results in accessory cell-dependent 
IFN-γ production. Journal of 
Immunology. 2005;175(3):1636-1642. 
DOI: 10.4049/jimmunol.175.3.1636
[95] Souza-Fonseca-Guimaraes F,  
Parlato M, Philippart F, Misset B, 
Cavaillon JM, Adib-Conquy M. Toll-like 
receptors expression and interferon-γ 
production by NK cells in human sepsis. 
Critical Care. 2012;16(5):R206. DOI: 
10.1186/cc11838
[96] Martinez J, Huang X, Yang Y. Direct 
TLR2 signaling is critical for NK cell 
activation and function in response 
to vaccinia viral infection. PLoS 
Pathogens. 2010;6(3):e1000811. DOI: 
10.1371/journal.ppat.1000811
[97] Cañeda-Guzmán IC, Salaiza-Suazo 
N, Fernández-Figueroa EA, Carrada-
Figueroa G, Aguirre-García M, Becker 
I. NK cell activity differs between 
patients with localized and diffuse 
cutaneous leishmaniasis infected with 
leishmania mexicana: A comparative 
study of TLRs and cytokines. PLoS 
ONE. 2014;9(11):e112410. DOI: 10.1371/
journal.pone.0112410. eCollection 2014
[98] Lindgren Å, Pavlovic V, Flach CF, 
Sjöling Å, Lundin S. Interferon-gamma 
secretion is induced in IL-12 stimulated 
human NK cells by recognition of 
Helicobacter pylori or TLR2 ligands. 
Innate Immunity. 2011;17(2):191-203. 
DOI: 10.1177/1753425909357970
[99] Kanevskiy L, Telford WG, 
Sapozhnikov AM, Kovalenko EI.  
Lipopolysaccharide induces IFN-γ 
production in human NK cells. Frontiers 
in Immunology. 2013;4:1-10. DOI: 
10.3389/fimmu.2013.00011
[100] Roda JM, Parihar R, 
Carson WE. CpG-containing 
oligodeoxynucleotides act through 
TLR9 to enhance the NK cell cytokine 
response to antibody-coated tumor 
cells. Journal of Immunology. 
2005;175(3):1619-1627. DOI: 10.4049/
jimmunol.175.3.1619
[101] Merlo A, Calcaterra C, Mènard S,  
Balsari A. Cross-talk between Toll-
like receptors 5 and 9 on activation of 
human immune responses. Journal of 
Leukocyte Biology. 2007;82(3):509-518. 
DOI: 10.1189/jlb.0207100
[102] Tsujimoto H, Uchida T, Efron PA, 
Scumpia PO, Verma A, Matsumoto T,  
et al. Flagellin enhances NK cell 
proliferation and activation directly 
and through dendritic cell-NK cell 
interactions. Journal of Leukocyte 
Biology. 2005;78(4):888-897. DOI: 
10.1189/jlb.0105051
[103] Vacchelli E, Prada N, Kepp O,  
Galluzzi L. Current trends of 
35





[104] Lu H. TLR agonists for cancer 
immunotherapy: Tipping the balance 
between the immune stimulatory 
and inhibitory effects. Frontiers in 
Immunology. 2014;5:83. DOI: 10.3389/
fimmu.2014.00083
[105] Li K, Qu S, Chen X, Wu Q , Shi M.  
Promising targets for cancer 
immunotherapy: TLRs, RLRs, and 
STING-mediated innate immune 
pathways. International Journal of 




TLR-Mediated Host Immune 
Response to Parasitic Infectious 
Diseases
M. Magdalena Aguirre-García, Araceli Rojas-Bernabé, 
A. Pamela Gómez-García and Alma R. Escalona-Montaño
Abstract
Toll-like receptors (TLRs) are important for the host immune response to a variety 
of pathogens, including bacteria, viruses, fungi, and parasites. These receptors 
become activated upon recognizing pathogen-associated molecular patterns (PAMPs) 
and thus initiate the innate immune response to the corresponding pathogen. A key 
aspect of TLRs is their activation of signaling that leads to cytokine production and 
an inflammatory response. Additionally, TLRs act as the bridge between innate and 
acquired immunity, enhancing phagocytosis and the process of killing parasites. We 
herein focus on how parasites (protozoans and helminths) and their derived prod-
ucts have the capability of stimulating or evading the host response by triggering or 
inhibiting TLR activation. Parasites often develop successful survival strategies that 
imply interference with the host immune response. Accordingly, many of these organ-
isms have molecules that modulate inflammation and other aspects of host immunity. 
Taking advantage of such mechanisms, there are some anti-inflammatory therapies 
based on human infection with helminths. Helminths and protozoans influence the 
activity of various TLRs, especially TLR2, TLR4, and TLR9. A better understanding 
of the role of TLRs and their parasite-derived ligands should certainly provide new 
therapeutic tools for combatting various parasitic and inflammatory diseases.
Keywords: TLRs, protozoans, helminths, immune response, disease
1. Introduction
Toll-like receptors (TLRs) have the important function of recognizing a variety 
of pathogens, including bacteria, viruses, fungi, and parasites. They recognize 
pathogen-associated molecular patterns (PAMPs) and consequently initiate the 
innate immune response. The well-known TLRs that are responsible for binding to 
PAMPs act as a bridge between innate and acquired immunity. Accordingly, they are 
not only involved in the production of cytokines and chemokines but also enhance 
phagocytosis and the process of killing parasites.
Parasites are organisms that live on or inside an organism and benefit by deriving 
nutrients at the expense of the host. We herein review how protozoan and helminth 
parasites trigger differential activation of TLRs in order to regulate host immune 
cells. In some cases, the activation of these TLR receptors by PAMPs contributes 
to an effective control of the infection, while in other cases there is a negative 
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Toll-like receptors (TLRs) have the important function of recognizing a variety 
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innate immune response. The well-known TLRs that are responsible for binding to 
PAMPs act as a bridge between innate and acquired immunity. Accordingly, they are 
not only involved in the production of cytokines and chemokines but also enhance 
phagocytosis and the process of killing parasites.
Parasites are organisms that live on or inside an organism and benefit by deriving 
nutrients at the expense of the host. We herein review how protozoan and helminth 
parasites trigger differential activation of TLRs in order to regulate host immune 
cells. In some cases, the activation of these TLR receptors by PAMPs contributes 
to an effective control of the infection, while in other cases there is a negative 
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regulation resulting in the exacerbation of the infection, as shown in distinct 
in vivo animal models. In patients with diverse clinical manifestations of parasitic 
infections, TLRs and cytokines play a key role in the host response to the disease. A 
better understanding of the role of TLRs and their ligands should certainly provide 
new therapeutic tools and perhaps allow for the development of vaccines to control 
parasitic infections.
2. Protozoan parasites
Among the many protozoan parasites, those presently examined are Leishmania 
spp., Trypanosoma spp., Naegleria fowleri, Plasmodium spp., Toxoplasma gondii, 
Giardia lamblia, Entamoeba histolytica, Trichomonas vaginalis, Blastocystis spp., and 
Acanthamoeba spp.
2.1 Leishmania spp.
Leishmaniasis, an infectious disease endemic in 88 countries representing 5 conti-
nents, is caused by parasitic protozoa in the genus Leishmania [1]. This parasite gives 
rise to a variety of disorders, ranging from cutaneous lesions to visceral disease [2]. 
The latter can be generated by Leishmania donovani, L. infantum, and L. chagasi [3].
Regarding cutaneous lesions, the most pathogenic agents of American cutane-
ous leishmaniasis in Brazil are L. (Viannia) braziliensis and L. (L.) amazonensis, 
capable of inducing localized cutaneous leishmaniasis, borderline disseminated 
cutaneous leishmaniasis, anergic diffuse cutaneous leishmaniasis, and mucosal 
leishmaniasis [4]. In Mexico, L. mexicana evokes a wide spectrum of cutaneous 
diseases. For instance, localized cutaneous leishmaniasis is characterized by ulcers 
at the site of parasite inoculation, while parasites in diffuse cutaneous leishmaniasis 
spread throughout the skin and form disfiguring nodules [5]. In Iran, cutaneous 
leishmaniasis is endemic in 18 of 31 provinces, and approximately one-fifth of the 
cases belong to anthroponotic cutaneous leishmaniasis, stemming from L. tropica 
[6]. L. panamensis, a member of the Viannia subgenus of Leishmania, is known to 
provoke mucosal leishmaniasis. It produces destructive lesions of the nasal, oral, 
and hypopharyngeal mucosa [1].
2.2 Trypanosoma spp.
The causal agent of Chagas disease, Trypanosoma cruzi, was first described by the 
Brazilian physician Carlos Chagas in 1909 [7]. This pathology is endemic in Central 
and South America, and evidence exists of some cases in the United States, Europe, 
and Japan due to travel and migration. The parasite is an intracellular protozoan of the 
Trypanosomatidae family, transmitted to humans by blood-feeding reduviid bugs.
There are two phases of Chagas disease. The acute phase is generally asymp-
tomatic, although some patients present symptoms such as fever, nausea, vomiting, 
anorexia, and diarrhea [8]. In the chronic phase, infected individuals can remain 
asymptomatic for decades, although around 30% eventually develop cardiac or 
gastrointestinal complications characteristic of the disease.
2.3 Other protozoans
Naegleria fowleri is a protozoan that invades the central nervous system and 
provokes primary amoebic meningoencephalitis. During the process of infection, it 
induces an important inflammatory response [9].
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Acanthamoeba spp. are free-living amoebae found in lakes, rivers, swimming 
pools, thermal baths, and tap water [10]. They infect humans and animals as 
opportunistic pathogens in immunocompromised hosts [11]. These parasites are 
able to generate severe diseases, including amebic Acanthamoeba keratitis, a painful 
sight-threatening infection of the cornea, and granulomatous amebic encephalitis, a 
fatal disease of the central nervous system.
Giardia lamblia, the causal agent of giardiasis, colonizes the lumen of the upper 
small intestine. The parasite adheres to the surface of enterocytes without traversing 
the enterocyte barrier [12].
P. falciparum, the protozoan parasite responsible for malaria, is transmitted 
by the bite of mosquitoes. It results in a wide spectrum of clinical manifestations 
during the vector-parasite-host interaction. The first asexual reproduction process 
occurs in the human liver [13].
Trichomonas vaginalis is a flagellated protozoan parasite that infects the human 
genitourinary tract. It is the causative organism of trichomoniasis, one of the most 
prevalent sexually transmitted diseases in the world [14].
Entamoeba histolytica, the etiologic agent of amebiasis, is a pathogenic enteric 
protozoan. The manifestations of the disease range from mild diarrhea to severe 
dysentery, with liver abscesses forming in rare cases [15].
Blastocystis, an enteric parasite, colonizes the colonic epithelia of human and 
animal hosts [16]. Infection with this parasite gives rise to diarrhea, abdominal pain, 
flatulence, vomiting, and bloating [17].
3. Helminth parasites
The word helminth is derived from the Greek “helmins,” which means parasite 
worm. Helminth is an umbrella term that includes many species of worms from 
different genera, having parasitism in common. They are quite frequently found in 
the population. The immune response depends largely on the type of parasite and 
its interaction with the host.
These large extracellular organisms have a complicated life cycle. They fre-
quently migrate through blood vessels and tissues until reaching the definitive 
organ, such as the intestine, lungs, liver, or lymphatic organs. Some invade and 
colonize various cell types.
Because helminths have developed strategies of evasion of the host immune 
response, they are often able to survive. Hence, they can weaken the immune 
response and survive for years in the infected host, establishing chronic infection 
[18]. When the host immune response is adequately activated, on the other hand, 
infections are eliminated quickly.
Fasciola hepatica is a trematode worm that mainly affects livestock (e.g., cows, 
sheep, and goats) and humans. It is transmitted through the ingestion of aquatic 
plants contaminated with metacercaria. Ascaris lumbricoides, a parasitic intestinal 
worm, is transmitted by ingesting water contaminated with embryonic eggs. 
Trichuris trichiura and T. suis, other species of intestinal worms, remain in the large 
intestine of mammals in the form of adult larvae. The infection occurs after the 
ingestion of the eggs, which hatch in the small intestine and release the infective 
larvae [19]. Schistosoma mansoni are larvae of worms that live in waters and ponds 
contaminated by feces. They are able to penetrate the skin of people who bath or 
swim in contaminated pools. In the adult stage, these parasites produce eggs that 
are excreted through the stool [20]. Strongyloides stercoralis is an infection generated 
by the larvae. These are acquired through the skin and later lodge themselves in the 
intestine. Trichinella spiralis is a parasitic nematode, which infects the muscle tissue 
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regulation resulting in the exacerbation of the infection, as shown in distinct 
in vivo animal models. In patients with diverse clinical manifestations of parasitic 
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2. Protozoan parasites
Among the many protozoan parasites, those presently examined are Leishmania 
spp., Trypanosoma spp., Naegleria fowleri, Plasmodium spp., Toxoplasma gondii, 
Giardia lamblia, Entamoeba histolytica, Trichomonas vaginalis, Blastocystis spp., and 
Acanthamoeba spp.
2.1 Leishmania spp.
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Acanthamoeba spp. are free-living amoebae found in lakes, rivers, swimming 
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fatal disease of the central nervous system.
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small intestine. The parasite adheres to the surface of enterocytes without traversing 
the enterocyte barrier [12].
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during the vector-parasite-host interaction. The first asexual reproduction process 
occurs in the human liver [13].
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prevalent sexually transmitted diseases in the world [14].
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plants contaminated with metacercaria. Ascaris lumbricoides, a parasitic intestinal 
worm, is transmitted by ingesting water contaminated with embryonic eggs. 
Trichuris trichiura and T. suis, other species of intestinal worms, remain in the large 
intestine of mammals in the form of adult larvae. The infection occurs after the 
ingestion of the eggs, which hatch in the small intestine and release the infective 
larvae [19]. Schistosoma mansoni are larvae of worms that live in waters and ponds 
contaminated by feces. They are able to penetrate the skin of people who bath or 
swim in contaminated pools. In the adult stage, these parasites produce eggs that 
are excreted through the stool [20]. Strongyloides stercoralis is an infection generated 
by the larvae. These are acquired through the skin and later lodge themselves in the 
intestine. Trichinella spiralis is a parasitic nematode, which infects the muscle tissue 
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of practically all mammals. Toxocara canis, round worms found in dogs, can infect 
humans if ingested in the form of the infective eggs of Toxocara. The larvae migrate 
to the intestine, liver, or lungs.
4.  Molecules and protozoan and helminth parasites activate through 
TLRs
4.1 Leishmania spp. protozoans
L. major prompts the activation of the IL-1β promoter and mRNA expression in 
macrophages through the MyD88-pathway [21]. Additionally, L. major LPG upregu-
lates the expression of TLR2 in NK cells and the production of cytokines, such as 
IFN-γ, TNF-α, and nuclear factor NFκB [22].
Amastigotes from L. (V.) braziliensis reduce the expression of TLR4 on the 
membrane of macrophages. This receptor modulates the production of TNF-α and 
IL-10 [23]. L. infantum promastigotes stimulate the production of IFN-α/β in plas-
macytoid dendritic cells and the release of IL-12 by myeloid dendritic cells. Both 
these cytokines are dependent on TLR9 [24]. The expression of TLR9 and the 
production of TNF-α and IL-12 were observed in macrophages exposed to DNA 
from L. mexicana promastigotes [25]. Similarly, DNA from L. major was identi-
fied as the specific ligand that triggered TLR9-dependent activation of dendritic 
cells [26]. On the other hand, antigens of L. donovani stimulated the production 
of TNF-α, IL-12, and IFN-γ and increased TLR2 gene expression on RAW264.7 
macrophages [27].
L. panamensis infection upregulates the expression of TLR1, TLR2, TLR3, and 
TLR4 and the production of TNF-α in human primary macrophages [28]. In periph-
eral blood mononuclear cells, L. mexicana LPG fostered the production of TNF-α, 
IL-1β, IL-12 p40, IL-12 p70, and IL-10 and the expression of TLR2 and TLR4. The 
triggering of the latter TLRs led to phosphorylation of the extracellular regulated 
kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) [29].
4.2 Other protozoans
Glycosylphosphatidylinositol (GPI), a molecule derived from trypomastigotes, 
was found to be a potent activator of TLR2 from human and mouse origin [30]. 
Another family of GPIs, glycoinositolphospholipid (GIPL), has been purified from 
epimastigotes and triggers NF-κB activation via TLR4 [31].
Whether the recognition of different GPI anchors is mediated by TLR2 or TLR4 
depends on their variable lipid moiety composition. There is one report of RA (high 
virulence) and K 98 (low virulence) strains of T. cruzi used to obtain total lipid 
extracts. The authors demonstrated that the total lipids from both strains promote 
the formation of lipid bodies and the release of pro-inflammatory molecules, 
including cyclooxygenase-2, TNF-α, and nitric oxide (NO) in macrophages as well 
as HEK cells, all through a TLR2/6-dependent pathway [32].
P. falciparum GPI contributes to the pathology of malaria by inducing the release 
of cytokines. In vitro studies have shown that this molecule is recognized by TLR2 
and to a lesser degree by TLR4 [33]. Hemozoin stimulates the production of IFN-γ 
and inflammatory cytokines by triggering TLR9 in dendritic cells [34].
T. vaginalis parasites enhance TLR2 gene expression and activate NOD-like 
receptor type 3 (NLRP3) inflammasome in mouse macrophages and THP-1 human 
macrophages, respectively [35]. They also regulate the production of pro-inflamma-
tory cytokines by the activation of MAPK and NFκB p65 and prompt pyroptotic cell 
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death through the release of IL-1β [36]. TLR4 upregulation has been reported in a 
prostate stromal cell line exposed to T. vaginalis [37].
Profiling like molecules and heat shock protein 70 from T. gondii activates dendritic 
cells through TLR4 and TLR11 [38]. The lipopeptidophosphoglycan (LPPG) and DNA 
from E. histolytica are recognized by TLR2, TLR4, and TLR9, triggering the release 
of IL-10, IL-12p40, TNF-α cytokines, and IL-8 from human monocytes [39, 40]. 
Unmethylated CpG oligodeoxynucleotides (CpG ODN) from the same parasite gener-
ate MMP-9 expression via the TLR9-dependent activation of ERK and p38 MAPK fol-
lowed by the activation of NFκB [41]. G. lamblia trophozoites trigger TLR2, resulting 
in the activation of ERK and MAPK and the production of pro-inflammatory cytokines 
in peritoneal macrophages of wild-type mice [42]. Live Blastocystis spp. parasites and 
whole cell lysate alone cannot trigger TLRs in THP-1 human monocytes. ST4WR1 para-
sites inhibit LPS-mediated activation of NF-κB in these same cells [43]. N. fowleri elicits 
the expression and production of pro-inflammatory cytokines and β-defensing-2, 
mainly through the canonical TLR4 pathway in a time-dependent manner [44].
4.3 Helminths
The host immune response mounted against helminth infections is activated 
through TLRs, which are triggered by the glycoproteins, secretion/excretion prod-
ucts, and various other molecules of the parasites [45].
Cathepsin cysteine  protease (FheCL1) of F. hepatica inhibits the secretion of 
various inflammatory mediators, such as TNF-α, IL-12, and NO [46]. This is carried 
out by the null activation of macrophages through the degradation of TLR3 in the 
endosome in a TRIF-dependent pathway independent of MyD88 [47]. Glucans pro-
mote the production of high levels of IL-10 and IL-4, thus favoring a Th2 response. 
These glycoconjugates modulate the function and maturation of dendritic cells. In 
the process of phase changes, Fasciola employs an immunosuppressive mechanism 
that favors a Th2 response [48], in part by releasing various excretory/secretory 
substances that inhibit the maturation of dendritic cells and trigger TLRs via the 
MyD88-dependent signaling pathway.
The excretory/secretory molecules of Taenia crassiceps initiate the phosphory-
lation of cRAF by means of MGL (lectins) and TLR2, as well as decreasing the 
maturation of dendritic cells and the production of IL-12 and TNF-α. These mol-
ecules also modulate the signaling pathways of NFκB p65 and p38 MAPK activated 
by LPS through TLR4 [49, 50] and regulate the type C receptor of lectin [51]. The 
carbohydrates of the parasite induce the production of IL-6 through TLRs [52].
On the other hand, the lysophosphatidylserine and lipopolysaccharide of A. lum-
bricoides generate signaling through TLR2, modulate a Th2 response (leading to the 
secretion of IL-10), and promote phosphorylation of ERK 1/2. This helminth binds 
to hyaluronic acid (the main constituent of connective tissue), activates dendritic 
cells by TLR4 (in adult parasites, or in larvae depending on the larval concentra-
tion), and provokes inflammatory processes. Through its antioxidant properties, it 
can eliminate free radicals and act as a barrier to tissue degradation.
Trichuris trichiura inhibits the function of TLR4 by suppressing LPS-induced 
production and the secretion of TNF-α [53]. Similarly, cathepsin B1 secreted by S. 
mansoni inhibits the recognition of TLR3 and TLR4 by inactivating the MyD88-
independent pathway and modulating Th2 responses. Phospholipids and glyco-
phosphatidylserine trigger TLR2 in dendritic cells, eliciting a Th2 response and the 
stimulation of Tregs to secrete IL-10.
The soluble antigen of S. mansoni suppresses the production of cytokines IL-1β, 
IL-6, IL-12, and TNF-α as well as increases the secretion of TGF-β and the produc-
tion of IL-10 in dendritic cells. Activated B cells augment the production of IL-10. 
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Both processes are dependent on the triggering of TLR2 and activation of MyD88, 
the latter of which promotes ERK1/2 phosphorylation [20]. dsRNA from S. mansoni 
binds to TLR3 in dendritic cells, thus positively regulating the expression of IFN 
type 1 genes [54–56].
Although the TLR4 receptor is not essential for killing the larva of S. stercoralis 
during the innate immune response, it is indeed crucial for killing the parasites 
during the adaptive immune response [57].
Phosphorylcholine is a glycoprotein released by T. spiralis that binds to TLR4 
[58]. Several TLRs decrease the susceptibility of effector T cells to Treg-mediated 
suppression [59]. During the first week of infection, the gene expression of TLR1, 
Figure 1. 
TLR activation by PAMPs of parasites.
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TLR2, TLR4, TLR5, and TLR9 increases significantly in the intestinal and muscular 
phases [60]. Infection also activates dendritic cells through TLR2 and TLR4 [61]. 
Since the TLR4/MyD88/NF-κB signaling pathway affects the secretion of inflam-
matory cytokines in macrophages, it may participate in immune suppression. In this 
sense, T. spiralis infection modulates the expression of TLR2 and TLR4 during dif-
ferent stages. Cytokine levels are regulated via TLR4-mediated signaling pathway, 
suggesting that TLR4 modulates host immunosuppression during infection [62].
Infection with Toxocara prompts cells to produce cytokines such as IL-4, IL-5, 
and IL-13, which generate increased IgE levels [63]. Toxocara canis inhibits the 
response of TLR2 to the activation of dendritic cells and competes with the host 
for lectins, thus blocking host immunity [64]. The activation of TLRs pathways by 
PAMPs of protozoans and helminths is summarized in Figure 1.
5. TLRs contribute to the effective control of parasite infection
5.1 Leishmania spp.
Infection by L. major in TLR4-deficient mice proliferates and correlates with 
a higher activity of arginase. In contrast, the same infection in TLR4-competent 
mice leads to low parasite replication that correlates with higher levels of inducible 
nitric oxide synthase. Hence, TLR4 competence could resolve cutaneous lesions and 
control parasite growth [65, 66].
TLR2 is unique among TLRs because it forms heterodimers with TLR1 or TLR6 
and modulates downstream signaling pathways. In peritoneal macrophages from 
BALB/c mice infected with L. major promastigotes, the expression of TLR1 and 
TLR2 increases but not that of TLR6. TLR2-TLR2 association increases but TLR2-
TLR6 association diminishes. The disparity in the formation of heterodimers 
between TLR2 and TLR1 or TLR2 and TLR6 brings about a TLR2 functional dual-
ity [67]. Additionally, LPG from L. major participates in the modulation of TLR9 
expression and function.
The question arises as to whether the functional duality of TLR2 contributes to such 
modulation. The co-administration of CpG and the anti-TLR2 antibody reduces infec-
tion in susceptible BALB/c mice, establishing a relationship between LPG, TLR2, and 
TLR9 during an L. major infection [27]. In C57BL/6 mice deficient in either TLR2, 4, or 
9, only the TLR9-deficient animals are more susceptible to infection with L. major. The 
deficiency of TLR9 inhibits the development of the curative Th1 response [26]. This effect 
has also been observed in TLR9-deficient mice infected with L. infantum. Therefore, 
TLR9 appears to play a key role in infections by L. major or L. infantum [2]. On the other 
hand, TLR11 and TLR12 play an important role in an L. major infection, evidenced by the 
fact that the silencing of these receptors reduces the parasite burden, enhances the level of 
IFN-γ, and diminishes the production of IL-4 [68].
Bone marrow-derived dendritic cells of MyD88−/− and TLR2−/− mice were 
infected with L. braziliensis. Compared to control mice, the infected dendritic cells 
from MyD88−/− mice showed low levels of activation and decreased production 
of cytokine IL-12p40, leading to greater infection by L. braziliensis and a limited 
expansion of CD4+ T cells that produce IFN-γ and IL-17 during infection. In con-
trast, TLR2−/− mice were more resistant to infection than control mice, which was 
associated with increased production of IFN-γ. Thus, MyD88 seems to be essential 
for the recognition of L. braziliensis, and TLR2 apparently has a regulatory role in 
modulating the immune response to the same parasite [69]. In peripheral blood 
mononuclear cells from cutaneous leishmaniasis patients infected with L. brazil-
iensis, an evaluation was made of the expression of co-stimulatory molecules CD80, 
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IFN-γ, and diminishes the production of IL-4 [68].
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infected with L. braziliensis. Compared to control mice, the infected dendritic cells 
from MyD88−/− mice showed low levels of activation and decreased production 
of cytokine IL-12p40, leading to greater infection by L. braziliensis and a limited 
expansion of CD4+ T cells that produce IFN-γ and IL-17 during infection. In con-
trast, TLR2−/− mice were more resistant to infection than control mice, which was 
associated with increased production of IFN-γ. Thus, MyD88 seems to be essential 
for the recognition of L. braziliensis, and TLR2 apparently has a regulatory role in 
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CD86, and TLR9. Monocytes decreased the expression of these co-stimulatory 
molecules, but their expression was higher when the cells were exposed to soluble 
Leishmania antigen [70].
In the spleen of mice infected with L. chagasi, possible correlations were ana-
lyzed between TLR2 and TLR4 mRNA expression and the production of cytokines 
and nitric oxide (NO). Whereas the mRNA expression of TLR2, TLR4, IL-17, TNF-
α, and TGF-β increases in the early stage of infection, it decreases during the late 
stage, which correlates with parasite load. The mRNA expression of IFN-γ and IL-12 
declines at the peak of infection [3].
On the other hand, mice with the A20 protein silenced (a protein that inhibits 
NFκB activation by modulating the function of IKK, TRAF6, and NEMO) were 
infected with L. donovan, finding enhancement of the activation of NFκB and the 
host-protective pro-inflammatory response (compared to normal mice), which 
correlates with effective parasite clearance [71].
5.2 Other protozoans
Single-nucleotide polymorphisms have a role in innate immune responses and 
in susceptibility/resistance to infection. However, the genetic association of TLR4 
and TNF-α polymorphisms is a determinant factor for the development of disease 
in Chagas disease. It has been reported the greatest parasite load exists in individu-
als with the C/C-Asp/Asp-Thr/Thr combination of homozygous genotypes at the 
TNF-α promoter 1031 and on the TLR4 polypeptide. The former homozygous 
genotype is represented by C/C. The latter homozygous genotypes encode Asp/Asp 
and Thr/Thr at codons 299 and 399, respectively [72]. Two TLR1 polymorphisms, 
rs4833095 (Asn248Ser) and rs5743618 (Ser602Ile), were assessed among 302 
primiparous Ghanaian women for their association with P. falciparum infection 
and placental malaria and susceptibility to placental malaria [73]. It was found that 
TLR4-Asp299Gly and the TLR4-Thr399Ile variants confer greater risk of severe 
malaria in Ghanaian children [74]. The single-nucleotide polymorphism of TLR6 
S249P may be a risk factor for the development of malaria [75]. Regarding TLR5, 
the single-nucleotide polymorphism of the TIR domain (TIRAP) S180 L provides 
protection against malaria, while the single-nucleotide polymorphism of R392 stop 
codon increases susceptibility to the same disease [76]. An rs4986790 polymor-
phism of the TLR4 gene can modulate the susceptibility toward a P. vivax infection. 
The AA genotype proved to be protective against the development of this parasite in 
a local population of Pakistan [77]. Additionally, TLR4 A299G, TLR6 S249, and TLR 
9-1486C/T influence the levels of circulating cytokines IL-6, IFN-γ, IL-12, IL-10, 
and IL-4 during a P. vivax infection [78].
Mice deficient in the adaptor protein MyD88 and IL-18 were more susceptible to 
P. yoelii infection and increased parasitemia during the early phase of the infection. 
Greater lethality was observed in the MyD88-deficient animals. In mice deficient 
in IL-1R, parasitemia showed a slight increment during infection with P. yoelii [79]. 
During infection with the same parasite, there was a high level of parasite burden in 
TLR2−/− mice, which was closely associated with a reduction in pro-inflammatory 
cytokines in the liver [80].
On the other hand, the TLR9 variant −1237C/C correlates with acute parasitemia 
during a P. vivax infection [81]. An endoplasmic reticulum resident protein, UNC93B1, 
is critical for host resistance to T. cruzi and T. gondii [80, 82]. Its function is the translo-
cation of nucleotide-sensing TLRs from the endoplasmic reticulum to endolysosomes. 
Interestingly, TLR2−/− and AKT-blocked mice that are infected with Giardia display 
a decreased parasite burden, an increased weight gain rate, and a shorter parasite 
persistence compared to normal mice infected with the same protozoan [42].
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5.3 Helminths
The immune responses against helminth infections do not efficiently protect the 
host. The immune system is unable to eliminate chronic infection, and the immune 
memory fails to protect against reinfection, even after a cure mediated by pharma-
cological treatment [83].
For an S. mansoni or A. lumbricoides infection, dendritic cells are fundamental in 
the protection and activation of host defensive responses. When TLR receptors on 
the surface of dendritic cells bind to the ligands of the S. mansoni, A. lumbricoides, and 
T. trichiura parasites, there is an increased expression of co-stimulatory molecules 
(CD40, CD80, and CD86) and synthesis of pro-inflammatory mediators, such as 
IL-12 and TNF-α, that evoke a Th1 lymphocyte response [84, 85]. For intestinal 
parasites, the mRNA expression of TLR1, TLR2, TLR3, TLR4, and TLR9 is regu-
lated in the early stages of infection. During the adult stage of an infection with 
T. spiralis, TLR1 and TLR4 activate the signaling pathway dependent on MyD88. 
Once newborn larvae appear, however, all expression of TLRs is inhibited, except 
for TLR2. The expression of TLR2/4 in the small intestine and muscle tissue during 
infection could be closely associated with immune responses mediated by Treg 
cells and greater expression of cytokines such as IL-10 and TGF-β [86, 87]. During 
an infection by S. mansoni, TLR2 and TLR4 limit the activation of the intestinal 
immune response. Consequently, the deficiency of these TLRs promotes the expul-
sion of adult worms. In the course of the first weeks of infection of animals with 
such deficiency, the expression of several TLRs increases, an active state that begins 
to decrease as of the fourth week. This favors an early activation of the immune 
response in the host and the prompt expulsion of the parasites [88].
6. Negative regulation by TLRs
6.1 Leishmania donovani, Giardia lamblia, and Schistosoma mansoni
L. donovani infection results in a suppression of TLR2- and TLR4-stimulated 
production of IL-12p40 and an increase in IL-10 production. Additionally, the 
parasites modulated the MAPK pathway by suppressing TLR2-dependent MAPK 
and ERK phosphorylation [89].
An in vitro infection with G. lamblia leads to a decreased production of pro-
inflammatory cytokines by activating the AKT signaling pathway via TLR2.
Helminths are regulated by the expression of soluble antigens, which in parasites 
such as S. mansoni and F. hepatica exert an inhibitory effect on the maturation of den-
dritic cells induced by TLR ligands. The dendritic cells activated by soluble antigens 
produce a smaller amount of IL-12 than those activated only with the ligand for TLR4 
[90–92]. The soluble antigen extracts of S. mansoni inhibit the ability of CpG, poly 
I:C, hyaluronic acid, and LPS to stimulate the production of IL-12 or increase the 
surface expression of CD80, CD86, and MHC class II in dendritic cells. Therefore, 
these extracts decrease the production of IL-12, IL-6, and TNF-α and the expression 
of co-stimulatory CD80/86 molecules, which in turn suppresses the Th1 response and 
favors the Th2 response elicited by LPS [93, 94]. The negative regulation of TLRs can 
reduce the production of pro-inflammatory cytokines, which could protect the host 
from autoimmune pathogenesis. The mechanism of this action is the regulation of 
the Th1/2 cell balance and the modulation of TLR4 expression [92, 95, 96].
In order to adapt to the immune system, some helminth parasites activate and/or 
downregulate TLRs, as well as interfere with the expression of several genes related 
to the transduction pathway [86]. Several studies suggest that continuous exposure 
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On the other hand, the TLR9 variant −1237C/C correlates with acute parasitemia 
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memory fails to protect against reinfection, even after a cure mediated by pharma-
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For an S. mansoni or A. lumbricoides infection, dendritic cells are fundamental in 
the protection and activation of host defensive responses. When TLR receptors on 
the surface of dendritic cells bind to the ligands of the S. mansoni, A. lumbricoides, and 
T. trichiura parasites, there is an increased expression of co-stimulatory molecules 
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from autoimmune pathogenesis. The mechanism of this action is the regulation of 
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In order to adapt to the immune system, some helminth parasites activate and/or 
downregulate TLRs, as well as interfere with the expression of several genes related 
to the transduction pathway [86]. Several studies suggest that continuous exposure 
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to helminth antigens may negatively regulate the response of cells to PAMPs derived 
from these parasites, implying a weakened immune response in individuals infected 
with helminths.
6.2 Highly virulent parasites downregulate TLR expression
According to an in vitro assay, T. cruzi strains with low virulence cause relatively 
high expression of TLR4 and high levels of pro-inflammatory cytokines such as 
IL-12 and TNF-α. Contrarily, virulent T. cruzi strains maintain a low expression of 
TLR4 and reduced production of TNF-α [97]. Likewise, at 2 days post-infection with 
Acanthamoeba strains Ac55 and Ac43, the mRNA expression of TLR2 and TLR4 was 
elevated in the brain of mice (versus control animals) [98]. Compared to uninfected 
mice, moreover, Acanthamoeba sp. generated a high expression of the mRNA and high 
levels of TLR2 in the brain of animals at 2, 4, 8, 16, and 30 days post-infection [99].
7. TLRs in the outcome of disease
7.1 Leishmaniasis
Splenic biopsies and peripheral blood samples (to obtain mononuclear cell isolates) 
were taken from patients with visceral leishmaniasis in India, detecting the mRNA 
expression of TLR2 and TLR4 but not TLR9. The mRNA expression of IL-10 and IFN-γ 
was greater in pre-treatment versus posttreatment splenic biopsies. Additionally, the 
levels of IFN-γ and IL-10 mRNA were higher in peripheral blood mononuclear cells for 
pre-treatment versus posttreatment patients and healthy controls [100].
In Brazil, the peripheral blood mononuclear cells and lymphocytes (CD14+ and 
CD3+) were analyzed in 13 patients diagnosed with visceral leishmaniasis before 
and after treatment. Compared to healthy controls, there was a greater expression 
before treatment of TLR2 and TLR4 in lymphocytes and monocytes. Additionally, 
the levels of TNF-α, IL-10, and TGF-β increased, and those of IFN-γ, IL-17, and 
NO decreased. Although the expression of these two receptors did not change in 
lymphocytes after treatment, in monocytes they were found to be lower for TNF-α 
and IL-10 and higher for TGF-β, IFN-γ, IL-17, and NO [101].
Samples of whole blood taken from patients in Eastern Sudan with visceral leish-
maniasis were stimulated with live L. donovani promastigotes. The expression of 
TLR2, TLR4, and TLR9 was found, which correlated with the production of IFN-γ, 
TNF-α, and IL-10 [102]. Similarly, the expression of TLR2 and TLR4 was measured 
in peripheral blood mononuclear cells of patients with cutaneous leishmaniasis, 
both those with healing and non-healing wounds, observing a significantly greater 
level in the macrophages of individuals with the healing versus non-healing lesions. 
This suggests a possible role of TLR2 and TLR4 in the outcome of cutaneous leish-
maniasis lesions [103].
It is known that L. (V.) braziliensis and L. (L.) amazonensis interact with these 
same TLRs to promote a differential T-cell immune response and cytokine expression 
in mucosal leishmaniasis and anthroponotic cutaneous leishmaniasis. Biopsies taken 
from skin and mucosal lesions of infected patients were examined by immunohis-
tochemistry, finding an important expression of TLR2, TLR4, and TLR9. Whereas 
tissues associated with L. (V.) braziliensis exhibited strong expression of TLR2 and 
TLR4, those tissues linked to L. (L.) amazonensis displayed similar results in rela-
tion to TLR9. The greatest expression of CD4+ T cells was encountered in mucosal 
leishmaniasis and the lowest in anergic diffuse cutaneous leishmaniasis. Similarly, 
CD8+ T cells showed their lowest expression in the latter disorder compared to the 
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other forms of the disease. There was greater expression of TNF-α in anergic diffuse 
cutaneous leishmaniasis versus mucosal leishmaniasis and of IL-10 and TGF-β in 
mucosal leishmaniasis versus anergic diffuse cutaneous leishmaniasis [4].
Although NK cells are detected in individuals infected with L. mexicana and 
suffering from localized cutaneous leishmaniasis as well as diffuse cutaneous 
leishmaniasis, the number of cells and the effector mechanisms differed drastically 
between the two groups. The number of NK cells, production of IFN-γ and TNF-α, 
and expression of TLR2, TLR1, and TLR6 were all lower than normal in patients 
with diffuse cutaneous leishmaniasis while being normal in those with localized 
cutaneous leishmaniasis. The altered protein expression found in NK cells of the 
former group correlated with the downregulation of IFN-γ gene expression in 
LPG-stimulated and non-stimulated cells. In conclusion, the lower number of NK 
cells and their limited activity in individuals with diffuse cutaneous leishmaniasis, 
evidenced by reduced TLR expression and cytokine production, are likely involved 
in the severity of the disease [5].
Peripheral blood was taken from patients with anthroponotic cutaneous leish-
maniasis, including those responsive and unresponsive to treatment as well as 
healthy controls. Some mononuclear cells from these blood samples were exposed to 
L. tropica and others unexposed. An evaluation was made of the gene expression of 
TLR2, TLR4, TLR9, and TNF-α and the activity of iNOS and arginase in monocytes 
from patients unresponsive and responsive to Glucantime treatment. Upon com-
paring the monocytes exposed and unexposed to L. tropica, the former exhibited 
greater expression of all three TLRs and TNF-α and lower expression of iNOS in 
both groups of patients (responsive and unresponsive to treatment). Additionally, 
there was a significant downregulation of TLR2 and TNF-α expression and upregu-
lation of TLR9 expression in isolates from unresponsive versus responsive individu-
als. Isolates from the former group also showed a significant increase in the level of 
arginase in monocytes stimulated with L. tropica and cultured promastigotes [6].
7.2 Chronic chagasic cardiomyopathy (CCC)
Chagas disease has different clinical forms: indeterminate, digestive, and 
cardiodigestive. CCC is associated with greater expression of TLR2, IL-12, and 
TNF-α. However, the expression of MyD88 mRNA is greater in cardiodigestive 
than indeterminate and cardiac patients. Serum mRNA expression of IL-12 and 
TNF-α transcripts was found in cardiac patients, who showed a higher production 
of TLR-induced inflammatory cytokines (TNF-α and IL-12) than indeterminate 
patients and uninfected individuals. Digestive and cardiodigestive clinical cases are 
correlated with elevated mRNA expression of TLR8 and IFN-β [104].
7.3 Helminth infections
During the interaction of S. mansoni with the host immune system, TLR4 activa-
tion provides a protective role against infection, while TLR2 activation is favorable 
for the parasite. The gene expression of the TLRs 1, 3, 7, and 8 is suppressed after 
infection. The antigens of A. lumbricoides promote the expression of TLR2 and thus 
engender a Th2 response [105–108].
8. Role of TLRs in strategies for the control of parasitic infections
TLRs have potential as therapeutic targets, either alone or in combination with 
conventional immunotherapy and pharmacotherapy. In recent years, antagonists 
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of TLRs or agonists of their negative regulators have been investigated as vaccine 
adjuvants to enhance an effective immune response against tumors, allergies, and 
infectious diseases [109].
The vaccine adjuvant properties of TLR7 and/or TLR8 agonists imiquimod and 
R848 were tested in the model of infection by L. major, determining the immune 
response before and after infection. Protective immunity was generated following 
subcutaneous but not intramuscular vaccination [110]. In another study, the effect 
of L. major polyclonal anti-murine TLR2 and TLR4 antibodies was assessed on 
cutaneous leishmaniasis and inflammatory arthritis. Both antibodies suppressed 
the development of clinical parameters, accompanied by reduced pro-inflammatory 
cytokine production. Hence, anti-TLR2 and TLR4 antibodies possibly have a syner-
gistic therapeutic effect on inflammatory disease [111].
In visceral leishmaniasis, evaluation was made of anti-Leishmania immune 
responses. The protective efficacy of the glycosphingophospholipid (GSPL) antigen 
of L. donovani parasites when acting as a ligand for β-(1-4)-galactose terminal NKT 
cells suggests an important role of TLR4. This receptor may function as an upstream 
sensor by GSPL and induce the intracellular inflammatory signaling necessary for 
killing parasites. Treatment with GSPL was able to cause a highly effective T-cell 
response that contributed to good control of infection. Therefore, the synergism 
of TLR4 and NKT cells prompted GSPL to evoke a host-protective immunological 
response in experimental visceral leishmaniasis [112].
The collateral effects of a malaria infection during pregnancy correlate with 
immune activation in placental tissue. Since TLR4 plays a key role in this process, 
its blockage could be a potential strategy for therapeutic intervention to reduce the 
incidence of malaria-induced pathology both in the mother and the fetus [113].
Skin scarification with the P. falciparum peptide vaccine in combination with a 
TLR agonist produces systemic neutralizing antibodies with the potential of block-
ing parasite egress from the skin (and thus avoiding the invasion of liver cells) [114].
A good adjuvant formulation is crucial in the development of a successful 
vaccine. In the amebiasis model, the nanoliposome adjuvant containing synergistic 
TLR4 and TLR7/8 agonists successfully elicited balanced systemic humoral and 
cellular immune responses. The immunization protected against infection with up 
to 55% efficacy [115].
Since helminths use various molecules to regulate the host immune response, 
some of these may have potential therapeutic action against allergies and other 
inflammatory diseases. This anti-inflammatory strategy has been successful in 
treating diseases in animal models. Helminth-derived molecules are potent immu-
nomodulators that could possibly be used for the design of new anti-inflammatory 
drugs. For example, the nematodes T. suis and T. spiralis induce a significant sup-
pression of symptoms in autoimmune encephalomyelitis, an animal model validated 
for multiple sclerosis. Therefore, infection with live nematodes is not a prerequisite 
for the suppression of inflammation [53, 116].
Crohn’s disease and ulcerative colitis are closely related to inflammatory pro-
cesses. Some therapies, such as the ingestion of eggs of T. suis, promote a TLR2- and 
TLR4-regulated decline in inflammatory activity as well as a reduction in adverse 
effects of inflammation. This is based on the ability of helminths to polarize the 
response of helper T cells to a Th2 type, which inhibits inflammation. F. hepatica, on 
the other hand, exerts influence on dendritic cells activated by CpG, thus fostering 
the development of Tregs and a decrease in the severity and incidence of the disease 
[117]. S. mansoni alleviates allergies and reduces inflammation in airways.  
A. suum diminishes ocular allergic disease and T. spiralis, by evoking a Th2 response, 
and inhibits the production of IFN-γ to relieve colitis. These results are interest-
ing because they demonstrate the interference of a helminth infection with the 
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establishment of an inflammatory immune response that favors other pathologies 
[118]. The aforementioned evidence of helminths regulating the immune response 
through TLRs could be instrumental in the development of therapeutic targets 
as well as in the inhibition or stimulation of their expression. Further research is 
needed to clarify the potential role of helminths in the modulation of the inflamma-
tory response.
9. Conclusion
TLRs, one of the best characterized families of receptors, have a critical role 
in the host defense against infection. Additionally, they play a key role in the 
capacity of different protozoans and helminths to be able to generate a continuous 
activation of the host immune system by modulating the elements of the innate 
and/or adaptive response. Such intervention by these parasites in the immune 
response is aimed at promoting their survival inside the host. Single-nucleotide 
polymorphisms in TLRs participate importantly in increasing parasitemia in the 
host. However, agonists of TLRs can have a dual role. Whereas they may serve as 
adjuvants or vaccines to promote the maturation of dendritic cells and thus induce 
an adaptive immune response, they are also capable of triggering inflammatory 
cytokine production that has a pathogenic role in many diseases. Consequently, 
antibodies to TLRs and inhibitors of TLR signaling pathways have considerable 
potential as therapeutic agents. It is still necessary to clarify their mechanisms 
for modulating the response of these receptors to be able to design and develop 
innovative therapeutic targets.
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Abstract
Toll-like receptors (TLRs), a major component of innate immune system, 
are expressed as membrane or cytosolic receptors on neutrophils, monocytes, 
macrophages, dendritic cells (DCs), B lymphocytes, Th1, Th2, and regulatory T 
lymphocytes. It recognizes pathogen-associated molecular patterns (PAMPs) and Toll-
interleukin1 (IL-1) receptor (TIR) of various invading pathogens. Downstream signal-
ing of TLRs activates NF-κB, which acts as a transcription factor of pro-inflammatory 
cytokines, chemokines, and costimulatory molecules. A balance between pro- and 
anti-inflammatory cytokine protects host body from infectious agents and also induces 
the healing process. Some of parasitic infections by protozoans and helminths such 
as Malaria, Leishmaniasis, Trypanosomiasis, Toxoplasmosis, Amoebiasis, Filariasis, 
Schistosomiasis, Ascariasis, Taeniasis, and Fasciolosis are the leading cause of death 
and economic loss in both developing and developed nations. Frequent exposure to 
parasites, immigration, refugee resettlement, increasing immunodeficiency, climate 
change, drug resistance, lack of vaccination, etc. are the major cause of emerging and 
re-emerging of the above-stated diseases. However, TLR activation by parasites could 
stimulate antigen presenting cells and ultimately clear the pathogens by phagocytosis. 
So, a better understanding of host-parasite interaction in relation to TLR signaling 
pathway will improve the controlling method of these pathogens in immunotherapy.
Keywords: Toll-like receptors, pathogen-associated molecular patterns,  
protozoan parasite, helminth infection
1. Introduction
Increasing cases of parasitic infections (due to protozoans and helminths) and 
high rate of mortality are the greatest problem of today’s world. Some of these 
diseases such as Malaria, Filariasis, Trypanosomiasis, Leishmaniasis, Toxoplasmosis, 
Amoebiasis, Ascariasis, Schistosomiasis, and Taeniasis affect over half a billion 
people worldwide and cause economic loss in both developing and developed coun-
tries [1]. Overpopulations, migration of people into large urban areas, and unhygienic 
environment are the main reasons for making these diseases epidemic [2]. However, 
the tragedy is that only 5% of total health expenditure was given for research work on 
parasitic diseases [3]. Currently, there is no effective vaccine available for these major 
problems. So, a better understanding of pathogenesis during infection, resistance 
mechanism of pathogens, host protective immune response initiation, and progres-
sion is needed for developing effective vaccines or therapeutic interventions [4].
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Among the two types of vertebrate immune system, innate immunity provides 
the first line of defense against parasites. Previous studies stated innate immunity 
as nonspecific response, and it induces the acquired immunity (slower and specific 
response) by providing pathogens to T and B cells [5]. However, recent evidence 
proved that innate immune system also had a great degree of specificity and can 
provide host defense against invading parasites. This is because of the presence of 
five classes of pattern recognition receptors: TLRs (Toll-like receptors), C-type 
lectin receptors, NOD-like receptors (nucleotide-binding oligomerization domain 
leucine-rich repeat-containing receptors), RIG-I (retinoic acid inducible gene I 
protein) helicase receptors, and cytosolic dsDNA sensors [6, 7]. Among them, TLRs 
form a bridge between innate and adaptive immunity and play a very important 
role in parasite eradication. TLRs recognize specific pathogen-associated molecular 
patterns (PAMPs) in pathogens and initiate opsonization, phagocytosis, pro-
inflammatory and anti-inflammatory response, and apoptosis [7, 8].
2. Cells expressing TLRs
TLRs, a major component of innate immunity, are Type-1 transmembrane 
glycoproteins present in both vertebrates and invertebrates [9]. Toll-like receptors 
are named due to their similarity with Drosophila Toll protein (Toll) [10]. All TLRs 
have a highly variable extracellular domain containing leucine-rich repeat (LRR) 
domain for ligand binding and intracellular TIR homology domain [11]. Toll-like 
receptors and interleukin-1 receptor together form “Interleukin-1 receptor/Toll-like 
receptor” superfamily whose all members have a common Toll-IL-1 receptor (TIR) 
domain [12]. Till date, 10 humans and 12 mice functional TLRs were identified. 
Although humans and mice have similar TLR1–9, TLR10 is nonfunctional in mice 
and TLR11–13 are lost in humans [13]. TLR1, TLR2, TLR4, TLR5, and TLR6 recog-
nize extracellular PAMPs, which are expressed on cell surface, whereas TLR3, TLR7, 
TLR8, and TLR9 are expressed within endoplasmic reticulum (ER), endosomes, 
lysosomes, and endolysosomes and identify nucleic acids [14]. The presence of 
TLRs on specific intracellular vesicles restricts their activation by self-nucleic acids 
released by apoptotic cells [15]. TLR11 (a relative of TLR5) and TLR13 are expressed 
in intracellular vesicles [16], but cognate PAMP of TLR13 has not been identified yet 
[17]. Table 1 shows the distribution of various TLRs in different cells.
TLRs can be classified on the basis of their recognized ligands—TLR1/TLR2 
heterodimer (triacylated lipopeptides), TLR2/TLR6 heterodimer (diacylated 
lipopeptides), TLR4 (lipopolysaccharide), TLR3 (double-stranded RNA), TLR5 
Cells Expressing TLRs
Neutrophils TLR 1, 2, 4, 5, 6, 7, 8
Monocytes/macrophages TLR 1, 2, 4, 5, 6, 7, 8
Myeloid dendritic cells TLR 2, 3, 4, 7, 8
Plasmacytoid dendritic cells (PDCs) TLR 1, 6, 7, 9
B lymphocytes TLR 1, 3, 6, 7, 9, 10
T lymphocytes (Th1/Th2) TLR 2, 3, 5, 9
T lymphocytes (regulatory) TLR 2, 5, 8
Peripheral blood mononuclear cell (PBMC) TLR 2, 4, 5, 7, 8, 9
Table 1. 
Different Toll-like receptors expressed by immune cells [7, 16].
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(flagellin), TLR 7/8 (single-stranded RNA), and TLR9 (unmethylated CpG motif) 
[18, 19]. These ligands for TLRs are of bacterial, viral, protozoan, fungal, and 
helminth membrane bound or endogenously released molecules such as hyaluronic 
acid, fibrinogen, fibronectin, b-defensins, heparan sulfate proteoglycans, heat 
shock proteins, nucleic acids, and synthetically derived molecules [20].
3. TLR signaling pathway
TLRs present on dendritic cells (DCs) [both myeloid DCs (mDCs) and plasma-
cytoid DCs (pDCs)], neutrophils, macrophages, natural killer (NK), and natural 
killer T (NKT) cells induce dendritic cell maturation, MHC molecule upregulation, 
and costimulatory molecule production (CD40, CD80, and CD86) [21, 22]. The 
cytokines released by TLR signaling ultimately activate Th1 cells (via IL-12 from 
DCs) and Th2 cells (via IL-4 from B cell) [21, 23].
Toll-interleukin-1 receptor (TIR) domain is responsible for transducing the signal 
from TLRs to their adaptor proteins. The C-terminus of all TLRs, IL-1 and IL-18 and 
adaptor proteins of TLRs have this TIR domain. Six adaptor proteins involved in TLR 
signaling are MyD88 (myeloid differentiation factor 88), TIRAP (Toll-IL-1 receptor 
domain-containing adaptor protein) and MAL (MyD88 adapter-like), TRIF (TIR 
domain-containing adaptor inducing interferon-β) and TICAM-1, TRAM (TRIF-
related adaptor protein) and TICAM-2, SARM (sterile-α and HEAT/Armadillo 
motifs-containing protein) and MyD88-5, and BCAP (B Cell Adaptor for PI3K) [24]. 
TLR signaling occurs via two separate pathways: MyD88 (myeloid differentiation 
primary response protein)-dependent pathway and MyD88-independent pathway. 
MyD88-dependent pathway stimulates all TLRs except TLR-3, which gets stimulated 
by MyD88-independent pathway. However, in case of TLR4, both MyD88-dependent 
and independent pathways operate [25]. MyD88 (an adaptor molecule) activates 
IRAK-4 (interleukin-1 receptor-associated kinase-4) alone or in combination with 
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cytokines released by TLR signaling ultimately activate Th1 cells (via IL-12 from 
DCs) and Th2 cells (via IL-4 from B cell) [21, 23].
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adaptor proteins of TLRs have this TIR domain. Six adaptor proteins involved in TLR 
signaling are MyD88 (myeloid differentiation factor 88), TIRAP (Toll-IL-1 receptor 
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MyD88-dependent pathway stimulates all TLRs except TLR-3, which gets stimulated 
by MyD88-independent pathway. However, in case of TLR4, both MyD88-dependent 
and independent pathways operate [25]. MyD88 (an adaptor molecule) activates 
IRAK-4 (interleukin-1 receptor-associated kinase-4) alone or in combination with 





adapter-like). Then, IRAK-4 phosphorylates IRAK-1 [26] which in turn phos-
phorylates IRAK-2. IRAK-2 ubiquitinates TRAF6 (tumor necrosis factor receptor-
associated factor 6) and induces two signaling pathways: (1) AP-1 (activator protein 
1) activation via MAK 4/7 (mitogen-activated protein kinase) phosphorylation and 
(2) TAK1 (transforming growth factor-β-activated kinase 1) activation ultimately 
leads to MAPK (mitogen-activated protein kinase) and IKK complex [27] stimula-
tion and nuclear factor κB (NF-κB) translocation inside the nucleus via degradation 
of its inhibitor. Both AP-1 and NF-κB induce the expression of pro-inflammatory 
cytokines and chemokines. A different MyD88-dependent pathway stimulates TLR 
7, 8, and 9, which acts as a ligand for viral nucleic acids. MyD88-associated IRAK1 
(interleukin-1 receptor-associated kinase-1) phosphorylates IRF7 (interferon-
regulatory factor-7), which regulates Type I interferon expression [28]. TLR signal-
ing through MyD88-independent pathway occurs via two adaptor molecules—TRIF 
(Toll-IL-1 receptor domain-containing adaptor inducing interferon-β) and TRAM 
(TRIF-related adaptor molecules) (Figure 1). This induces Type 1 interferon by 
IRF-3 (interferon-regulatory factor-3), NF-κB activation, and expression of co-
stimulatory molecules [29].
4. Protozoan infections
Different protozoan (Plasmodium, Leishmania, Trypanosoma, Toxoplasma, and 
Entamoeba) PAMPs induced pathogenic reactions through TLR signaling pathway.
4.1 Malaria
Malaria, one of the most life-threatening diseases of human history, has infected 
about 219 million people over 90 countries with around 1 million deaths per year. 
Plasmodium, an intracellular protozoan parasite, is the causative agent of malaria. 
It is transmitted by infected female Anopheles mosquito biting, and four species of 
Plasmodium are responsible for human malarial infection. Among Plasmodium falci-
parum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae, P. falciparum 
is the deadliest. Recently, another species named Plasmodium knowlesi has been found 
to infect humans [30]. In the early presymptomatic stage, a very low level of plasmo-
dium can induce inflammatory response [31]. The innate immune genes such as TLRs, 
PRRs, and inflammatory cytokines are already upregulated, and these lead to elevate 
the level of TNF, IFN, and IL-12 from plasmodium-infected peripheral blood mono-
nuclear cells (PBMCs) up to 48 h of infection [32, 33]. These inflammatory responses 
are associated with the pathophysiological condition and clinical symptoms of 
malaria including anemia, cerebral malaria, and ultimate death [34]. Cerebral malaria 
is caused due to overexpression and binding of adhesion molecules such as intracellu-
lar adhesion molecule 1 (ICAM-1), vascular cellular adhesion molecule 1 (VCAM-1), 
endothelial/leukocyte adhesion molecule (ELAM-1), and CD36 [35] on brain endo-
thelial cell receptors. Thus, inflammatory response leads to sequestration of infected 
red blood cells in host brain [36]. Furthermore, TNF and IFN suppress hematopoiesis 
and lead to anemia during malarial infection [37]. The potential immunomodula-
tors of the malarial parasites are: (1) plasmodial glycosylphosphatidylinositol (GPI) 
anchors, (2) hemozoin, and (3) plasmodial DNA. All of these three molecules are 
referred as “malaria toxin” released during schizogony and cause inflammation and 
symptoms of malaria [38, 39].
Homodimer of TLR4 and heterodimer of TLR1/TLR2 and TLR4/TLR6 can 
bind to GPIs released during erythrocytic phase of P. falciparum infection [40]. 
GPI induces TLR-mediated proinflammatory cytokines (TNFα and IL-1) [41] and 
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nitric oxide [42] release from macrophages. It also induces cerebral malaria at later 
course of infection [43]. Plasmodium 2-Cys peroxiredoxin also acts as a TLR4 ligand 
in monocyte and mast cells and causes cytokine production [44]. Hemozoin is 
released during each life cycle of P. falciparum infection and makes a complex with 
plasmodial DNA. This complex acts as a TLR9 ligand and leads to the production 
of proinflammatory cytokines (TNFα and IL-1β) [45]. Hemozoin DNA complex 
induces cerebral malaria by caspase 1-mediated inflammasome (NLRP3) formation 
by TLR9 in case of P. chabaudi infection [46] but is absent in P. berghei spoprozoite 
infection [47]. Although in case of both mice and humans, Plasmodium infection 
renders no TLR stimulation in dendritic cells. The infant exposed to TLR-mediated 
cytokine profiles (IL-10) is associated with higher risk of P. falciparum maternal 
infection during delivery [48]. RNA of P. chabaudi acts as a ligand for TLR7 and 
induces IFNγ, IL-10, IL-12, and TNF release at 24 h of infection [49]. In case of P. 
vivax infection, TLR5 and TLR7 hinder parasitic growth, but TLR9 is associated with 
high inflammation and cytokine production [50]. The 19 kDa C-terminal fragment 
of merozoite surface protein 1 (MSp1) in P. vivax acts as a ligand for TLR5 [51]. 
P. yoelii infection in peritoneal macrophages enhances TLR and parasite-specific 
immune response [52] (Figure 2). Other than Th1 response, malaria parasite-
derived molecules also induce Th2 response via IL-4-inducing  
factor (released by PI3K-Akt-NF-κB signaling) in DC [53].
4.2 Leishmaniasis
Leishmaniasis is one of the deadliest parasitic infections with an estimation of 
200,000–400,000 worldwide infections each year. A protozoan parasite is the caus-
ative agent of this disease, which is transmitted to humans by the biting of female 
Phlebotomus sandfly. The pathology of this infection and causative parasitic species 
includes cutaneous (i.e., L. major, L. mexicana, and L. guyanensis), mucocutaneous  
(i.e., L. amazonensis and L. braziliensis), or visceral leishmaniasis (L. donovani and  
L. chagasi) [54]. Several reports indicate that few Leishmania-derived molecules could 
interact with innate immune receptors (TLRs) of host and result in inflammatory 
Figure 2. 
TLR signaling during Plasmodium infection.
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and lead to anemia during malarial infection [37]. The potential immunomodula-
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bind to GPIs released during erythrocytic phase of P. falciparum infection [40]. 
GPI induces TLR-mediated proinflammatory cytokines (TNFα and IL-1) [41] and 
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nitric oxide [42] release from macrophages. It also induces cerebral malaria at later 
course of infection [43]. Plasmodium 2-Cys peroxiredoxin also acts as a TLR4 ligand 
in monocyte and mast cells and causes cytokine production [44]. Hemozoin is 
released during each life cycle of P. falciparum infection and makes a complex with 
plasmodial DNA. This complex acts as a TLR9 ligand and leads to the production 
of proinflammatory cytokines (TNFα and IL-1β) [45]. Hemozoin DNA complex 
induces cerebral malaria by caspase 1-mediated inflammasome (NLRP3) formation 
by TLR9 in case of P. chabaudi infection [46] but is absent in P. berghei spoprozoite 
infection [47]. Although in case of both mice and humans, Plasmodium infection 
renders no TLR stimulation in dendritic cells. The infant exposed to TLR-mediated 
cytokine profiles (IL-10) is associated with higher risk of P. falciparum maternal 
infection during delivery [48]. RNA of P. chabaudi acts as a ligand for TLR7 and 
induces IFNγ, IL-10, IL-12, and TNF release at 24 h of infection [49]. In case of P. 
vivax infection, TLR5 and TLR7 hinder parasitic growth, but TLR9 is associated with 
high inflammation and cytokine production [50]. The 19 kDa C-terminal fragment 
of merozoite surface protein 1 (MSp1) in P. vivax acts as a ligand for TLR5 [51]. 
P. yoelii infection in peritoneal macrophages enhances TLR and parasite-specific 
immune response [52] (Figure 2). Other than Th1 response, malaria parasite-
derived molecules also induce Th2 response via IL-4-inducing  
factor (released by PI3K-Akt-NF-κB signaling) in DC [53].
4.2 Leishmaniasis
Leishmaniasis is one of the deadliest parasitic infections with an estimation of 
200,000–400,000 worldwide infections each year. A protozoan parasite is the caus-
ative agent of this disease, which is transmitted to humans by the biting of female 
Phlebotomus sandfly. The pathology of this infection and causative parasitic species 
includes cutaneous (i.e., L. major, L. mexicana, and L. guyanensis), mucocutaneous  
(i.e., L. amazonensis and L. braziliensis), or visceral leishmaniasis (L. donovani and  
L. chagasi) [54]. Several reports indicate that few Leishmania-derived molecules could 
interact with innate immune receptors (TLRs) of host and result in inflammatory 
Figure 2. 
TLR signaling during Plasmodium infection.
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response. This inflammation effectively deprives parasites from the host by inducing 
efficient adaptive responses.
Lipophosphoglycan (LPG) occurs as a surface protein of L. major, L. mexicana, 
L. aethiopica, and L. tropica and acts as a major ligand for TLR-mediated host 
immune response. LPG’s secreted form is structurally similar to membrane bound 
form with differences in sugar types of glycan and in number of phosphorylated oli-
gosaccharide repeats. Membrane bound LPG induces ROS production and Th2 cell 
differentiation, whereas soluble LPG causes Th1-promoting cytokine production 
[55]. Inside NK cells, LPG of L. tropica induces TNFα, IFNγ, nitric oxide (NO), and 
reactive oxygen species (Th1 response) release via TLR2 upregulation and stimula-
tion [56, 57]. TLR2 can also induce immune response by altering TLR9 expression 
[58]. However, in case of L. braziliensis and L. amazonensis, parasite could decrease 
IL-12 production, increase IL-10 production by TLR2-mediated p38 MAPK inhibi-
tion in macrophages, and thus increase pathogenesis. TLR2/TLR4 dimerization 
induces the expression of SOCS-1 and SOCS-3 (suppressor of cytokine signaling 
protein) by LPG [59]. A protein structurally related to silent information regulator 
2 (SIR2) family could activate B lymphocytes, major histocompatibility complex 
(MHC) II, CD40 and CD86 (costimulatory molecules) overexpression, DC matura-
tion, and TNFα and IL12 secretion through TLR2 [60]. HO-1 (heme oxygenase-1) 
mediated inhibition of TLR2, 4, 5, and 9 (but not TLR3) association with their 
adaptor proteins resulted in downregulation of TNFα and IL-12 production in  
L. chagasi and L. donovani infection [61]. This inflammatory imbalance occurs due 
to MAPKp38 phosphorylation inhibition and ERK 1/2 phosphorylation activation 
in macrophages. In addition, L. donovani, L. mexicana (expressed p8 proteogly-
colipid complex), and L. major suppressed TLR4 activation by releasing TGFβ 
that activates A20, a complex deubiquitinating enzyme, through SRC homology 
region-2 domain containing phosphatase-1 (SHP-1) and IRAK inactivation [62]. 
Proteoglycolipid complex (P8), host-derived Apolipoprotein E (ApoE), and four 
glycolipids of L. pifanoi amastigote were the ligands of TLR4 and control the 
parasite [55]. P8 activates TLR4 of parasitophorous vacuole, which induces IL1 and 
TNFα production and aids in phagocytosis of L. pifanoi. At early stage of infection, 
neutrophil-derived serine protease and elastase results in parasite death, but at later 
stage, bone marrow derived macrophages (M2b macrophage) phagocytose neu-
trophil and helps in L. major replication by Th2-type response [63]. L. panamensis 
infection results in TNF α production through TLR-1, TLR-2, TLR-3, and TLR-4 
pathway in human primary macrophages [64], metacyclic promastigote of L. mexi-
cana induce phosphorylation of MAP kinases (ERK, p38, and JNK) through TLR4 
and MФ(bone marrow-derived macrophages), iNOS, cyclooxygenase-2 (COX-2), 
prostaglandin E2 (PGE2), NO, and arginase-1 are act as the inflammatory response 
mediators [65]. Leishmania parasites grow inside the phagolysosome of the host 
cells, which reflect that endosomally localized TLRs are also involved in pathogen-
esis [66]. In case of L. donovani infection, TLR7 activates IRF-5 and induces Th1 
responses of host [67]. Cytosine-phosphate-guanosine motifs in DNA of L. major 
induce TLR9-mediated NK cell activation and IL12 production from bone marrow-
derived DC [68, 69]. Recent reports show that viral RNA present in L. guyanensis 
(LRV1-Lg), L. major (LRV2-Lmj) [70], and L. aethiopica (LRV2-Lae) serves as a 
ligand for TLR3 [71]. TLR3 produces NO and TNFα during L. donovani infection 
and mediates leishmanicidal activity [72] (Figure 3).
4.3 Trypanosomiasis
The protozoan parasites of the genus Trypanosoma cause a group of disease 
in several vertebrates, called trypanosomiasis or trypanosomosis. In humans, 
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Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense cause African 
trypanosomiasis or sleeping sickness (transmitted by tsetse fly), and Trypanosoma 
cruzi causes American trypanosomiasis or chagas disease (blood feeding 
Triatominae bugs) [73]. All of these parasites cause millions of death per year in 
both sub-Saharan African and Latin American countries. The disease remains 
asymptomatic for several years and ultimately affects the central nervous system, 
heart, and GI tract [74].
TLR receptor plays an important role in internalization of the parasite through 
phagocytosis and induces immune response for parasite eradication from cells [75]. 
GPI anchored mucin-like glycoproteins (tGPI-mucin contains unsaturated alkyl-
acylglycerol) of the T. cruzi trypomastigote membrane activates MAPK (by phos-
phorylation) and IkB (inhibitor of NF-κB), which triggers TLR2-mediated cytokine 
production by macrophages [76]. A TLR2-TLR6 and CD14 complex recognize the 
free GPI (glycoinositophospholipids containing ceramide) from T. cruzi parasite 
(epimastigote) [77]. Tc25, a T. cruzi derived protein, induces TLR2-mediated pro-
inflammatory cytokine release from host cells [78]. However, role of GPI anchors 
VSGs of T. brucei Trypomastigotes in specific TLR-mediated macrophage activation 
and proinflammatory cytokine (TNFα, IL-6, and NO) production have not been 
elucidated yet [79]. T. cruzi and T. brucei genomic DNA (contains unmethylated 
CpG motifs) have TLR9-mediated TNFα and IFNα/β stimulation and penetration 
of T cells in brain parenchyma [80, 81] (Figure 4).
4.4 Toxoplasmosis
Toxoplasma gondii, an obligate intracellular apicomplexan parasite, is a leading 
cause of food borne disease in a wide range of worm-blooded animals worldwide 
[82]. T. gondii causes asymptomatic toxoplasmosis in healthy adults and produces 
severe toxoplasmic encephalitis in immune compromised people [83]. Moreover, it 
causes congenital toxoplasmosis in fetus leading to death and abortion [84]. Inside 
its intermediate host humans, mice, etc., T. gondii proliferates asexually to form 
tachyzoite and bradyzoite stages [85].
Figure 3. 
TLR signaling induced by different Leishmania ligands.
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TLR11 and TLR12 recognize T. gondii profiling (TgPRF) and induce IL12 and 
IFNα production in conventional dendritic cells (cDCs), macrophages, and plas-
macytoid dendritic cells (pDCs). This IFNα induces IFNγ production from NK 
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cells. T. gondii infection also induces IFNβ production in inflammatory monocytes 
(IMs) and TLR4-mediated phagocytic uptake of the parasite [86]. Endosomal TLRs 
(TLR3, TLR7, and TLR9) stimulate IL12 production in human PBMCs in response to 
DNA and mRNA of T. gondii tachyzoites when the cells were primed with IFNγ [87]. 
GPIs present in parasite membrane aggravate TLR2- and TLR4-mediated TNFα 
production in inflammatory response [88]. In some cases, tachyzoites differenti-
ate into bradyzoites inside the central nervous system and cause neurological and 
behavioral abnormalities [89]. TLR2 signaling pathway makes chronic inflamma-
tion in different central nervous system cell types [85] (Figure 5).
4.5 Amoebiasis
Entamoeba histolytica is a protozoan parasite, which causes amebiasis in humans. 
It is one of the deadliest diseases after malaria and causes almost 40,000–100,000 
deaths per year in underdeveloped countries [90]. The clinical symptoms include 
diarrhea, dysentery, pain in lower abdomen, and liver abscess, which occur due to 
invasion of amoeba in host lung, heart, brain, skin, genital, etc. [91]. The lipophos-
phopeptidoglycan (LPPG) present on the surface of E. histolytica induces TLR2- and 
TLR4-mediated NF-κB activation and cytokine (IL-8, IL-10, IL-12p40, and TNFα) 
release from human monocytes [92]. The Gal/GalNAc lectin (Gal-lectin), a surface 
molecule of E. histolytica, upregulates cytokines and TLR2 genes via NF-κB and 
MAP kinase activation in macrophages and dendritic cells [93]. TLR9 recognizes 
E. histolytica genomic DNA and helps in TNFα production in macrophages [94] 
(Figure 5).
5. Helminth infections
Although several studies were conducted on TLR signaling in response to 
intracellular parasites, only a few examination reflects the interaction of helminths 
with TLRs.
5.1 Filariasis
Lymphatic filariasis (commonly called elephantiasis), caused by three species 
of nematode parasites, Wuchereria bancrofti, Brugia malayi, and B. timori, is a 
major health problem in tropical countries. During initial stage, infection remains 
asymptomatic. Acute condition displays local inflammation of skin, lymph nodes, 
and lymphatic vessels, which ultimately leads to edema in chronic condition [95]. 
Wolbachia, an intracellular symbiotic bacterium of filarial nematode, is the major 
mediator of inflammatory response in case of lymphatic filariasis and onchocer-
ciasis [2]. WSP protein in outer membrane of Wolbachia sp. induces TLR2- and 
TLR4-mediated inflammation in macrophages and DCs [96].
In case of chronic infection, filarial nematode downregulates host immune 
response via TLR4-mediated T cell apoptosis [97]. Live microfilariae of B. malayi 
can downregulate mRNA and protein expression of TLR1, TLR2, TLR4, and TLR9 
and activate TLR2 upon antigen stimulation on B cells and monocytes [98]. In DCs, 
live microfilariae and microfilarial antigen (MF Ag) diminish IL-12, IFNα, and 
cytokine production via inhibition of NF-κB complex formation [99]. Microfilariae 
infective stage (L3) of B. malayi also shows partial inhibition of Langerhans cells 
(LCs) that lead to CD4+ T cell proliferation [100]. Circulating B cells (called Breg) 
express TLR2 and TLR4 and maintain a worm favorable condition via induction 
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GPIs present in parasite membrane aggravate TLR2- and TLR4-mediated TNFα 
production in inflammatory response [88]. In some cases, tachyzoites differenti-
ate into bradyzoites inside the central nervous system and cause neurological and 
behavioral abnormalities [89]. TLR2 signaling pathway makes chronic inflamma-
tion in different central nervous system cell types [85] (Figure 5).
4.5 Amoebiasis
Entamoeba histolytica is a protozoan parasite, which causes amebiasis in humans. 
It is one of the deadliest diseases after malaria and causes almost 40,000–100,000 
deaths per year in underdeveloped countries [90]. The clinical symptoms include 
diarrhea, dysentery, pain in lower abdomen, and liver abscess, which occur due to 
invasion of amoeba in host lung, heart, brain, skin, genital, etc. [91]. The lipophos-
phopeptidoglycan (LPPG) present on the surface of E. histolytica induces TLR2- and 
TLR4-mediated NF-κB activation and cytokine (IL-8, IL-10, IL-12p40, and TNFα) 
release from human monocytes [92]. The Gal/GalNAc lectin (Gal-lectin), a surface 
molecule of E. histolytica, upregulates cytokines and TLR2 genes via NF-κB and 
MAP kinase activation in macrophages and dendritic cells [93]. TLR9 recognizes 
E. histolytica genomic DNA and helps in TNFα production in macrophages [94] 
(Figure 5).
5. Helminth infections
Although several studies were conducted on TLR signaling in response to 
intracellular parasites, only a few examination reflects the interaction of helminths 
with TLRs.
5.1 Filariasis
Lymphatic filariasis (commonly called elephantiasis), caused by three species 
of nematode parasites, Wuchereria bancrofti, Brugia malayi, and B. timori, is a 
major health problem in tropical countries. During initial stage, infection remains 
asymptomatic. Acute condition displays local inflammation of skin, lymph nodes, 
and lymphatic vessels, which ultimately leads to edema in chronic condition [95]. 
Wolbachia, an intracellular symbiotic bacterium of filarial nematode, is the major 
mediator of inflammatory response in case of lymphatic filariasis and onchocer-
ciasis [2]. WSP protein in outer membrane of Wolbachia sp. induces TLR2- and 
TLR4-mediated inflammation in macrophages and DCs [96].
In case of chronic infection, filarial nematode downregulates host immune 
response via TLR4-mediated T cell apoptosis [97]. Live microfilariae of B. malayi 
can downregulate mRNA and protein expression of TLR1, TLR2, TLR4, and TLR9 
and activate TLR2 upon antigen stimulation on B cells and monocytes [98]. In DCs, 
live microfilariae and microfilarial antigen (MF Ag) diminish IL-12, IFNα, and 
cytokine production via inhibition of NF-κB complex formation [99]. Microfilariae 
infective stage (L3) of B. malayi also shows partial inhibition of Langerhans cells 
(LCs) that lead to CD4+ T cell proliferation [100]. Circulating B cells (called Breg) 
express TLR2 and TLR4 and maintain a worm favorable condition via induction 
of Treg, IL-10, and filarial-specific IgG. However, Breg-mediated response causes 
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asymptomatic infection in initial stages but leads to secondary infection by bacteria 
and virus in filarial patients [92]. A phosphocholine-containing glycoprotein  
(ES-62) of Acanthocheilonema viteae (rodent filarial nematode) inhibits B and T 
lymphocyte activation. The secretory ES-62 inhibits TLR4-mediated IL-12 and 
TNFα production [101] (Figure 6).
5.2 Schistosomiasis
Schistosomiasis is a worldwide distributed parasitic disease caused by a 
flatworm, Schistosoma. It accounts for 260 million infected people in tropical 
and sub-tropical regions (Africa, South America, the Middle East, East Asia, and 
the Philippines) [102]. S. mansoni, S. intercalatum, S. haematobium, S. japonicum, 
and S. mekongi are the five species of schistosomes that cause disease in humans. 
S. mansoni, S. japonicum, and S. intercalatum are responsible for intestinal schis-
tosomiasis, while S. haematobium causes urinary schistosomiasis and is most 
important in terms of public health [102]. Fresh water snail of the genus Bulinus 
(S. haematobium), Biomphalaria (S. mansoni), and Oncomelania (S. japonicum) 
acts as an intermediate host of Schistosoma parasites [103].
S. japonicum eggs are deposited in the liver, lung, and intestinal wall of host, 
which induce granulomatous inflammation and progressive fibrosis. Th cells, natu-
ral killer (NK) cells, NKT cells, myeloid-derived suppressor cells (MDSCs), and 
macrophages are mainly involved in fight against S. japonicum and its eggs [104]. 
Expressions of TLR1, TLR3, TLR7, TLR8, and NF-κB are greatly repressed at the 
initial stage of schistosomiasis. TLR3 modulates Th2 response in lung in S. mansoni 
infection and in NK cells during S. japonica infection [105]. S. mansoni is known to 
attenuate Th1 responses (decrease IFN𝛾𝛾, TNF𝛼𝛼, IL-12, and NO) but to promote Th2 
immune responses (increase IL-10 and TGF𝛽𝛽) [106]. Although TLR4 protects the 
host from Schistosoma infection, TLR2 favors the parasite growth [107]. Both SEA 
(soluble egg antigen) and ES products of S. mansoni act as a strong inducer of Th2 
response [108]. It induces transcription of markers CD40 and CD86 and cytokines 
IFNβ, TNFα, and IL-12-p40 in mouse myeloid DCs [109]. Glycans present in 
S. mansoni induce Treg by TLR2-mediated DC differentiation and IL-10 secre-
tion [110]. Schistosoma egg product LFNP III also stimulates IL-10 production 
Figure 6. 
TLR signaling pathway induced by Helminth pathogens.
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from TLR2 and promotes Treg activation [111]. An immunomodulatory peptide, 
SJMHE1 of S. japonicum, induces TLR2-mediated Treg activation. The lysophos-
phatidylserine and glycolipids [112] of scistosome also activate TLR2 in DCs [113] 
(Figure 6).
5.3 Taeniasis
The pork tapeworm (Taenia solium) is a cestoda parasite transmitted to humans 
by feeding cystic larvae infected pork. Here, pig acts as an intermediate host, which 
swallows T. solium egg containing human stool and develops larva inside their 
body [114]. The cysticercosis cyst causes neurocysticercosis (NCC) in the nervous 
system, and adult taenia produces intestinal taeniasis in humans. Both are endemic 
in Latin America, sub-Saharan Africa, India, vast parts of China, and South East 
Asia [115].
TLR4 and TLR2 play an important role in developing murine NCC caused 
by Mesocestoides corti [116]. The carbohydrate of T. crassiceps induces TLR4- and 
TLR2-mediated cytokine release (IL-6 and IL-4) [117]. However, molecules derived 
from T. sodium did not induce TLR2- or TLR4-mediated cytokine release in human 
lymphocytes [118]. Both T. solium and T. crassiceps express several glycolipids 
(GSL-1) and phospholipids that may act as PAMPs. T. crassiceps expresses lysophos-
phatidylcholine [119], also present on Schistosome, and triggers TLR2 response. 
Although the mechanism of these molecules inducing TLR signaling has not yet 
been evaluated, the host may use a similar pathway of this parasite recognition 
[120] (Figure 6).
5.4 Ascariasis
Phospholipids from schistosomes and Ascaris worm trigger TLR2, and lysophos-
phatidylserine can activate DCs to induce Th2 and IL-10-producing Treg [121].
5.5 Fasciolosis
F. hepatica tegumental antigens (FhTeg), F. hepatica ES, and ES-derived enzymes 
(thioredoxin peroxidase 2-Cys peroxiredoxin, fatty acid-binding protein) inhibit 
TLR4- and TLR3-mediated inflammatory response and facilitate parasite survival 
inside the host [122]. The protease activity of F. hepatica Cathepsin L1 (FheCL1) 
causes endosomal degradation of TLR3 and downregulates IL-1 production [123].
6. Conclusion
In conclusion, induction of TLR signaling pathway by infectious pathogen 
recognition provides a better understanding of innate immune defense mechanism 
against this disease. Immunotherapy emerges as a promising therapeutic approach 
for parasitic infection treatment over the past few years. Although no effective 
drugs have emerged, vaccine adjuvants yield promising results due to induction of 
cellular immunity via TLR. Large scales of clinical studies were conducted for devel-
oping potent and well-tolerated adjuvants. The protozoan and helminth parasites 
can cause activation (to a small degree) and negative regulation (to a larger degree) 
of TLRs resulting in increasing or decreasing parasite burden [103]. TLR agonists 
or antagonists are small molecule mimics, natural ligands used for treating Type I 
allergy, cancer, and infectious diseases. MF59 (Novartis) and AS04 (GSK) are some 
examples of TLR4 agonist licensed for human use [124]. GLA (TLR4 ligand) and 
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asymptomatic infection in initial stages but leads to secondary infection by bacteria 
and virus in filarial patients [92]. A phosphocholine-containing glycoprotein  
(ES-62) of Acanthocheilonema viteae (rodent filarial nematode) inhibits B and T 
lymphocyte activation. The secretory ES-62 inhibits TLR4-mediated IL-12 and 
TNFα production [101] (Figure 6).
5.2 Schistosomiasis
Schistosomiasis is a worldwide distributed parasitic disease caused by a 
flatworm, Schistosoma. It accounts for 260 million infected people in tropical 
and sub-tropical regions (Africa, South America, the Middle East, East Asia, and 
the Philippines) [102]. S. mansoni, S. intercalatum, S. haematobium, S. japonicum, 
and S. mekongi are the five species of schistosomes that cause disease in humans. 
S. mansoni, S. japonicum, and S. intercalatum are responsible for intestinal schis-
tosomiasis, while S. haematobium causes urinary schistosomiasis and is most 
important in terms of public health [102]. Fresh water snail of the genus Bulinus 
(S. haematobium), Biomphalaria (S. mansoni), and Oncomelania (S. japonicum) 
acts as an intermediate host of Schistosoma parasites [103].
S. japonicum eggs are deposited in the liver, lung, and intestinal wall of host, 
which induce granulomatous inflammation and progressive fibrosis. Th cells, natu-
ral killer (NK) cells, NKT cells, myeloid-derived suppressor cells (MDSCs), and 
macrophages are mainly involved in fight against S. japonicum and its eggs [104]. 
Expressions of TLR1, TLR3, TLR7, TLR8, and NF-κB are greatly repressed at the 
initial stage of schistosomiasis. TLR3 modulates Th2 response in lung in S. mansoni 
infection and in NK cells during S. japonica infection [105]. S. mansoni is known to 
attenuate Th1 responses (decrease IFN𝛾𝛾, TNF𝛼𝛼, IL-12, and NO) but to promote Th2 
immune responses (increase IL-10 and TGF𝛽𝛽) [106]. Although TLR4 protects the 
host from Schistosoma infection, TLR2 favors the parasite growth [107]. Both SEA 
(soluble egg antigen) and ES products of S. mansoni act as a strong inducer of Th2 
response [108]. It induces transcription of markers CD40 and CD86 and cytokines 
IFNβ, TNFα, and IL-12-p40 in mouse myeloid DCs [109]. Glycans present in 
S. mansoni induce Treg by TLR2-mediated DC differentiation and IL-10 secre-
tion [110]. Schistosoma egg product LFNP III also stimulates IL-10 production 
Figure 6. 
TLR signaling pathway induced by Helminth pathogens.
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from TLR2 and promotes Treg activation [111]. An immunomodulatory peptide, 
SJMHE1 of S. japonicum, induces TLR2-mediated Treg activation. The lysophos-
phatidylserine and glycolipids [112] of scistosome also activate TLR2 in DCs [113] 
(Figure 6).
5.3 Taeniasis
The pork tapeworm (Taenia solium) is a cestoda parasite transmitted to humans 
by feeding cystic larvae infected pork. Here, pig acts as an intermediate host, which 
swallows T. solium egg containing human stool and develops larva inside their 
body [114]. The cysticercosis cyst causes neurocysticercosis (NCC) in the nervous 
system, and adult taenia produces intestinal taeniasis in humans. Both are endemic 
in Latin America, sub-Saharan Africa, India, vast parts of China, and South East 
Asia [115].
TLR4 and TLR2 play an important role in developing murine NCC caused 
by Mesocestoides corti [116]. The carbohydrate of T. crassiceps induces TLR4- and 
TLR2-mediated cytokine release (IL-6 and IL-4) [117]. However, molecules derived 
from T. sodium did not induce TLR2- or TLR4-mediated cytokine release in human 
lymphocytes [118]. Both T. solium and T. crassiceps express several glycolipids 
(GSL-1) and phospholipids that may act as PAMPs. T. crassiceps expresses lysophos-
phatidylcholine [119], also present on Schistosome, and triggers TLR2 response. 
Although the mechanism of these molecules inducing TLR signaling has not yet 
been evaluated, the host may use a similar pathway of this parasite recognition 
[120] (Figure 6).
5.4 Ascariasis
Phospholipids from schistosomes and Ascaris worm trigger TLR2, and lysophos-
phatidylserine can activate DCs to induce Th2 and IL-10-producing Treg [121].
5.5 Fasciolosis
F. hepatica tegumental antigens (FhTeg), F. hepatica ES, and ES-derived enzymes 
(thioredoxin peroxidase 2-Cys peroxiredoxin, fatty acid-binding protein) inhibit 
TLR4- and TLR3-mediated inflammatory response and facilitate parasite survival 
inside the host [122]. The protease activity of F. hepatica Cathepsin L1 (FheCL1) 
causes endosomal degradation of TLR3 and downregulates IL-1 production [123].
6. Conclusion
In conclusion, induction of TLR signaling pathway by infectious pathogen 
recognition provides a better understanding of innate immune defense mechanism 
against this disease. Immunotherapy emerges as a promising therapeutic approach 
for parasitic infection treatment over the past few years. Although no effective 
drugs have emerged, vaccine adjuvants yield promising results due to induction of 
cellular immunity via TLR. Large scales of clinical studies were conducted for devel-
oping potent and well-tolerated adjuvants. The protozoan and helminth parasites 
can cause activation (to a small degree) and negative regulation (to a larger degree) 
of TLRs resulting in increasing or decreasing parasite burden [103]. TLR agonists 
or antagonists are small molecule mimics, natural ligands used for treating Type I 
allergy, cancer, and infectious diseases. MF59 (Novartis) and AS04 (GSK) are some 
examples of TLR4 agonist licensed for human use [124]. GLA (TLR4 ligand) and 
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3M-052 (TLR7/8) ligands are now in clinical trial. Recently, RTS,S/AS01, a recom-
binant chimeric protein (c-terminal of circumsporozoite antigen fused with HPB 
antigen, and “ASO1” refers to the adjuvant formulation MPL and QS21, a natural 
glucoside), is used for treating Malaria [125]. Several new drugs have been chemi-
cally synthesized for better understanding of the interaction of TLRs with their 
ligands. The knowledge from these studies will provide a greater opportunity for 
developing plant-derived new therapeutic drugs. So, major efforts are required for 
targeting TLRs in pathological conditions.
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Approach to TLR Cascades in 
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Abstract
Sterile inflammatory response constitutes a main event in several neurodegener-
ative disorders. Alzheimer’s disease (AD) and Parkinson’s disease (PD), the leading 
degenerative pathologies of the central nervous system worldwide, exhibit a strong 
inflammatory component. Microglial and astrocytic reactivity, increased levels of 
inflammatory mediators, neuronal damage, and death are part of the pathological 
scenario leading to the progressive failure of the brain neuronal network. In this 
regard, the link between the toll-like receptors (TLRs)-mediated inflammatory 
cascade and the molecular hallmarks of AD and PD have been demonstrated 
elsewhere. Moreover, the long-lasting exposure to the inflammatory environment 
is considered one of the key elements leading to the establishment and progression 
of these pathologies. Accordingly, the modulation of the inflammatory response 
has emerged as a main target of new therapeutic approaches to fight these diseases. 
In this regard, and based on our previous works on this subject, we describe the 
pathological profile of both pathologies but in the inflammatory context. Thus, in 
the present chapter, we will introduce the main aspects of both diseases and how 
they interplay with the TLR-mediated response. We believe that this chapter should 
provide a concise overview of the roles of TLRs in the inflammatory cascades trig-
gered during AD and PD pathophysiology.
Keywords: neurodegeneration, neuroinflammatory response, toll-like receptors, 
Alzheimer’s disease, Parkinson’s disease
1. Introduction
The aging of the world population has been demonstrated systematically by 
several demographic studies. Regrettably, increased life expectancy has led to an 
increased prevalence of age-related disorders including neurodegenerative diseases. 
In this regard, Alzheimer’s and Parkinson’s diseases constitute the most relevant 
issues for the public health system of different countries. Accordingly, during the 
last decades, significant efforts have been committed to improve our understanding 
of the molecular cascades responsible for an altered aging process as well as for the 
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establishment and progression of neurodegenerative disorders, mainly Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) [1].
Relevantly, though AD and PD possess their very own pathological character-
istics, the neuroinflammatory milieu has emerged as a central event of the chronic 
degenerative process. From the prodromal stage of these disorders up to the more 
advanced ones, inflammation seems to accompany or, in some cases, to drive the 
progression of AD and PD. Importantly, inflammation, as part of the nonspecific 
immune response, plays a critical role in maintenance of system homeostasis, allow-
ing to prevent or to control the detrimental effects induced by a wide variety of 
xenobiotics to the cellular components of the biological systems. Remarkably, from 
an unspecific harmful stimulus, a whole range of responses are triggered including 
complement cascade activation and cytokines release as well as activation of the 
immune cells located at the site of the insult. To properly eliminate the initial cause 
of distress and to repair the damaged tissue, the inflammatory response must be 
delicately balanced considering not only pro-inflammatory but anti-inflammatory 
mediators as well. Tumor necrosis factor 1 (TNF-1α), interleukins (IL-1, IL-8, 
IL-10), interferon (INF-γ), transforming growth factor 1 (TGF-1), complement 
proteins, act together to develop a coordinated response against primary, unspecific 
stimuli [2, 3]. In this regard, the compromise of this essential system relates with 
severe, and often lethal, conditions including immunodeficiency syndromes as 
well as autoimmune diseases. Relevantly, during the last decades, a lot of attention 
has been also given to the effects of chronic inflammatory condition as the start-
ing point of different degenerative conditions. Among these, neurodegenerative 
disorders, such as Alzheimer’s and Parkinson’s diseases, have found in the inflam-
matory response a critical milieu of events able to determinate the main molecular 
and cellular events verified during each of these diseases [4].
2. Central nervous system (CNS) immunocompetence
CNS is a highly specialized structure whose functions require specific microen-
vironmental conditions. Moreover, neuronal activity and, thus, the health of the 
neuronal network depend on the maintenance of ion gradients whose concentration 
differs significantly from the rest of the body compartments [5]. To ensure these 
conditions, the CNS remains partially isolated by the existence of the blood-brain 
barrier (BBB), a highly complex semipermeable cellular barrier whose main 
function is to prevent both exogenous and endogenous elements to alter the brain 
homeostasis [5–7]. Regarding the immune response, microglial population con-
stitutes the only immune system cellular representative within the brain with the 
astrocytes acting as a companion to exert immune surveillance and to act as the first 
line of response against harmful events within the brain. Although some additional 
peripheral immune cells including cluster of differentiation 11b and c (CD11b, 
CD11c)-positive cells localize to the CNS during some inflammatory conditions, 
it is believed that this situation is caused because of an altered permeability of the 
BBB as a consequence of the primary insult [8]. In this sense, the brain parenchyma 
has been defined as an anti-inflammatory environment due the increased levels of 
relevant anti-inflammatory mediators including the transforming growth factor β 
(TGFβ) and interleukin (IL)-10, preventing both the immune cell spreading across 
the CNS and an excessively strong immune response [8–10]. However, this latter 
condition does not imply that the CNS cannot answer to immune challenges; on the 
contrary, the CNS is a fully immunocompetent system, but with this mechanism 
being tightly controlled in order to avoid secondary damage caused by extensive 
inflammation and detrimental cell damage end products, such as reactive oxygen 
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species (ROS). In this context, during the last years, it has been evidenced that 
sustained inflammatory challenge, whether systemic or local to the CNS, will alter 
significantly the neuronal environment affecting severely the neuronal function 
and the health of the neuronal network. Regrettably, it has been suggested that 
prior to AD and PD establishment as well as during their progression, a chronic 
inflammatory condition has developed, contributing to the molecular alterations 
observed during these pathologies.
3. Toll-like receptors
A significant characteristic of AD and PD is that these pathologies exhibit a strong 
inflammatory component even when both are sterile conditions. In this sense, the 
innate immune system works through the pattern recognition receptors (PRRs) which 
recognize molecular patterns related to pathogens (pathogen-associated molecular 
patterns, PAMPs) and to endogenous molecules indicative of cell damage (damage-
associated molecular patterns, DAMPs), such as high-mobility group protein B1 
(HMGB1), S100 proteins, heat shock proteins (HSPs), DNA, mitochondrial DNA 
(mt-DNA), and ATP [11–15]. The toll-like receptors (TLRs) family constitutes a highly 
relevant type of PRR necessary not only to unleash the initial immune response but 
also to connect the first unspecific defense with the secondary adaptive immunity [12].
Depending on the species, 11–13 TLR subtypes can be found. Relevantly, the 
localization of these receptors within the cells differs between the different TLRs. 
In this regard, while TLRs 1, 2, 4, 5, and 6 are expressed at the cell membrane, its 
main objective being to sense the extracellular compartment, the TLRs 3, 7, 8, and 
9 are located inside the cells, mainly associated with endosomes and sensing the 
internal microenvironment for viral components, such as RNA and DNA [12, 16]. 
The presence of TLRs has been determined not only in several cell components of 
the peripheral immune system but also in the different cell types found in the brain 
including astrocytes, microglia, neurons, and oligodendrocytes, suggesting that 
each of these cell types can sense and trigger an immune response in the presence of 
different harmful molecular patterns. Interestingly, it has been demonstrated that 
not all the cells within the brain express the same pattern of TLRs. For example, 
microglia and neurons express all TLR subtypes, while astrocytes express a more 
limited repertoire, including TLR2, TLR3, TLR4, TLR9, and TLR11 [16, 17].
3.1 TLR inflammatory cascade
The signaling cascade triggered after TLRs’ activation involves the cross talk 
with several additional pathways able to critically modify cell physiology. In this 
sense, canonical TLR-mediated signaling involves the myeloid differentiation 
factor 88 (MyD88) cascade. In this pathway, TLR activation couples with MyD88 
inducing the activation of interleukin-1 receptor-associated kinase (IRAK) and, 
subsequently, the activation of the tumor necrosis factor receptor-associated factor 
6. This event allows the recruitment of the transforming growth factor-β-activated 
kinase-1 (TAK1) which, together with the TAK1-binding proteins, leads to the 
phosphorylation of IκB causing the activation of the IKK complex and the release 
of the nuclear factor-κB (NF-κB), triggering the NF-κB-dependent inflamma-
tory response [11, 18, 19]. Importantly, TLR 3 and TLR 4 can also signal via the 
TIR-containing adaptor inducing interferon-β (IFN-β) (TRIF). In this additional 
pathway, additional to the release of NF-κB, it also causes an increased expression 
of IFN-β by means of the IKKε/TANK-binding kinase-1 (TBK1)-dependent phos-
phorylation of the interferon regulatory factor 3 and 7 (IRF3 and IRF7) [7, 19, 20]. 
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The main objective of these TLR-mediated processes is to regulate the expression of 
several pro-inflammatory and anti-inflammatory mediators including IL-1, IL-6, 
IL-10, IL-11, IL-12, tumor necrosis factor (TNF), TGF, IFN, CCL2, CCL5, CXCL8, 
and CXCL10, among others [4, 11, 18, 19].
Additionally, TLR activation can also signal through complementary molecular 
pathways. Indeed, TAK1 activation also induces nemo-like kinase (NLK) and the 
c-Jun N-terminal kinases (JNK) pathway [18–21]. Similarly, MyD88 can signal 
through the phosphatidylinositide-3 kinase (PI3K)/Akt pathway, modulating the 
activity of the glycogen synthase kinase 3 β (GSK3β) [22, 23]. On the other hand, 
it has been demonstrated that TLR2 and TLR4 can activate the PI3K/Akt pathway 
through the Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of 
the Rho family of GTPases [23]. Complimentarily, the Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) (JAK/STAT) pathway is known to 
respond to a variety of PAMPs/DAMPs and cytokines, including different inter-
leukins and INF-β. Relevantly, different studies have demonstrated that several 
members of the TLR family can phosphorylate different STAT members, suggesting 
a direct modulation of the JAK/STAT pathway [24, 25]. As is possible to observe, the 
molecular cascades that could be triggered secondarily to TLR activation are related 
with critical cellular processes including cell cycle modulation, apoptosis, and 
cytoskeleton remodeling, among others. This situation depicts the complexity of 
the immune response and the relevance of its modulation in the context of different 
pathologies including neurodegenerative ones, such as AD and PD.
4. Alzheimer’s and Parkinson’s diseases: Aβ/SNCA and TLRs
4.1 Alzheimer’s disease
AD constitutes the main form of dementia in the elderly population. Although, 
AD is recognized by the memory impairment and the reduced cognitive perfor-
mance, the clinical scenario starts with mood alterations at the very beginning of 
the disease followed by the compromise of the short-term memory and the loss of 
long-term memory as the pathology progresses. Histologically, AD is characterized 
by the atrophy of the frontal cortex, limbic area, and hippocampus. On the other 
hand, the molecular hallmarks of AD are the formation of the amyloid-β (Aβ) 
plaques, constituted by the aggregated forms of the amyloid-β peptide, and the 
intraneuronal formation of neurofibrillary tangles (NFTs) composed of hyperphos-
phorylated tau protein [26]. Relevantly, beyond these hallmarks, AD also exhibits 
increased oxidative stress, mitochondrial dysfunction, and chronic inflammatory 
response. Altogether, these molecular alterations will lead to synaptic damage, 
neuronal loss, and neuronal circuitry breakdown [26, 27].
Relevantly, even when genetic conditions can lead to an early onset AD presen-
tation, this accounts only for a small number of cases worldwide, with over 95% 
of the cases being termed as sporadic or late-onset AD. In this latter case, age and 
lifestyle have been defined as the main risk factors associated with the appearance 
of the disease [26, 27]. In agreement with the amyloid hypothesis of AD, these risk 
factors have a direct impact on the levels of Aβ leading to its increased production 
and subsequent accumulation within the brain [28, 29]. In this regard, different 
studies have linked the synaptic failure, mitochondrial dysfunction, tau hyper-
phosphorylation, glial activation, and neuronal death with increased levels of Aβ 
[27, 30]. Importantly, in the context of neuroinflammation, the ability of Aβ to 
induce the inflammatory response through the TLR2, TLR4, and TLR6, as well as 
their co-receptors including CD36, CD14, and CD47 has been widely demonstrated 
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[31–33]. However, it must to be noticed that systemic inflammatory conditions 
have been linked with an increased risk of AD development, suggesting that the 
pro-inflammatory mediators are able to alter brain homeostasis leading to neuronal 
damage and to the beginning of the neurodegenerative process [34–38].
4.2 Parkinson’s disease
PD corresponds to the second most common neurodegenerative disorder. PD 
is characterized by dopaminergic circuitry impairment caused by the loss of the 
dopaminergic neurons, mainly at the substantia nigra pars compacta (SNpc). 
Defined as synucleinopathy, PD exhibits neuronal inclusions of aggregated 
α-synuclein (SNCA) protein which can be located at the cell soma and/or neurites, 
forming the Lewy bodies and Lewy neurites [39]. SNCA plays relevant roles in the 
synaptic activity as it is linked with the recycling of synaptic vesicle pools [40–42]. 
Moreover, SNCA interferes with the dopamine metabolism affecting both the 
tyrosine hydroxylase, the enzyme in charge of synthetizing dopamine, and the 
dopamine transporter (DAT) [43, 44]. Similar to AD, even when the main signs 
of PD are associated with motor impairment, the pathological scenario begins 
much earlier with sleep disturbances and loss of olfaction which often passes 
unadvised to the patients or their relatives. Dementia is also an additional feature 
of the pathology and the affectation of memory can be part of the clinical picture. 
Although SNCA aggregation explains the damage to the dopaminergic neurons, 
the mechanisms behind SNCA dynamics have remained elusive [39, 45, 46]. 
Although PD can also emerge as a genetics-related disease with several genes linked 
to an early presentation, only a small proportion of the cases share this condition 
worldwide [39, 47]. In the same way, the vast majority of PD cases are linked to 
aging and lifestyle with the exposure of the patients to chemical xenobiotics, such 
as pesticides and recreational drugs being of most relevance [48]. Importantly, the 
SNCA aggregation is also related to the additional features observed during the 
pathological process, including mitochondrial dysfunction, increased oxidative 
stress, and neuroinflammation. Moreover, oxidative stress plays a central role in the 
pathophysiology of PD and the contribution of the ROS to the inflammatory milieu 
seems to be part of the establishment and progression of the disease.
Regarding the SNCA and inflammatory triggering, different researchers have 
demonstrated that depending on the aggregation status of SNCA, this protein can 
activate the TLRs, at least TLR2 and TLR4 [49–52]. Moreover, SNCA can be incor-
porated by the surrounding cells, particularly astrocytes, leading to the formation 
of SNCA inclusions also in these latter cells and helping to spread the SNCA pathol-
ogy across the brain [53, 54]. Relevantly, PD can also be influenced by the systemic 
inflammatory status. Indeed, it has been recently demonstrated that increased 
levels of inflammatory mediators favor SNCA aggregation [55, 56].
4.3 Aβ/SNCA secondary inflammatory cascade
Although we have indicated that both Aβ and SNCA can activate the TLRs, we have 
only spoken about the direct activation induced by these molecules on some represen-
tatives of the TLR family. However, we must realize that once the TLRs are activated, 
a full repertory of pro-inflammatory mediators is released to the environment. In 
this context, Aβ induces the expression of IL-1, IL-6, IL-12, TNF-α, cyclooxygenase 2 
(COX2), and the inducible nitric oxide synthase (iNOS) [57]. Additionally, because of 
the cellular damage caused, it will also induce the release of further DAMPs  
[26, 27, 58]. Similarly, TLRs activated after SNCA challenge will increase the expression 
of TNF-α, IL-6, and CXCL1 [49–51]. In the case of SNCA, the cell damage also will 
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cause the release of several DAMPs. Relevantly, the pro-inflammatory mediators and 
the subsequent DAMPs induced by Aβ and SNCA are able to further activate addi-
tional members of the TLR family, enhancing the inflammatory response. If we take 
into account that in both pathologies the levels of Aβ and SNCA are steadily increasing, 
the concept of a chronic inflammatory condition emerges as a potential mechanism to 
explain the progression of both diseases. Moreover, some of these pro-inflammatory 
mediators can also have a direct impact on the neuronal activity. Such is the case of 
the glial TNF-α-mediated expression of the AMPA receptors within the postsynaptic 
terminal. In this case, the increased production and release of TNF-α by the astrocytes, 
perhaps induced by the chronic exposure to the inflammatory stimulus, will cause the 
hyperexcitability of the neurons leading to glutamate excitotoxicity [59–62].
4.4 Microglial priming
Relevantly, an additional effect caused by Aβ and SNCA should be considered. 
It has been demonstrated that both molecules are also able to induce a phenomenon 
termed “microglial priming.” In this regard, microglial population which remains 
in a resting state when exposed to different inflammatory mediators, DAMPs, and/
or PAMPs can differentiate into two activated phenotypes, the M1 and M2. While 
the M1 is considered as a pro-inflammatory activation state, the M2 is defined as the 
anti-inflammatory microglial phenotype. Interestingly, it has been evidenced that in 
the presence of INF-γ and the TLR-mediated signaling, microglia usually undergo 
M1 transformation. Moreover, when microglia became “primed” usually changes to 
the M2 phenotype but develops a significant sensibility to new exposures to harmful 
stimuli, exhibiting an over dimensioned response and causing the abnormal rais-
ing of pro-inflammatory molecules because of a shift to the M1 phenotype [63–66]. 
Thus, Aβ and SNCA seem to be favoring not only the activation of the microglia to 
the pro-inflammatory phenotype (M1), but also the increase in the responsiveness of 
the microglia to the harmful stimuli. In both cases, the result will be an over activation 
of the microglia with the subsequent release of increased levels of pro-inflammatory 
mediators and ROS, enhancing the damage induced by the initial exposure to Aβ and 
SNCA [67–69]. Similarly, the chronic exposure to these inflammatory mediators can 
induce the repolarization of the microglia changing from the M2 to the M1 phenotype 
[70]. However, additional research is necessary to properly address the significance of 
microglial priming and the effects of the exposure to different levels of pro-inflam-
matory stimuli [71]. Indeed, the work conducted by Pourbadie and cols. [72] seems 
to suggest that low doses of TLR ligands can exert beneficial effects on the neuronal 
circuitry.
4.5 Mitochondrial dysfunction
Another feature of both pathologies is the affectation of the mitochondrial func-
tionality. Both Aβ and SNCA have the ability to interact with this critical organelle. 
While Aβ has been detected outside and inside the mitochondria being able to 
directly induce the several mitochondria-related apoptotic pathways, such as the 
B-cell lymphoma 2 (BCL2)-beclin1 (BECN1) complex [73, 74], SNCA can induce 
the activation of the mitochondrial membrane permeability transition pore, pro-
moting mitochondrial swelling and leading to mitochondrial degradation. Indeed, 
when SNCA degradation is blocked by means of proteasome inhibition, mitochon-
dria result as one of the first organelles to be affected. Moreover, TOM40, a protein 
that is part of the mitochondrial import machinery, has proven to be determinant 
of the SNCA-mediated mitochondrial failure [75–77]. Importantly, one of the most 
critical end points of the mitochondrial failure is the increased production of ROS 
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which is able to induce the activation of microglia and astrocytes as well as to trigger 
the inflammatory response mediated by the TLRs. Vice versa, the increased levels of 
pro-inflammatory mediators, such as TNF-α, induced by the activation of the TLRs 
by means of the Aβ and SNCA can also lead to mitochondrial dysfunction mainly 
through mitochondrial fragmentation [78].
5. Aging and neuroinflammation: self-conditioning to autodestruction?
Although aging constitutes a natural process, it has been considered from long 
ago as the main factor for several age-related conditions. However, we must realize 
that even when aging implies the progressive decay of several biological systems, 
the main issue with aging is the time span of exposure to different exogenous and 
potentially harmful stimuli (http://www.iarc.fr) [79, 80]. If we include the genetic 
and epigenetic heterogeneity between subjects as another factor to consider, it is 
almost evident that the aging process will follow different pathways depending on 
the particularities of each subject [81–83].
As previously mentioned, several works have evidenced the link between 
aging and neurodegenerative disorders. In the context of neuroinflammation, the 
immune system decay and a pro-inflammatory status are part of the aging process. 
Because of the increased levels of circulating inflammatory cytokines and the 
impaired performance of the cellular components involved in the immune response, 
a chronic exposure to an inflammatory environment verifies for all the biological 
systems. Regrettably, it has been demonstrated that the brain exhibits the same 
age-related pro-inflammatory deviation [84–87]. This general inflammatory status 
of the brain is currently termed as inflammaging.
In general terms, inflammaging is defined by the loss of the inflammatory 
homeostasis shifting to a pro-inflammatory condition with aging as the determi-
nant factor. Moreover, it has been evidenced that inflammaging is caused by the 
deregulated function of the inflammasomes, the intracellular structures where 
several pro-inflammatory mediators are synthetized including several cytokines 
[84, 88–90]. Moreover, some works have also suggested that inflammaging involves 
not the deregulation of TLR expression, but the signal cascades triggered after its 
activation through different microRNAs [91].
On the other hand, inflammaging can also relate with cell senescence. 
Regrettably, cell senescence also verifies in the immune system and affects the 
immune cells of both the peripheral system and the CNS. Although astrocytes are 
believed to be the only cells able to express senescence markers, different researches 
have evidenced that microglia also exhibit several age-related morphological and 
biochemical changes. Indeed, the increased levels of activation markers including 
the cluster of differentiation 11b, 11c, and 14, along with the increased production of 
TNF-α, IL-1β, IL-6, and reactive oxygen species (ROS) allow to dimension the effect 
of senescence on the physiology of the immunocompetent cells within the brain [92].
6. Concluding remarks
Inflammatory milieu is an extremely complex event. Moreover, it becomes even 
more complicated when we introduce the neurodegenerative process as part of the 
inflammatory equation. In this case, the final outcome will not only be determined 
by the production and release of the pro-inflammatory mediators and the specific 
responses triggered in the different cell types present in the brain, but it will also 
depend on the physiological status of these cells. Aging, and the differential exposure 
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to xenobiotics, will certainly determine the health status of the cells and its ability 
to answer properly to the inflammatory stimulus and to resist a pro-inflammatory 
condition. At the basis of all these processes, the molecular mechanisms triggered by 
the TLRs play a critical role during both AD and PD establishment and progression. 
Moreover, through the cross talk with additional signaling pathways, TLR cascade is 
able to interfere with different aspects of the cell physiology from energy production 
to cytoskeleton rearrangements. On the other hand, less is known regarding other 
representatives of the TLR family and their impact on AD/PD pathophysiology. For 
example, some evidence seems to suggest that while TLR9 will exert a protective 
effect in the context of the neurodegenerative process driven by Aβ and SNCA, TLR3 
will also enhance the release of pro-inflammatory mediators [93].
To date, significant evidence seems to confirm the key role of the inflammatory 
milieu in the neurodegenerative process and this situation should prompt researchers 
to increase their efforts to understand this cascade of events and to unveil the miss-
ing points of an inflammatory-based hypothesis of the neurodegenerative disorders.
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